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It is well known that athletes seek out ergogenic aids to enhance sporting performance. However, 
due to the sensitivity of the subject, it is difficult to know the extent of ergogenic aid use. An 
understanding of the prevalence, patterns of use and factors influencing the decision-making 
process amongst cyclists will help to improve prevention and educational strategies. There is little 
available literature documenting these characteristics in South African cyclists. 
 
Aim and objectives 
The aim of this study was to describe the use of ergogenic aids in South African cyclists during 
training and competition. The specific objectives of this study were to: (a) To obtain information on 
the use of ergogenic aids in male and female South African cyclists, with regard to the type of 
ergogenic aids used, and the pattern of use during training and competition; (b) To determine South 
African cyclists’ perception of the effect of ergogenic aids; (c) To determine the sources of 
information influencing South African cyclists’ use of ergogenic aids and (d) To explore the socio-
demographic and training factors that may predict the use of ergogenic aids, such as age, level of 
education and training, and competition history. 
 
Methods 
This study used a descriptive correlational study design method. Participants included male and 
female cyclists between 18 and 65 years old. Participants that did not give informed consent and 
who failed to meet the training and medical screening criteria were excluded from the study. 
Participants were recruited through electronic correspondence, cycling clubs and cycling-specific 
media platforms. A self-developed questionnaire was designed to obtain information on ergogenic 
aid use in cyclists during training and competition, as well as to determine cyclists’ pattern of use 
and their perceived effect of ergogenic aids. The questionnaire was available in English and 
Afrikaans, and explored both legal and illegal ergogenic aid use. A panel of experts reviewed and 
validated the questionnaire. The online questionnaire was anonymous; with all referring uniform 







The number of respondents was 467. Two hundred and seven questionnaires (n=177 males; n=30 
females) were included for data analysis. Two hundred and sixty participants did not qualify for the 
following reasons: they did not provide informed consent, they failed to meet the training and 
medical screening criteria, did not use the ergogenic aids listed, and did not complete more than 
30% of the questionnaire. The mean age of participants was ± 44 years. Participants used an average 
of three ergogenic aids. Four participants (0.8%) reported using illegal/banned ergogenic aids, which 
included anabolic steroids, human growth hormone, and/or cortisone.  
Nutritional ergogenic aids (42.0%) were used most often, followed by pharmacological aids (23.4%) 
and illegal/banned ergogenic aids (0.8%). Sports drinks/gels had the highest reported use (90.8%), 
followed by carbohydrates and protein (56.5%), caffeine (44.9%) and electrolytes (40.1%). Most 
ergogenic aids (75.0%) were used for both training and competition. Non-steroidal anti-
inflammatories (66.7%), analgesics (43.8%) and cortisone (100%) were most frequently used only 
when participants were stiff and/or injured. The most frequent perceived effect of ergogenic aids by 
participants (58.3%) was increased endurance and time to fatigue. Self-experimentation and fellow 
cyclists were influential sources of information in the decision to use certain aids. The use of reliable 
information resources, such as research articles was reportedly low (<12.0%), which correlated with 
the findings of the inappropriate use of most ergogenic aids. Age, preferred cycling event, average 
weekly mileage, and the amount of recovery days taken after an event, were significant factors for 
predicting the use of specific ergogenic aids. 
 
Conclusion 
The findings of this study suggest that the use of ergogenic aids to enhance performance occurs at 
all levels of cycling participation. The prevalence of use of legal ergogenic aids is high and is 
associated with misconceptions and inappropriate use, thus potentially risking the health of 
individuals. A key criterion of the World Anti-Doping Agency (WADA), South African Institute for 
Drug-Free Sport (SAIDS) and Cycling South Africa is the protection of the athlete’ health. Therefore it 
is important that these regulatory and organisational authorities collaborate to promote, provide 
and disseminate accurate information about ergogenic aids to the cycling community. Improved and 
focussed educational interventions may also assist in changing behaviour and influencing safe 





CHAPTER 1: INTRODUCTION AND SCOPE OF THE 
DISSERTATION 
1.1 INTRODUCTION 
Cycling is a common form of exercise for athletes of all ages and its popularity has increased at both 
recreational and professional levels (1,2). The sport is associated with complex physiological 
requirements due to interactions between high intensity and endurance exercise (1). The demands of 
both training and competition push cyclists to their physical limits (3). 
Cyclists continually aim to improve performance during training and competition and this has led to 
a shift towards the use of ergogenic aids. Nutritional, pharmacological and physiological ergogenic 
aids are used in an attempt to improve race performance and maximise training adaptations (4). The 
use of ergogenic aids is not only limited to competitive cyclists. Illegal/banned ergogenic aids within 
cycling include erythropoietin (EPO), human growth hormone (HGH), anabolic steroids and cortisone 
(5). Athletes misuse these substances for the pharmacological and physiological effects they have on 
performance (5). The use of these substances within the sporting domain is often inaccurate in 
relation to means of administration and quantities used. The side effects may also be substantial, for 
example, the use of anabolic steroids is associated with an increased risk of cardiovascular events (5). 
 
The consumption of ergogenic aids is common across all sporting disciplines. Amongst professional 
athletes there is an estimated prevalence of use of ergogenic aids ranging from 57% to 94% (6). The 
type of ergogenic aids used and the pattern of use is largely sport-dependent. The highest use tends 
to occur in individual endurance-type sports, such as athletics and cycling (6). It is difficult to know 
the extent of doping due to the sensitivity of the subject (7). Only a handful of studies have reported 
the prevalence of use of ergogenic aids amongst cyclists which ranged from 10.3% to 17.5% (6-10). 
To date there is very little scientific evidence supporting the performance-enhancing effects of legal 
ergogenic aids, as well as the safety profiles and long-term effects of both legal and illegal/banned 
ergogenic aids. Many of the proposed benefits are based on anecdotal data and results vary widely 
across studies (6,11). As a result, ergogenic aids are often used by athletes without a full 
understanding of the potential benefits or risks associated with the different aids (12).  
The attitudes and knowledge among cyclists towards doping and the use of ergogenic aids remain a 
relatively unexplored issue (6,13). An understanding of the reasons for use and the sources of 




Educational measures should aim to reduce the improper use of ergogenic aids. Effective anti-
doping strategies within cycling should be based on the type, frequency and pattern of use of 
ergogenic aids (6). 
However, there is a lack of evidence regarding the prevalence of use of ergogenic aids in South 
African cyclists. Therefore, the aim of the present investigation was to examine the use of ergogenic 
aids in South African cyclists during training and competition. 
 
1.2 AIM AND OBJECTIVES 
1.2.1 Aim 
The aim of this study was to describe the use of ergogenic aids in South African cyclists during 
training and competition. 
 
1.2.2 Specific objectives 
The specific objectives were: 
 To obtain information on the use of ergogenic aids in male and female South African cyclists, 
with regard to the type of ergogenic aids used, and the pattern of use during training and 
competition; 
 To determine South African cyclists’ perception of the effect of ergogenic aids; 
 To determine the sources of information influencing South African cyclists’ use of ergogenic 
aids; 
 To explore the socio-demographic and training factors that may predict the use of ergogenic 
aids, such as age, level of education and training and competition history. 
 
1.2.3 Significance of the dissertation 
There is little available literature on the use of ergogenic aids in cyclists, especially in South Africa.  
The findings of this study may improve knowledge regarding the prevalence of use of ergogenic aids 
in cyclists. The identification of the practices employed and cyclists’ knowledge of the mechanisms 
of the action of ergogenic aids is necessary to ensure safe and healthy participation in cycling. The 
objectives stated in Section 1.2.2 therefore need to be fully investigated to improve educational 
interventions regarding the use of legal ergogenic aids, and for effective doping deterrence methods 




1.3 PLAN OF DEVELOPMENT 
In preparation for the investigational phase of this dissertation, a comprehensive review of the 
literature on ergogenic aids commonly used by cyclists will be presented (Chapter Two). This will be 
followed by a descriptive questionnaire-based study designed to determine which ergogenic aids 
cyclists are using during training and competition (Chapter Three). Furthermore, Chapter Three will 
include the limitations of this study and recommendations for future research. A Summary and 





CHAPTER 2: LITERATURE REVIEW 
2.1 INTRODUCTION 
Participation in cycling is growing at an exponential rate each year (1,2). Races are held in all 
environments and over various terrains with a three- to four month competitive season for 
professionals (1,3). Cyclists may participate in competitions comprising of one-day events, multi-day 
events (three- to ten-days) and three-week events (3,14). The variations in terrain, long distances and 
time trials demand different performance attributes from cyclists, but all these types of events push 
cyclists to fatigue in both training and competition (3). 
Athletes exploit ergogenic aids to address the metabolic disturbances that may result from high-
intensity training and competition in an attempt to improve their performance (15,16). Ergogenic aids 
may be defined as “any means of enhancing energy utilisation, including energy production, control, 
and efficiency” (11). There are five categories of ergogenic aids, namely: mechanical aids (e.g. 
lightweight bicycle frames); nutritional aids (e.g. protein supplementation); psychological aids (e.g. 
hypnosis); physiological aids (e.g. blood doping) and pharmacological aids (e.g. caffeine 
supplementation) (11). 
Mechanical, psychological and nutritional ergogenic aids receive little media attention; nonetheless 
they are considered performance enhancing. Over the last few decades cycling has become 
synonymous with doping; where pharmacological and physiological ergogenic aids receive the most 
attention (17,18). These include caffeine, EPO, blood transfusions and HGH (11,18). There is little 
scientific literature documenting what cyclists are actually using and results may vary widely 
between studies (11). Most evidence is anecdotal and the popularity of many substances precedes 
scientific validation (19). The health of an athlete may be negatively affected by the use of ergogenic 
aids and therefore it is important to investigate exactly what cyclists are using (20). To our knowledge, 
no study has investigated the use of ergogenic aids in South African cyclists.  
This literature review will discuss the sport of cycling, cycling participation and training, fatigue and 
recovery from endurance exercise, with particular reference to cycling. It will present commonly 
used nutritional, pharmacological and physiological ergogenic aids in cyclists and examine the 
evidence for the performance benefits of these different aids, as well as the potential side effects. 






PubMed, Google Scholar and EBSCOhost were searched using the following keywords: “ergogenic 
aids”, “doping”, “drugs in sport”, “endurance”, “cycling”, “prevalence”, “South African cycling” 
“supplements”, “performance”, “training”, “recovery”, “fatigue”, “sports drinks”, “carbohydrates and 
cycling performance”, “protein and cycling performance”, “creatine and cycling performance”, 
“amino acids and cycling performance”, “electrolytes and cycling performance”, “caffeine and cycling 
performance”, “Vitamin B and cycling performance”, “anti-inflammatories and cycling performance”, 
“analgesics and cycling performance”, “blood doping and cycling performance”, “EPO and cycling 
performance”, “anabolic steroids and cycling performance”, “human growth hormone and cycling 
performance” and “corticosteroids and cycling performance”. Reference lists of all relevant studies 
were reviewed for additional publications. Caffeine, blood transfusions, EPO, creatine 
supplementation and nutrition (carbohydrates and protein) were the most researched ergogenic 
aids in cycling.   
 
2.2 CYCLING AS A SPORT 
2.2.1 Participation in cycling 
The interest in road cycling events began near the end of the 19th century and the enthusiasm and 
growth for the sport continues. Well-known cycling races are viewed on television all around the 
world and can attract millions of spectators (21). There were reported to be 3.2 million South African 
cycling spectators in 2009 (2). The first recorded cycling race took place in Paris; 31 May 1868. A year 
later in 1869, the first city to city race (123 km) took place: Paris to Rouen (21). Road cycling has been 
a part of the Olympic Games since 1896 when the Olympics first began (21).  
Mountain biking competitions were first started in the United States of America (USA) in the early 
1980s (21). In the last decade, mountain biking has become increasingly popular in many parts of the 
world (22). In the USA, mountain biking events attract nearly 40 million participants annually (23). 
Although mountain biking participation is half that of hiking participation, its participation is 





Cycling was ranked as one of the top 15 sporting codes in South Africa in 2009, and the 10th most 
popular participation sport overall amongst Caucasians (2). There are currently 145 registered cycling 
events held each year in South Africa (2). South Africa is also home to the world’s largest individually 
timed cycle race (Cape Argus Pick ‘n Pay Cycle Tour) where approximately 35 000 cyclists compete in 
this mass start event (24,25). Cross-sectional studies show that cycling provides valuable health 
benefits (26). Denmark reported a 20% increase in cycling participation from 1996 to 2002 and an 
increased life expectancy of five months for males (26).  
In 2009 there were approximately 526,900 South Africans participating in cycling (2). A 7.7% growth 
rate in cycling participation was reported from 2008 to 2009 (2). Cycling South Africa recently 
reported a 55.6% increase in licensed members from 2012 to 2013 (2). This positive growth trend in 
cycling participation therefore warrants more concern about the health risks associated with the use 
of ergogenic aids (11).  
 
2.2.2 The disciplines within cycling 
Cycling offers a diverse nature of events; however, it is largely an endurance sport (6). It requires 
extreme physiological and metabolic demands of the body (17,27). Passfield and Doust(28) showed that 
as little as five minutes of cycling correlated strongly to maximal aerobic power (VO2max). There are 
five major disciplines within the sport supported by Cycling South Africa, namely: road, mountain 
biking, track, bicycle motorcross (BMX) and para-cycling (2).  Endurance cycling, both on-road and off-
road is regarded as strenuous exercise, with the Tour de France being one of the toughest, if not the 
toughest sporting competition (17,27). This review will focus on road cycling and mountain biking. 
Road cycling has a mass start in which all the participants start together in a bunch (21). There are 
several road racing formats that may include; point-to-point cycling, circuit route cycling or stage 
race cycling (21). In a professional road cycling season there may be 90 to 100 competition days (3). 
Races vary between one day, one week or three weeks in length, with stage distances varying from 5 
km to 300 km (3,29). A professional cyclist may cover a distance of 35 000 km a year (27). An amateur 
cycling season, on the other hand, typically consists of 50 competition days, with races not normally 




Competition requirements for both professional and amateur cyclists may include long, flat stages; 
mountainous ascents and time trials (3).  There may be individual or group time trials depending on 
the race format. Time trials are generally raced over a 40 km to 50 km distance, where cyclists set off 
individually at regular intervals of one to two minutes (21). The participant with the fastest time is the 
winner. Team time trials are similar to individual time trials with a minimum of two cyclists and a 
maximum of ten cyclists per team (21). 
Mountain biking events can either be held over short (five to nine kilometres), undulating circuits 
which are a part of the Olympic programme or longer mountainous marathon versions (60 km to 
120 km) (21). The various terrains include steep ascents, technical descents, rocky paths and obstacles 
(21). Cyclists of all calibre start together in the longer mountain biking events, whereas the short 
circuit events are generally for more advanced cyclists (21). 
Power output when climbing uphill in both disciplines is directly influenced by the weight of the 
cyclist and their bicycle. As a result, cyclists specialising in climbing mountainous terrain try to be as 
light and as lean as possible (1). Outdoor training and competitive events may present a variety of 
factors which cyclists need to overcome to maintain maximum power output and peak performance. 
The physiological demands of competitive cycling need to be determined so that training strategies 
and performance can be optimised (14). 
 
2.3 TRAINING FOR ENDURANCE CYCLING 
2.3.1 Physiological adaptations to endurance cycling training 
An improvement in exercise capacity is underpinned by the ability of skeletal muscle to adapt to 
repetitive bouts of exercise training (3,30). Physiological events that occur after exercise may be the 
stimulus for chronic adaptations to training (30). A multitude of adaptions occur in many physiological 
systems (muscular, cardiovascular and endocrine) as a result of endurance cycling (31). It is well-
documented that endurance training leads to an increase in the number of capillaries in muscles, 
thereby increasing the amount of oxygen delivered to the muscles to maximise endurance 
performance (31). The extent of any adaptation as a result of physical training is directly related to the 







                  
 
 
Figure 2.1: Magnitude of skeletal muscle adaptation is directly related to the training stimulus; and 
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Physiological factors influencing a cyclist’s ability and performance include the individual’s VO2max, 
muscle fibre type, muscle capillarisation and cycling efficiency (1,32). Research has shown that 
endurance athletes have a high VO2max, which is consistent with observations seen in professional 
cyclists (1). A professional cyclist’s relative VO2max is typically in the range of 70 ml.kg
-1.min-1 to 85 
ml.kg-1.min-1 (1,33,34). This is high in comparison to the average VO2max (43 ml.kg
-1.min-1) for healthy 
individuals (34). Studies have shown that the VO2max for amateur cyclists are very similar to 
professionals, however the difference is in their power output achieved at VO2max 
(1). 
Physiologically, an athlete with a high proportion of type 1 muscle fibres has the ability to sustain 
high power outputs over a prolonged period of time, thus making them a good candidate for 
endurance cycling (1). A greater gross efficiency (lower submaximal oxygen costs) during cycling has 
been associated with a high proportion of type 1 fibres in the vastus lateralis muscle (35). The number 
of type 1 fibres in the vastus lateralis muscle of cyclists is highly related to the number of years spent 
performing endurance cycling (31). The literature also highlights the importance of muscle 
capillarisation for endurance sports (1,31). A high density of capillaries allows for an abundant supply 
of both oxygen and nutrients to sustain the large energy output requirements (1). Specific studies on 
cycling performance and capillarisation are limited. However, Coyle et al(36) found a high correlation 
(r=0.74) between capillary density and time to fatigue. Neuromuscular recruitment also improves in 
response to sport-specific training patterns (31). After a bout of short-term resistance training the 
observed improvements in dynamic muscular strength are attributed to better neuromuscular 
recruitment patterns rather than increases in muscle fibre size (31). Collectively these training-
induced neuromuscular adaptations enable cyclists to recruit more muscle fibres, therefore 
producing power over a larger active muscle mass while pedalling (31). 
Another training adaptation that enhances endurance cycling performance is that highly trained 
(professional and amateur) cyclists oxidise less carbohydrates (CHO) and more fat compared to less 
well-trained (recreational) cyclists at the same absolute intensity (31). This shift in substrate selection 
by the working muscles may play a major role in enhancing endurance capacity. As discussed later in 
Section 2.4 (page 11), the depletion of endogenous carbohydrate stores (a major fuel source during 
exercise) may be linked to fatigue during prolonged cycling (27,31). All of these training-induced 
adaptations of skeletal muscle can improve a cyclist’s performance capacity; however, all are a result 
of high-volume, high-intensity training (18). Please refer to detailed reviews by Hawley and Septo 
(2001)(31) and Coyle et al (1991)(37), as further discussion of training adaptations is beyond the scope 





Power output during a cycling race is not only influenced by innate physiological ability, but also by 
positioning of the cyclist on the bike, pacing strategies, training and nutrition (1,38). Competitive 
cycling is thus characterised by the interrelationship between all of these factors (1). 
 
2.3.2 Important components of endurance cycling training 
Many studies have investigated the benefits of training on performance (3,30,31,37,39). However, the 
majority of these studies have used untrained individuals. Untrained individuals have large 
improvements in VO2max after a training programme, whereas highly trained individuals show smaller 
improvements after training (39). There is not much literature describing the effects of additional 
training on elite athletes, especially cyclists (39).  
The goal of endurance training in cycling is to maintain a high average power output over a 
prolonged distance and time (3,30).  The volume (how many minutes or hours in a session per day), 
frequency (how many training sessions per week) and intensity of exercise sessions, are all 
important components of training programmes. Improved performance or decreased performance 
(fatigue) can be directly related to the sum of these training variables (30). 
To reach an overload in training stimulus, cyclists will generally increase training volume and 
frequency. When overload can no longer be induced with increases in volume and frequency, 
interval training will be employed (27,40). High-intensity intermittent training (interval training) has 
been shown to improve maximum short-term power output, VO2max and both glycolytic and 
oxidative enzyme activity (27,31). Interval training lasting only 30 seconds, at 175% of peak power, with 
four-and-a-half minutes recovery, repeated 12 times, was just as effective as improving in a 40 km 
time trial, as was four-minute bouts of interval training (27). The underlying mechanisms of the 
efficiency of this type of short-term, high-intensity training, is the increased ability of the cyclist to 
sustain a higher fraction of VO2max or power output for a longer period of time, due to an improved 
muscle buffering capacity (27). The 40 km time trial induced in the laboratory is highly reproducible in 
trained cyclists, and is thus often used to test the efficacy of training protocols (27). The average 
amount of power output that can be maintained in one hour is the best predictor of a 40 km time 
trial performance (27). 
In summary, cyclists wanting to increase overall training stimulus should start by increasing training 
volume and frequency (27). Training volume and frequency require a large amount of free time (40).  
For the recreational and amateur cyclists, free time may be limited due to work commitments and 
societal pressures. On the other hand, although professional cyclists have the time to train, 




These factors, although different across competitive levels, may conjure curiosity in the use of 
ergogenic aids. Consideration of the potential factors limiting training and natural performance 
enhancement may suggest that the use of ergogenic aids is not only limited to professional cyclists. 
 
2.3.3 Training implications for endurance cyclists 
Cyclists often train every day, or are involved in multi-day events. Strategic development of training 
schedules is required to achieve peak performance. Too much cycling, combined with too little rest 
and recovery, may lead to overtraining. Overtraining causes tissue breakdown and a decline in 
performance, as well as an increased risk of injury (15,41). The lack of recovery or incomplete recovery 
between successive training sessions and competition may result in cyclists being unable to continue 
to train at full capacity and at the required intensity (15,27,41-43). If the balance between training and 
recovery is not corrected, the “overtraining syndrome” (OTS) may develop (27).  
The OTS may manifest in both physiological and psychological symptoms, representing the point at 
which an athlete has surpassed their capacity to exercise (chronic fatigue) (27,44). Decreased 
performance which may last months, irritability, lack of motivation and sleeping problems may 
develop (27,44).  Heart rate is commonly used to monitor cyclists, as it is one of the most sensitive 
indicators of training status (27). Lucia et al(45) found that a decrease in maximum heart rate was the 
best marker indicating fatigue over a three-week cycling race. To treat OTS, the factors which lead to 
over-training in both activities of daily living and training must be eliminated (27). Rest, sleep and the 
quality and quantity of nutrition are all important components of healing (27). 
In summary if training and recovery are not balanced, the OTS may develop leading to performance 
incompetence (27). Cyclists train hard to achieve peak performance and often there is the 
misconception that a reduction in training may cause de-training and decreased exercise 
performance (40). Cyclists therefore look towards ergogenic aids to maximise training and minimise 
recovery time while maintaining positive increases in performance capacity.  
 
2.4 FATIGUE IN CYCLING 
It is important for both cyclists and coaches to understand fatigue and the factors determining 
cycling performance and fatigue. If these factors can be identified, training adaptations which are 
most important for improving performance can be exploited and training structures can be 




Abbiss and Laursen(3) define fatigue as “sensations of tiredness and associated decrements in 
muscular performance and function”. In cycling terms, fatigue can be described as the inability to 
maintain an expected or required power output (27). As a result, fatigue is generally viewed as a 
negative effect of exercise as it often results in reduced function and performance (46). On the other 
hand, Kay et al(47) advocates that fatigue can be viewed as a safety mechanism, which is modulated 
by peripheral and central input, causing a decrease in exercise intensity or complete cessation of 
exercise to prevent injury (47).  
Controversy exists in the literature as to what exactly causes fatigue (3). Various models have been 
developed by several researchers, majority of which explain a linear approach to the underlying 
mechanisms of fatigue. The seven linear cause-effect models that have been reviewed by Abbiss and 
Laursen(3) include: cardiovascular fatigue, energy supply/depletion, neuromuscular fatigue, muscle 
trauma, biomechanical fatigue, thermoregulatory fatigue, psychological fatigue and the central 
governor model of fatigue. Recently a more complex non-linear model has been developed, namely 
the complex systems model of fatigue (3).  The different models will be briefly described in this 
section, as the nature of fatigue experienced by cyclists may influence the use of ergogenic aids. 
Please refer to a detailed review by Noakes(48) as a thorough discussion of the different models of 
fatigue is beyond the scope of this review.  
The cardiovascular model suggests that fatigue is due to the heart’s inability to supply an adequate 
and efficient amount of oxygen to the working muscles, as well as to remove waste products from 
the working muscles (3). The energy supply/energy depletion model may be divided into two parts. 
Firstly it states that fatigue may be due to the failure to supply enough adenosine triphosphate (ATP) 
to the working muscles (energy supply).  Secondly, it states that fatigue is a result of a depletion of 
fuel substrate in the form of muscle and liver glycogen, blood glucose and phosphocreatine (energy 
depletion) (3). This theory is criticised as ATP levels hardly ever reach below 40% even after exercise 
to exhaustion, and in such instances, levels lower than 40% would cause rigor mortis (3,41). 
The neuromuscular fatigue model is based on muscle excitation, recruitment and contraction 
mechanisms limiting performance. There are three viewpoints which explain where along the 
neuromuscular pathway inhibition may occur. There may be reduced central activation, causing a 
reduction in neural drive. Alternatively, there may be reduced responsiveness of the muscle to 
incoming stimuli. Finally, fatigue may result because of changes in the muscle affecting excitation-
contraction coupling mechanisms (3). During prolonged cycling the combination of central and 
peripheral alterations cause an increased perception of effort, although force and power production 
have decreased (3). Exercise-induced muscle damage (EIMD) can cause a number of unfavourable 




Exercise-induced muscle damage can be classified into three groups, namely: Type 1: muscle 
swelling, stiffness and delayed onset muscle soreness (DOMS), Type 2: tears in the muscle fibre, and 
Type 3: muscle cramps/pain during exercise or on cessation of exercise (3). Endurance cyclists tend to 
push high gears over extended periods of time, and therefore some form of EIMD, on the spectrum 
from Type 1 to Type 3 can be expected (3). 
The biomechanical model of fatigue underlines the efficiency of movement on the bicycle. The less 
efficient movement is the more energy is expended, resulting in reduced economy and early onset 
of fatigue (3). The thermoregulatory model looks at the influence of body temperature. It states that 
once a critical core body temperature has been reached, exercise capacity is reduced (3). The 
psychological/motivational model, associates fatigue with a reduced central drive due to lower 
motivation and/or interest for the exercise task itself, resulting in an increase in perceived exertion 
(5). Lastly, the Central Governor theory proposes that there is a regulator/governor situated in the 
central nervous system (CNS) which alters exercise intensity and performance according feedback 
from muscles and other organs (3).  
However, cycling performance is not limited by one linear model of fatigue, but rather by the 
interaction of several different models (3). The complex systems model of fatigue is a recent model 
described by Lambert et al(49) and St Clair Gibson and Noakes(50).  This model states that exercise 
performance is influenced and limited by a number of the linear models described above (3). The 
interactions between numerous physiological systems manipulate exercise performance through 
continuous feed-forward and feedback loops (3). The brain unconsciously integrates all peripheral 
feedback and manipulates exercise intensity and pacing strategies, allowing cyclists to finish exercise 
bouts efficiently without pushing one peripheral system out of homeostasis (3). 
Cycling performance is determined by the ability of the cyclist to resist fatigue (3). Coaches, cyclists 
and athletes are always looking for ways in which to further improve exercise performance (3). 
Understanding the different models of fatigue during prolonged cycling may help to understand the 
use of specific ergogenic aids among cyclists. There are many influences to consider in cycling 
performance (1). After a bout of intensive exercise in which cyclists have pushed themselves to near 
exhaustion, it is important to recover by replenishing losses and restoring homeostasis in the body. 
Maximising glycogen re-synthesis and minimising protein breakdown will help enhance subsequent 




2.5 RECOVERY FROM TRAINING AND COMPETITION 
Hard training must be balanced with the correct amount of recovery (27). Recovery is multi-
dimensional and factors related to age, gender, experience, environment and psychological well-
being can influence the rate of recovery (15). Recovery is a process whereby the muscles return to 
their pre-exercise state following exercise (51). It may also be defined as the time between successive 
workouts or competitions (41).  During this period the goal is to maintain the physiological 
adaptations attained during training and competition, and minimise the negative impact of training 
and competition (40). Recovery should form a key component of any successful training programme. 
Recovery is often overlooked due to fear of losing out on training time; however optimal 
performance necessitates full and optimal recovery (15,41).  
The physical and physiological stress of high-intensity training and competition may provisionally 
impair an athlete’s performance (15). Therefore it is important that both cyclists and coaches 
understand the mechanisms that cause or contribute to fatigue (41). These impairments may last for 
minutes, hours or even several days (15). Impairments resulting from metabolic disturbances, 
glycogen depletion and dehydration after bouts of intensive exercise are normally short term 
(hours). Impairments that are longer-lasting and exceed 24-hours may be related to DOMS, 
inflammation and EIMD (15,30,43).  
If the rate and quality of recovery was improved, much larger training volumes would be possible (41).  
Nutritional intake and “specialised” modalities are also said to influence the rate of recovery (41). 
Anecdotally, athletes use ergogenic aids to enhance recovery, with the goal of improving the ability 
to train and compete when fatigued, or to facilitate a more rapid return to training after 
competition.  At present, there is very little conclusive literature on the efficacy of recovery 
modalities. Most evidence is based on anecdotal data or previous studies which have poor 
methodologies and the results vary widely (15). There are a number of different recovery modalities 
used by athletes during training and competition (15,52). They may include passive recovery (rest and 
relaxation), active recovery, massage, cold/contrast water immersion, stretching, compression 
garments, and a combination of the above (15,52). Please refer to a detailed review by Barnett 
(2006)(15), as a detailed review of the specific modalities is beyond the scope of this current review. 
The ability of an athlete to withstand intensive training and continually enhance competition 
performance without yielding to injury, illness, fatigue and the OTS may be influenced by nutritional 
intake. A normal diet is often not considered as adequate by many athletes for optimal performance 





2.6 ERGOGENIC AIDS  
2.6.1 Definition of ergogenic aids 
When considering the factors that determine performance such as innate physiological ability, 
training and motivation, diet may be seen as only one of these factors. The use of specific food 
sources, vitamins and medications, for example, cannot compensate for poor training or lack of 
training on the part of the athlete, yet they may enhance a talented, competitive and motivated 
athlete to finish well (12,53). 
Ergogenic aids are substances used to enhance athletic performance (13). Ergogenic aids may 
facilitate sports performance and competition by enhancing physiological processes, depressing 
psychological inhibition and improving exercise capacity (13). A trend in the current literature 
revealed that the mostly frequently used ergogenic aids amongst athletes are vitamins, amino acids, 
creatine, CHO and sports drinks (12,53-59). The most commonly reported ergogenic aids used by cyclists 
include sports drinks, vitamins, amino acids, caffeine, protein (PRO) and non-steroidal anti-
inflammatory drugs (NSAIDs) (6,57). 
As stated earlier in Section 2.1 (page 4) there are five categories of ergogenic aids, and this review 
will focus only on the nutritional, pharmacological and physiological aids (11,18). Research on 
ergogenic aids is often contradictory (13). Substances are categorised differently across studies, 
making it difficult to compare findings and infer relationships and usage patterns (11,13). Considering 
the popular ergogenic aids reported to be used by cyclists in the literature, and anecdotal evidence 
of use amongst cyclists, the substances were categorised in the following way for the purpose of this 
review (11,18). Nutritional ergogenic aids included sports drinks/gels, CHO, PRO, amino acids, creatine 
and electrolytes. Pharmacological ergogenic aids included caffeine, vitamin supplementation, 
NSAIDs, analgesics, cortisone and HGH. The physiological ergogenic aids included blood transfusions, 
EPO and anabolic steroids (11,13). Furthermore, all ergogenic aids may be classified as either legal or 
illegal/banned substances (13). 
 
2.6.2 Classification of ergogenic aids 
In 1960 the International Olympic Committee (IOC) established a Medical Commission to combat the 
use of drugs in sport. A list of banned substance classes and methods was then published by the IOC 
in 1967 (60,61). At first, the list contained only substances which could be tested in laboratories. 
However, at the 1984 Olympic Games, a group of cyclists underwent blood transfusions. Blood 




This incident, which was later uncovered, led to the banned list including all drugs and doping 
methods, even if detection tests were not yet available (61). The incidence of doping in sports 
continued to increase internationally and became a major health concern. In 1999, an international 
committee called the World Anti-Doping Agency (WADA) was formed with the goal of reducing the 
use of drugs in sport. After working with the IOC, WADA published a list of banned substances in 
2004, supported by scientific trials and literature (60,61). 
The list of banned substances published by WADA is updated yearly following an extensive 
consultation process, and is easily accessible online (http://www.wada-ama.org/en/Science-
Medicine/Prohibited-List/) (62,63). For a substance to be placed on the list, the substance or the 
method must meet two of three criteria, namely: the method and/or substance can improve athletic 
performance; it poses a risk to health; and/or its use violates the principle of fairness in sport (63). 
Substances that are not found on the banned list (for example, caffeine and creatine), but which 
have an ergogenic effect, do not constitute doping (63). Caffeine, which was once on the banned list, 
is now on the WADA Monitoring Programme to assess its misuse in sport (63). 
WADA defines doping as “the occurrence of one or more of the anti-doping rule violations set forth in 
Article 2.1 through Article 2.8 of the WADA Code” (62). It is the athlete’s responsibility to know which 
of the substances and methods have been included on the banned list for cycling, and what 
constitutes an anti-doping rule violation. The anti-doping rule violations can be found in the WADA 
anti-doping code available at http://www.wada-ama.org/Documents/World_Anti-
Doping_Program/WADP-The-Code/WADA_Anti-Doping_CODE_2009_EN.pdf (62).  
The illegal/banned ergogenic aids and those substances requiring Therapeutic Use Exemption 
certificates (TUE) in this review include blood doping in the form of blood transfusions, EPO, HGH, 
anabolic steroids and corticosteroids (13). 
 
2.7 ERGOGENIC AIDS AND CYCLING 
2.7.1 Prevalence of ergogenic aid use in cycling 
The consumption of ergogenic aids is common in sports. The estimated prevalence of the use of 
ergogenic aids amongst athletes ranges from 46% to 100% (6,53,55,64). The use of ergogenic aids is 
sport-dependent, with the highest prevalence occurring in endurance sports, such as athletics, 
rowing and cycling (6). Athletes participating in individual sports are also more likely to consume 




Whilst the sport of cycling continues to grow, so does the competitive nature of the sport itself (13,27). 
The incidence of doping continues to increase, presenting a poor picture of top-of-the-range athletic 
performance (65). The common practice of doping amongst cyclists was brought to the fore recently 
following confessions by professional cyclists in the media (9). However, there has been a reduction 
in team doping since the last scandal, and it is now considered as a practice undertaken by certain 
individuals (9). The use of banned substances to accentuate physique and performance is not only 
limited to the competitive cycling world. It must be recognized that athletes at a recreational level 
are also exploring and using a variety of ergogenic aid products (66).  
Laure(10) by means of a questionnaire-based study, found a doping incidence of 17.5% in national and 
international cycling competitions, and a 10.3% incidence in local cycling competitions. Lenillan and 
Carstairs(9) investigated the incidence of doping in young semi-professional Swedish cyclists (n=8) 
through individual, semi-structured interviews. All the cyclists took products to improve 
performance, and all except for one cyclist reported that they would use illegal/banned products 
and methods if they turned professional. 
 
2.7.1.1 Reasons for using ergogenic aids in cycling 
A compelling attraction for athletes is the achievment of good results in performance with minimal 
effort (54). Cyclists are always looking for ways to alter their bodies for maximal performance (67). It is 
assumed that all professional cyclists train strenuously and therefore, any practice or substance 
providing a competitive edge may be encompassed as part of performance enhancement (52). As 
discussed, cyclists will exploit training strategies, technological innovations and scientific, as well as 
medical support, to seek ways of improving performance and defeating their opponent (67,68). 
Foregoing a potential advantage for maintaining the idealistic notions of sportsmanship, equity and 
fairness in competition may not always fall within the athlete’s logic of success (69). Devotion of time, 
long-term commitment and sacrifice in the professional cycling world often results in the cyclist 
trying to obtain for the best sponsorship, finance and, most importantly, individual glory (67,68,70). On 
the other hand, however, one might also say that doping is demand driven. Aggression, speed, size, 
strength and winning are sometimes seen as the qualities society demands of sport (8). 
Laraschi et al(6),using a questionnaire study, reported reasons to explain doping among cyclists 
(n=40). Fifty-seven percent of the study’s participants said cyclists dope to gain advantages in 
physical performance, to achieve results within a short time (40%), to obtain good results during 




Personal attitude and the social environment can influence the use of both legal and illegal/banned 
ergogenic aids. Of particular concern, are the young cyclists who are striving to become professional. 
They are exposed to high pressures and often turn to the more experienced cyclists for advice. These 
older and more experienced cyclists are more likely to have used banned substances at some stage 
in their careers (6). 
There is little evidence to support the use of most ergogenic aids based on the beneficial effects 
claimed in advertising (6,13). The advantages of using ergogenic substances on sporting performance is 
highly controversial and athletes risk jeopardising their long-term and immediate health in using 
some of these ergogenic aids (6,13). 
 
2.8 ERGOGENIC AIDS USED IN CYCLING: AN EVALUATION OF EVIDENCE  
The categories of ergogenic aids receiving the most attention in the literature on cycling 
performance are the nutritional aids, pharmacological aids and the physiological aids (18). The 
following section will evaluate the current evidence for the effectiveness of nutritional, 
pharmacological and physiological ergogenic aids on cycling performance.  
Short-duration, high-intensity exercise improves the buffering capacity of muscles and thus increases 
the ability of a cyclist to sustain a higher power output or percentage of VO2max over an increased 
period of time (27). Both of these parameters, average power output and relative VO2max are probably 
the most important predictors of cycling performance (34). The studies assessed in this review used 
these two performance parameters, along with time-to-fatigue to evaluate the ergogenic effect of 
specific aids used in cyclists. An increase in power output will enhance short-duration high-intensity 
exercise performance, important for the time trial component of cycling competitions. An increase in 
VO2max and time-to-fatigue are both largely related to enhancing endurance performance. The level 
of evidence (LOE) according to evidence-based medicine criteria will be evaluated in all clinical trials 
presented in this section of the review (71). 
 
2.8.1 Nutritional aids 
The nutritional requirements of endurance cyclists are often challenging to meet due to extensive 
training and competition programmes. The nutritional needs and practices of cyclists are aimed at 
providing the muscles with adequate substrate to improve race performance and maximise training 
adaptations (4,72). The detrimental effects of fatigue during endurance events may be reduced by 




With the world standard in sport continuing to advance to higher levels, the smallest advantage can 
have a tremendous impact on performance (30,42,52). Carbohydrates, PRO, amino acids, creatine and 
electrolytes will be discussed under nutritional ergogenic aids. These ergogenic aids will be reviewed 
as appropriate considering their physiological basis for use, strategies for use in cycling, current 
evidence for the effects of their use on cycling performance and the health risks associated with 
their use.  
 
2.8.1.1 Carbohydrates 
2.8.1.1.1 Physiological basis for CHO use 
There are a number of proposed mechanisms by which CHO improves performance (74). Some studies 
propose that liver and muscle (endogenous) glycogen is conserved when CHO is consumed during 
exercise (31,74). During prolonged cycling at a moderate intensity, the ingestion of CHO had little effect 
on plasma glucose concentration; however, plasma glucose concentration dropped significantly after 
two hours when CHO was not ingested, indicating that perhaps, CHO, in fact did have an effect on 
plasma glucose concentration (72,75). However the authors proposed that it was the maintenance of 
euglycaemia or high blood oxidation rates late in exercise that improves performance (74,76).  
Of late it has been hypothesised that CHO ingestion may have a central effect (72). Carter et al(77) 
conducted a study on trained cyclists (n=9) using a CHO solution and a placebo solution as a mouth 
wash (participants spat out the solution). The exercise protocol consisted of a 60-minute time trial. 
An improvement in performance was still observed in the CHO rinse group compared to the placebo 
group. The authors proposed that there may be receptors in the mouth communicating with the 
brain, and that metabolism and high blood glucose concentration do not necessarily play the only 
role (77). 
The time at which CHO is ingested has little effect on the rate of CHO oxidation (76). High rates of 
exogenous CHO oxidation should be reached as soon as possible after the onset of exercise. 
Repetitive ingestion throughout exercise has shown to increase the rate of gastric emptying and thus 
the rate at which CHO can be absorbed in the intestines (76). Oral CHO oxidation occurs at a rate of 1 
g.min-1. The optimal amount to be ingested is 60 g.h-1 to 70 g.h-1 during exercise lasting longer than 




2.8.1.1.2 Strategies for CHO use in cycling 
Strategies for manipulating CHO intake were first investigated by Swedish researchers in the late 
1960s (19,79). They demonstrated that endurance performance was improved following a high CHO 
diet by delaying the onset of fatigue (19,79). Carbo-loading and CHO diet manipulation became highly 
popular in the 1970s, and the commercial marketing of CHO products increased. The original carbo-
loading strategy initiated with athletes depleting their muscle glycogen stores through exercise, 
followed by two to five days of a CHO free diet, and finally ending with a high CHO diet for at least 
three days (19). Endurance athletes, especially cyclists, found weight maintenance on this regime to 
be difficult. Many studies have investigated the effects of CHO as an ergogenic aid, and it has been 
well accepted in the literature that CHO ingestion can improve endurance capacity, by delaying the 
onset of fatigue (4,42,74,76,78-86). 
Carbohydrate and fat stores are considered the most important substrate fuels for exercise 
(4,42,74,76,78-86). During low to moderate intensity exercise (25% to 65% VO2max) fatty acid oxidation 
provides majority of the total energy requirements (72,74,87). Fat sources in the body are relatively 
abundant, and are derived from plasma free fatty acids and intramuscular triglycerides (72). During 
high-intensity exercise (>75% VO2max) CHO metabolism predominates. Endogenous CHO sources 
include muscle glycogen, liver glycogen and plasma glucose from exogenous CHO intake (72,74,87). 
During the early stages of exercise, muscle glycogen supplies the majority of CHO energy. As exercise 
continues, muscle glycogen stores become depleted and the body relies more upon blood glucose 
(78). Muscle glycogen is considered a vital fuel source, and once reduced, the ability to perform at the 
required intensity is reduced and performance may diminish (88,89). It is well-accepted that endurance 
performance is influenced by the amount of glycogen stored in skeletal muscles, with fatigue often 
coinciding with skeletal muscle glycogen depletion (87,89,90). Research has investigated the influence of 
increasing muscle glycogen stores by examining the timing, frequency, amount and type of CHO 
supplementation (88). The goal of CHO ingestion is two-fold. Firstly, it is to optimise muscle glycogen 
stores leading up to an event, and secondly, to ensure the availability of CHO in the body in the later 
stages of prolonged exercise (>90 minutes). During prolonged exercise, if CHO stores are depleted, 




The types of CHO can be split into two groups according to their oxidation rates. Fructose and 
galactose have lower oxidation rates, whereas sucrose and glucose polymers are considered to be as 
efficient as glucose, as they have similar oxidation rates (76). Similarly, whether the CHO is in a liquid 
or solid form, the ergogenic potential is not affected (80). Therefore solutions containing glucose, 
sucrose and glucose polymers (maltodextrins) may be consumed and are equally beneficial (86).  
On the day of an event athletes should consume CHO three to six hours before the event (79). 
Carbohydrate ingestion 30 minutes before an event has shown to decrease endurance performance 
(75). It results in a faster decline in muscle glycogen and blood glucose concentration, thus decreasing 
the time to fatigue (75). Literature documenting the intake of CHO by female cyclists is scarce.  
Burke(4) examined the nutritional practices of male and female cyclists, and found that male cyclists 
have a CHO intake of 8 g.kg-1.day to 11 g.kg-1.day during intensive training. The recommended daily 
allowance (RDA) for CHO is 60% (7 g.kg-1.day to 10 g.kg-1.day) of total energy intake and for athletes 
training more than four to five hours per day, 10 g.kg-1.day to 12 g.kg-1.day is recommended (4,72). It 
was also found that pre-race and post-race CHO ingestion was the preferred practice.  
 
2.8.1.1.3 Current evidence for the effects of CHO on cycling performance 
The ergogenic effect of CHO ingestion has generally been demonstrated to improve endurance 
performance by delaying the onset of fatigue (80). Hawley et al(91) concluded that CHO loading during 
prolonged continuous exercise at a fixed submaximal work rate improves endurance performance by 
20%. Coyle et al(75) investigated the effects of CHO ingestion during prolonged cycling at 74% VO2max. 
Trained cyclists (n=10) exercised for 180 minutes, and were instructed to maintain the highest 
workload possible for the full two hours. Cyclists were given a glucose polymer 20 minutes after the 
start. Exercise time-to-fatigue significantly increased in the CHO group compared to the placebo 
group (p < 0.001). Ivy et al(92) also found that the ingestion of a glucose polymer in trained cyclists, 
cycling at 71% VO2max, for two hours, delayed fatigue in the CHO group compared to the placebo 
group.  These findings both demonstrate that CHO ingestion in trained cyclists, during prolonged 




However some studies have failed to show improvements in performance with CHO ingestion 
(16,80,93). Burke et al(93) observed that neither performance in a 100 km time trial nor average power 
output improved with a high CHO diet compared to a moderate CHO diet in endurance trained 
cyclists and triathletes (n=7). Pritchett et al(16) also failed to demonstrate an ergogenic effect of CHO 
ingestion on subsequent endurance performance in regional level cyclists and triathletes (n=10). 
Discrepancies between studies may be a result of different experimental designs, the type and 
amount of CHO ingested, as well as the method used to evaluate performance (74,80,93). 
Nutritional strategies involving CHO supplementation have also been investigated during recovery 
between exercise sessions, to enhance glycogen re-synthesis and thus subsequent performance 
(81,85,90,94). Fallowfield et al(85) were the first to demonstrate that the ingestion of a CHO-electrolyte 
drink after exercise enhances recovery. Runners completed two exercise protocols consisting of a 90 
minute run (or run until exhaustion) at 70% VO2max separated by a recovery period. Participants that 
consumed a 6.9% CHO solution within the first two hours of recovery ran 22.2 minutes longer in the 
subsequent run, compared to the placebo group. Muscle glycogen re-synthesis and storage peaks 
within the first hour after exercise (72). It is therefore recommended that ingestion of moderate to 
high glycaemic index CHO are ingested as soon as exercise is completed, at an amount of 1 g.kg-1.h-1 
to 1.8 g.kg-1.h-1 for maximum benefit. When recovery periods are limited, ingestion should start 
immediately (72). 
Recently the combination of a CHO and PRO supplement has been shown to improve performance 
and recovery over CHO supplementation alone and this will be reviewed in Section 2.8.1.2 (page 28) 
(81,89,90,94,95). Research has also examined the effects of a high fat diet over a high CHO diet on 
endurance performance. This type of diet is suggested to be beneficial for exercise where athletes 
have to carry their own supplies, energy expenditure is high and/or recovery time is limited (74). 
There is limited evidence supporting a high fat diet and health risks warrant caution in promoting 
such a diet. Research has shown though, that adaption to a high fat, low CHO diet is possible, while 
maintaining endurance capacity (74). Lambert et al(96) compared a high fat diet to a high CHO diet on 
endurance performance in trained cyclists. At moderate intensity exercise (60% VO2max) time to 
exhaustion was significantly longer after the high fat diet (p < 0.01), however there was no 





One of the major adaptations to endurance training is the increase in fat oxidation during exercise 
(74). As a result; research has delved into investigating the performance effects of a high fat diet in 
trained athletes with an increased capacity for fat oxidation. The evidence is currently equivocal and 
conclusive answers are absent. Table 2.1 provides a summary of relevant experimental studies that 
assessed the ergogenic effects of CHO and the combination of CHO and protein, CHO and 





Table 2.1: Summary of experimental studies that assessed the ergogenic effects of carbohydrates only, and a combination of carbohydrates  and 
protein/electrolytes/fat on cycling performance. 
Article Study design Sample size (n) Participants Intervention Exercise protocol Results Conclusion 
Coyle, Hagberg, Hurley, 








(9 males and 1 female) 
Highly trained cyclists -Glucose polymer 
solution vs. PLA 
solution 
-50% polycose solution 
after 20 min of exercise 
(140 ml) 
-Then 6% polycose 
solution at 60, 90 & 120 
min of exercise (300 
ml) 
-PLA group had same 
volume of flavoured 
solution 
-The highest workload 
the participant could 
maintain for 2 h at an 
average of 74% VO2max 
-Instructed to cycle 





improved in 7/10 
participants 
-TTF increased from 
126  min to  
159 min with CHO 
ingestion (p < 0.001) 
CHO feeding during 
prolonged exercise can 
postpone the 
development of fatigue 
and has an ergogenic 
effect on endurance 
cycling performance. 











Trained cyclists -7.75% CHO 
supplement (200 ml) 
-7.75% CHO/1.94% PRO 
supplement (200 ml) 
-Sweetened PLA 
supplement (200 ml) 
(Supplements were 
given before the start 
of exercise and then 
every 20 min until 80% 
VO2max was reached) 
 
-On 3 separate 
occasions participants 
cycled at intensities 
that varied between 
45% and 75% VO2max 
and then at 85% VO2max 
for 3 h or until fatigue 
-CHO supplementation 
significantly increased 
TTF (CHO 19.7 min vs. 
PLA 12.7 min) 
-The addition of PRO 
enhanced the effect of 




increased by an 
additional 36% with the 
addition of PRO 
The addition of PRO to 
a CHO supplement 
enhanced endurance 
cycling performance 
above that which 
occurred with a CHO 
supplement only. 
Burke, Hawley, 

















cyclists and triathletes 
-Individualised meal 
plans based on BW 
given 72 h before the 
trial 
-CHO-loading trial  
(9 g.kg-1) vs.  
PLA controlled 
moderate-CHO diet  
(6 g.kg-1)  
 
-2 x 100 km TT on 
separate occasions, 
interspersed with 4 x 4 
km and 5 x 1 km sprints 
-Time to complete the 
TTs or the average 
PO during the TTs did 
not differ between the 
trials 
 
CHO-loading did not 
provide an ergogenic 
effect on endurance 
cycling performance. 
 





Table 2.1 (continued): Summary of experimental studies that assessed the ergogenic effects of carbohydrates only; and a combination of carbohydrates  and 







not explained,  
the investigators 








-6.4% CHO rinse 
solution vs. PLA rinse 
solution 
(5 seconds rinse and 
spit) 
-1-h TT -CHO rinse trial 
significantly improved 
performance:  
CHO: 59.57 min vs. 
PLA: 61.37 min  
(p = 0.011) 
-There was also a 
significant increase in 
PO in the CHO trial 
compared to the PLA 
trial (p = 0.003) 
A CHO mouth rinse 
has an ergogenic 
effect. The 
mechanism 
responsible for the 
improvement 
performance may 
involve an increase in 
central drive or 
motivation rather 
than a metabolic 
cause. 
Temesi, Johnson, 
Raymond, Burdon & 
O’Connor
(97) 
A systematic review 
with meta-analysis,  
of single and double-
blinded, randomised, 
placebo-controlled, 




50 studies were 
included that met the 
review criteria 
Abled bodied male 
and female 
participants 
-CHO ingestion (not 
exceeding 8% and 
between 30 g/h and 
80 g/h during 
exercise) vs. PLA (the 
PLA was required to 
be closely matched to 
the CHO treatment 
for taste, sweetness, 
colour, and/or 
texture)  
-Cycling protocols of 
≥1 h evaluated via:  
1)TT: measuring time 
to complete a 
predetermined 
distance or 
amount of work;  
2)TT: measuring 
distance completed 





by a TT;  
4)TTF: measured at a 
predetermined 
exercise intensity, 








2.0% with CHO 
3)A mean 
performance 









of 54.2% with CHO 
The ingestion of CHO 
during endurance 
exercise of at least 1 
h improves 
performance. 






Table 2.1 (continued): Summary of experimental studies that assessed the ergogenic effects of carbohydrates only; and a combination of carbohydrates 
protein/electrolytes/fat on cycling performance. 
Pritchett, Bishop, 















Regional level cyclists 
and triathletes 
-Participants were 
given the recovery 
drinks: CHO-PRO 
(CHOC milk) or 
CHO beverage 
immediately after the 
first exercise session, 
and again 2 h into the 
recovery period 
-The beverages were 
iso-caloric 
-2 trials: the first 
exercise bout 




received either a CHO 
beverage or CHOC 
milk  
-Participants returned 
to the laboratory 15 h 
to 18 h later, and 
completed a ride to 
fatigue at 85% VO2max 
-There was no 
significant difference 
between trials in TTF 
CHO or CHO-PRO 
(CHOC milk) ingestion 
provided no 






successive work outs. 
Ivy, Goforth, Damon, 










LOE: II  
7 participants 
(males) 
Trained cyclists -Participants either 
received a CHO-PRO 
supplement or a high 
CHO supplement or a 
low CHO supplement 
10 min after exercise 
and again at 2 h post 
exercise 
-3 trials: 2 h of cycling 
at 65% to 75% VO2max, 
followed by 2 min 
sprints at maximum 
effort for 30 min 
-After 4 h of recovery, 
muscle glycogen was 
significantly greater 
for the CHO-PRO trial 
(p = 0.004) and high 
CHO trial (p = 0.013) 
Endurance 
performance was not 
assessed; however a 
CHO-PRO supplement 
was more effective in 
the restoration of 
muscle glycogen than 
a high CHO 
supplement. 











Trained cyclists -3 recovery drinks: 
given immediately 
post glycogen-






-3 trials: a glycogen-
depleting trial, a 4 h 
recovery period, and 
a cycle to fatigue at 
70% VO2max 
-Participants cycled 
51% and 43% longer 
after ingesting CHO-
PRO drink (CHOC 
milk) than after 
ingesting a CHO drink 
(p = 0.01) and a fluid 

















Table2.1 (continued): Summary of experimental studies that assessed the ergogenic effects of carbohydrates only; and a combination of carbohydrates 
protein/electrolytes/fat on cycling performance. 











Trained cyclists -CHO only trial (7.3%) 
vs. CHO-PRO trial 
(7.3%; 1.8%) beverages 
consumed every 15 min 
during trial and  
10 ml.kg-1 after exercise 
-Ride 1: 75% VO2max to 
fatigue, 12 h to 15 h 
later,  
-Ride 2: cycle to fatigue 
at 85% VO2max 
-Ride 1: participants 
rode 29% longer with 
the CHO-PRO beverage 
(p < 0.05) than with the 
CHO only beverage 
-Ride 2: participants 
rode 40% longer with 
CHO-PRO compared to 
CHO only beverage 
A CHO beverage with 
the addition of PRO 
produces significant 




Davis, Lamb, Pate, 











Well trained cyclists -PLA drink vs. low CHO-
electrolyte (2.5%) drink 
vs. moderate CHO-
electrolyte (6.0%) drink 
(first drink 15 min into 
exercise, then every 20 
min during exercise) 
-Ride 1: 2 h cycling at 
75% VO2max, then 30 
min rest 
-Ride 2: 30 min cycle at 
75% VO2max 
-Ride 2 was performed 
faster with the 
moderate CHO-
electrolyte drink 
compared to the PLA (p 
= 0.02) 
A CHO-electrolyte drink 












cyclists and triathletes 
-250 ml every 15 min of 
exercise of either PLA 
vs. CHO drink (6.0%) vs. 
CHO-MCT drink (6.0%; 
4.2%) 
-100 km TT  -When participants 
consumed either of the 
two CHO containing 
drinks (CHO or CHO-
MCT), times to 
complete the TT were 
reduced (p < 0.05) by 
7% and 5% 
respectively, compared 
with PLA  
(CHO: 166 min vs. 
CHO-MCT:169 min vs. 
PLA: 178 min) 
CHO ingestion 
during exercise 
improves 100 km TT 
performance compared 
with PLA, but the 
addition of MCT to a 
CHO beverage does not 


















-2 weeks high fat diet 
vs. 2 weeks high CHO 
diet 
-30 s Wingate test, 30 
min rest, followed by a 
cycle to fatigue at 90 % 
VO2max (HIE) followed 
by a cycle at 60% 
VO2max (MIE) 
-No difference in HIE 
-TTF was longer in the 
subsequent MIE in the 
high fat diet vs. high 
CHO diet (79.7 min vs. 
42.5 min; p < 0.01) 
There is an ergogenic 
effect on endurance 
performance in MIE 
following a 2 week 
adaption to a high fat 
diet. 
KEY: CHO: carbohydrate; PRO: protein; min: minutes; BW: body weight; VO2max: maximum aerobic capacity; TTF: time-to-fatigue; PLA: placebo; h: hours; MCT: medium 





Carbohydrates can be considered an effective nutritional ergogenic aid for endurance cycling 
performance. Carbohydrate ingestion delays the onset of fatigue during prolonged cycling (75,92,95,97). 
Beneficial effects have been shown when consuming CHO three to six hours before an event, and 
when ingesting 60 g.h-1 to 70 g.h-1 during exercise lasting longer than 90 minutes (72,76,78,79). The 
ergogenic potential is not affected by the form in which CHO are ingested (80). Both combinations of 
a CHO-electrolyte beverage and a CHO-protein beverage enhance muscle recovery post training 
and/or competition (72,81,88-90,95,99-102). An improved recovery rate will allow the capacity for larger 
training volumes, which provide the stimulus for enhanced physical adaptations that can further 
improve cycling performance (31).  
 
2.8.1.2 Protein and Amino acids 
One of the most popular and heavily marketed supplements today is PRO (103,104). Athletes 
supplement with PRO and amino acids with the hope to increase muscle mass and strength, and 
thus enhance performance (42,104-106). 
There are 20 amino acids, 11 of which are synthesized in the body and nine of which have to be 
obtained through the diet (essential amino acids) (105). Three essential amino acids; leucine, 
isoleucine and valine are known as branched chained amino acids (BCAA), due to their structural 
similarity (105). These BCAA have been popular in recent research with regards to their ability to 
enhance performance, though their benefit remains controversial (105). 
 
2.8.1.2.1 Physiological basis for PRO and amino acid use 
Branched chained amino acid availability has been hypothesized to play a role in central fatigue (106). 
During prolonged exercise, and specifically in endurance athletes, BCAA metabolism is activated. As 
exercise continues, there is a decline in plasma BCAA concentration and an increase in free fatty acid 
concentration. The increase in free fatty acids displaces tryptophan from albumin. The displaced and 
now free tryptophan readily crosses the blood brain barrier, and forms serotonin, which depresses 
the CNS and increases the perception of fatigue (95,104-106). As a result of this proposed mechanism of 
action on the CNS, research supplementing with BCAAs to increase time to fatigue, and thus 
endurance performance was undertaken. Research results are equivocal and BCAA supplementation 




The RDA for PRO is 0.8 g.kg-1.day for sedentary adults, with the requirements of athletes being 
greater at 1.2 g.kg-1.day to 1.8 g.kg-1.day for resistance and endurance sports alike (103-105). The 
additional needs for PRO are easily obtainable in the diet and thus supplementation maybe 
considered unnecessary. Athletes often ingest higher amounts of PRO than that of the RDA, and 
supplementation allows for minimal change to their diet with increased protein intake, but without 
increased fat ingestion (42,103). 
 
2.8.1.2.2 Current evidence for the effects of PRO on cycling performance 
Recently the combination of a CHO and PRO supplement has been shown to improve performance 
and recovery over CHO supplementation alone (81,88-90,95,99-102). Saunders et al(81) investigated the 
effects of a CHO-PRO beverage on cycling endurance. Cyclists (n=15) cycled to fatigue at 75% VO2max, 
had a 12 hour to 15 hour recovery period and then cycled at 85% VO2max until exhaustion.  
Both beverages were matched for CHO concentration (7.3%), with one of the CHO beverages having 
the addition of PRO. The beverages however were not matched for calorie content. Time-to-fatigue 
in the CHO-PRO trial was significantly increased (p < 0.05) during the first test (29% longer), and 
during the second test (40% longer) compared to the CHO-only trial (81). The increase from 29% to 
40% also suggests that the addition of PRO may enhance muscle recovery. Whether the higher 
calorie content in the PRO drink or the PRO itself caused an increase in performance, was unclear 
and remains unclear in current literature. Ivy et al(95) simulated a competitive cycling event, which 
lasted 180 minutes of varying intensity (45% to 75% VO2max and then 85% VO2max), also found that 
cyclists ingesting a CHO-PRO beverage were able to sustain exercise at 85% VO2max for 36% longer 
than when ingesting a CHO-only beverage. These two studies showed positive effects of the co-
ingestion of CHO and PRO for enhancing endurance performance and recovery, over CHO ingestion 
alone. However the major flaw of these studies is that, the calorie content of the beverages were 
not matched. With regards to the type of PRO used to date all studies which have shown enhanced 
endurance performance in cyclists, have used whey PRO or casein hydrolysate (81,95,107). 
The co-ingestion of CHO and PRO was also found to enhance recovery in many other studies 
(81,88,95,101,105). Zawadski et al(108) demonstrated that the co-ingestion of CHO and PRO was more 
effective in the replenishment of muscle glycogen in the four hours immediately after exercise, than 
CHO alone. The authors hypothesised that an increase in muscle glycogen storage would be due to 
an increase in the plasma insulin response, however, this was not found to be the case. Other 
studies however, have proposed this to be the mechanism by which the addition of PRO acts, as 




Thus it is thought that, if the effect of the insulin spike can be increased with the co-ingestion of CHO 
and PRO, compared to CHO alone, then recovery should be increased. A quicker recovery time will 
allow a quicker return to training at the required intensity or competition at full capacity (88). On the 
other hand, there are studies that have found no effect of the co-ingestion of CHO and PRO on 
muscle glycogen synthase during early recovery (100). 
The co-ingestion of CHO and PRO remains controversial as a high CHO intake post exercise has 
shown to enhance recovery effectively. It is suggested that co-ingestion only works if CHO intake is 
<1.2 g.kg-1.h-1 to achieve a maximal glycogen re-synthesis rate (72,100). There are very few studies 
demonstrating an ergogenic effect of PRO and amino acid supplementation on endurance cycling 
performance (42,104-106). Branched chained amino acids supplementation also currently lacks 
substantial scientific proof as an effective ergogenic aid. The additional needs of PRO for an athlete 
are easily obtainable in the diet, and thus supplementation is considered unnecessary. 
 
2.8.1.3 Creatine 
Creatine was first identified in 1835, however it was not until the 1990s that creatine 
supplementation to enhance performance became popular (11,109,110). The popularity stemmed from a 
study carried out by Harris et al(111) which was the first study to investigate the effects of creatine 
supplementation. The authors demonstrated that the ingestion of small amounts of creatine 
supplement (less than 1 g) had insignificant effects on the body, whereas higher amounts (5 g) 
increased skeletal muscle creatine by 15%.  
 
2.8.1.3.1 Physiological basis for creatine use 
Creatine is an amino acid derivative, which is synthesized in the liver, pancreas and kidney (11,110,112-
114). The RDA is 2 g, half of which is provided by endogenous synthesis and the rest via diet (20,42,112-
114). Of the total creatine in the body, 95% is stored in skeletal muscle, two thirds of which is stored 
as phosphocreatine, and the remaining third as free creatine (11,20,42,112-114). Phosphocreatine is 
primarily responsible for the re-synthesis of ATP from adenosine di-phosphate during anaerobic 
activity (11,20,42,112-114). The amount of ATP re-synthesized is dependent on the availability of 
phosphocreatine in the muscle (110). Short-duration, high-intensity exercise such as sprinting and 
weightlifting rely profoundly on the phosphocreatine-ATP energy system (110). During exercise 
phosphocreatine is depleted relatively quickly, re-synthesis of ATP thus decreases which results in an 




Creatine supplementation is thus proposed to be ergogenic as it has the potential to increase ATP 
production (11). The proposed mechanism states that an increase in creatine will increase 
phosphocreatine stores in skeletal muscle. This will lead to an increased rate of ATP regeneration, 
increasing maximal energy production (20). 
 
2.8.1.3.2 Strategies for creatine use 
Generally, the ergogenic dosage that has been consistent through the literature follows a loading 
protocol. This consists of 20 g.day to 30 g.day for five to seven days, followed by a maintenance dose 
of 2 g.day to 3 g.day over a longer period (11,20,42,112-114). There are many forms of creatine available, 
but most studies have used and have found beneficial effects with creatine monohydrate (11,20,42,112-
114).  Recently, the addition of CHO and a combination of CHO and PRO ingestion has shown to 
augment muscle retention of creatine (113). 
 
2.8.1.3.3 Current evidence for the effects of creatine on cycling performance 
Creatine supplementation has been extensively studied as a nutritional ergogenic aid for athletes 
and controversy still surrounds its use (113). Literature documents mixed results, which is thought to 
be due to athletes/participants having baseline values at creatine saturation levels, and are 
therefore “non-responders” (20). The creatine level prior to supplementation is the most important 
factor governing the increase in skeletal muscle creatine post supplementation (2,11,20,42,52,110,113,115). 
Ziegenfuss et al(116) conducted a double-blind placebo-controlled study, which assessed the effects of 
three days of creatine supplementation on cycling power output (n=20). The cycling protocol 
involved six ten second sprints at maximal effort pre-creatine/placebo supplementation and post-
creatine/placebo supplementation. Creatine supplementation resulted in a significant (p < 0.04) 
increase in total work during the first sprint and increased peak power during sprints two to six. 
The majority of the studies have concluded ergogenic effects of creatine in short-duration, high-
intensity exercise lasting less than 30 seconds (11,20,42,110,112-114,116,117). The one proposed mechanism of 
action is that creatine supplementation improves the rate of re-synthesis of phosphocreatine 
allowing a for faster recovery time. This translates into an increased capacity to do work during 
training, and therefore improved training adaptations and cycling performance (42,113). There are 
however, a few recent studies that have contradicted the ergogenic effects of creatine 




With regards to sports performance and creatine use, there is less evidence to support creatine 
supplementation on endurance performance, and in general activities lasting longer than three 
minutes (115). Only a few papers since the year 2000 have addressed the ergogenic effects that 
creatine might have on submaximal endurance performance (115). 
Rico-Sanz and Marco(121) in a randomized placebo-controlled study, assessed the effects of creatine 
supplementation on endurance cycling performance. The exercise protocol consisted of bouts of 
exercise at varying intensities. Participants were all highly trained cyclists (n=14). The creatine group 
increased time to fatigue from 29.9 minutes to 36.5 minutes, while there were no changes seen in 
the placebo group. From their results, the authors concluded that there was an ergogenic effect of 
creatine supplementation on endurance cycling performance. Table 2.2 provides a summary of 
relevant experimental studies, adapted from Bemben and Lamont(115) that assessed the ergogenic 
effects of creatine in both short term high intensity cycling and endurance cycling, from the year 
2000 onwards (116-122). 
 
2.8.1.3.4 Health concerns associated with creatine use 
The side effects of creatine supplementation are mostly based on anecdotal data, with no studies 
proving the documented short term effects of dehydration, cramping, nausea, seizures and 
gastrointestinal discomfort (11,20,42,110,112-114).  The only well researched side effect is an increase in 
weight, which is said to be a result of the osmotic effect of creatine (11,20,42,110,112-114). No studies to 
date have published results on the long term effect of creatine supplementation, and here warrants 
caution to its long term use (11,20,42,110,112-114). 
Creatine can be considered an effective nutritional ergogenic aid for short duration, high intensity 
exercise such as weight-lifting. Creatine however is not banned by the IOC as it is readily available in 
food sources such as fish and meat (11,20,42,110,112-114). Results on the effect of creatine 
supplementation on short duration high intensity cycling, such as time trials, are conflicting. More 
research specifically looking at the effect of creatine on cycling performance is needed. There are 
very few studies demonstrating an ergogenic effect of creatine supplementation on endurance 
cycling performance (121). This could be anticipated when considering the proposed mechanism of 
action of creatine. Creatine can therefore not be advocated as an effective ergogenic aid for 
endurance cycling due to the lack of evidence.  At present, short term supplementation is regarded 
as safe when the recommended regimes are followed, however the long term effects are unknown 






















-Creatine group (n=10): 
0.35 g.kg-1 FFM  for 3 
days vs. PLA  group 
(n=10): 0.35 g 
maltodextrin.kg-1 FFM 
for 3 days 
-6 x 10 s sprints at 
maximal effort, with 60 
s recovery between 
sprints (pre-trial and 




resulted in an increase 
in total work during the 
first sprint (p < 0.04), 
and an increase in peak 
power during sprints 2 
to 6 
There is an ergogenic 
effect of 3 days of 
creatine 
supplementation on 
short duration HI 
cycling. 











Physically active -Creatine group (n=9) 
20 g/day vs. PLA (n=10) 
20 g sucrose & 
maltodextrin/day for 6 
days  
-3 x Wingate cycle tests -No significant 
difference in mean PO 
-No change in peak 
power for both groups 
No ergogenic effect of 
creatine 
supplementation on 














-Group 1: 14 (older) 
sedentary 
-Group 2: 14 trained 
cyclists 
-Group 3: 14 (young) 
sedentary 
-Creatine group (n=7 
for each participant 
group 1-3) 15 g/day  vs. 
PLA group (n=7 for 
each participant group 
1-3) for 5 days  
 
-5 x maximal 10 s 
sprints with 60 s 
recovery between each 
sprint 
-Maximal PO was 
significantly increased 
in group 1 and group 3 
(the sedentary groups) 
This suggests that 
creatine has an 
ergogenic effect in 
short duration HI 
cycling. However, an 
effect was only seen in 
previously untrained 
older and younger 
populations, but not in 
previously trained 
individuals. 
Jones, Carter, Pringle  
& Campbell
(122) 




(males and females) 
Young and active -Creatine group (n=5) 
20 g/day for 5 days 
followed by 5 g/day 




(no time frame given) 




There was no ergogenic 









Table 2.2 (continued): Summary of experimental studies that assessed the ergogenic effects of creatine on cycling performance from 2000 onwards (ada pted 












Highly trained cyclists -Creatine group (n=7) 
20 g/day vs. PLA group 
(n=7) for 5 days 
-Cycling at intensities 
equal to 30% and 90% 
of peak power until 
fatigue 
-Participants cycled for 
a total of 5 x 3 min 
stages (alternating 30% 
and 90% of maximal 
PO) 
-Creatine group 
increased TTF from 
29.9 min to 36.5 min, 
while there were no 
changes observed in 
the PLA group 
There is an ergogenic 















Active  and young  
 
-Creatine group (n=4) 2 
x 15 g vs. PLA group 
(n=4) on day 1 of 
testing 
-Same protocol done 
14 days later 
-80 min sprint cycling 
task consisting of 10 
sets of multiple 6 s 
sprints 
-recovery varied from 
24 s to 84 s 
-There was no 
significant changes in 
cycling performance 
between the two 
groups 
There is no ergogenic 
effect of creatine 
supplementation on 










Active triathletes -Creatine group (n=8) 
20 g/day vs. PLA grp 
(n=8) for 20 days 
-4 x 20 s ‘all-out’ sprints 
with a 20 s recovery 
period 
-There was no 
significant difference in 
performance between 
the two groups 
There is no ergogenic 









Electrolytes are consumed by athletes and are marketed to athletes before, during and after 
exercises for a number of reasons (123). Recommendations put forward by the American College of 
Sports Medicine (ACSM) and IOC Consensus Document on fluid intake during exercise, advocates 
drinking sufficient amounts of fluid to replace the fluid lost during exercise through sweat ,to 
maintain euhydration (normal total body water) (123,124).  This guideline proposes that deficits in total 
body water (hypo-hydration) have detrimental effects on aerobic performance due to increased 
cardiovascular and thermal strain (123,125). The guideline also promotes sodium ingestion during 
exercise to replace the sodium lost through sweat during exercise (123,124). 
The ASCM and IOC guidelines are based on early studies, which found that when electrolytes were 
ingested during and/or after exercise, plasma volumes were well-maintained (125). This contributed to 
the addition of sodium in drinks and the marketing of sports drinks containing electrolytes to 
improve performance and aid recovery (125). Research investigating the mechanism of action, as a 
result of the addition of electrolytes to sports drinks (mainly sodium, potassium and magnesium) has 
not been identified. It is also unable to determine if one drink is superior to another based on the 
different kinds and amounts of electrolytes in the drinks (125,126). There is no documented evidence 
for enhanced performance or recovery when potassium and magnesium are added to sports 
beverages, and the results for the addition of sodium to sports beverages are conflicting (124,125). 
These guidelines have recently caused much debate within the literature. Noakes(124) advocates that 
fluid consumption both during and post exercise should be “ad libitum”, to thirst. He highlights the 
fact that the ACSM guidelines are not based on controlled, prospective clinical trials, and that all 
variables of exercise; intensity; duration; environmental conditions and the nature of the exercise 
have to be considered. Weight loss for example (due to water loss and slight dehydration) during 
cycling has an ergogenic effect as it improves cycling efficiency when climbing mountainous ascents 
(124). The promotion of fluid consumption “ad libitum” further reduces the risk of athletes over-
drinking and inducing hyponatraemic encephalopathy (124). It was concluded at the 2005 
International Consensus Conference on Exercise-Associated Hyponatraemia, that with the increasing 
consumption of salt (sodium) in the diet, above the RDA, that only during prolonged events (226 km 
Ironman), in extreme environmental conditions (heat and humidity), may a sodium deficit, as a 






The literature indicates somewhat conflicting results regarding this matter, with two schools of 
thought on fluid replacement and the benefits on aerobic performance. The evidence for the 
consumption of electrolytes to enhance performance and improve recovery is lacking, and there is 
no evidence supporting the use of electrolytes for the specific purpose of enhancing cycling 
performance. It may be further inferred that the addition of electrolytes is unnecessary in athletes 
who are consuming a well-balanced diet (126). 
 
2.8.2 Pharmacological aids 
Caffeine, vitamin supplementation, NSAIDs, analgesics, cortisone and HGH will be discussed under 
pharmacological ergogenic aids. These ergogenic aids will be reviewed considering their 
physiological basis for use, strategies for use in cycling, current evidence for the effects of their use 
on cycling performance and the health risks associated with their use.  
 
2.8.2.1 Caffeine 
Caffeine is a methyl xanthine that occurs naturally in coffee beans, tea leaves, cocoa, and plant 
species (127). Food sources containing caffeine are relatively accessible, inexpensive and socially 
accepted, thus it is thought to be the most commonly used “drug” worldwide (128,129). Sources include 
coffee, tea, energy drinks, soft drinks and chocolate (127,128). In 1895, synthetic production of caffeine 
began (128). Nowadays a variety of over-the-counter medications and prescription drugs also contain 
caffeine, for example, NSAIDs, analgesics, diuretics and simple cold and flu remedies (128). Caffeine is 
classified as a non-essential nutrient but when large dosages are used, it may have pharmacological 
effects (39,128). There is limited literature on the use of caffeine in sports as obtaining documented 
statistics on the frequency of use is difficult (130).  
 
2.8.2.1.1 Physiological basis for caffeine use 
There is conflicting evidence regarding the exact mechanism of action of caffeine (79,103). The release 
of adrenalin (epinephrine), which increases mobilization of free fatty acids from adipose tissue, 
increasing fat oxidation, thus sparing muscle glycogen and extending exercise time, is one proposed 
mechanism. Costill et al(131) demonstrated that after the ingestion of caffeine cyclists were able to 




When the authors tested the participants after the exercise protocol, a significant increase in lipid 
metabolism was found. However, many studies have not supported this proposed mechanism of 
increased fatty acids and therefore this notion is not widely accepted.  
Caffeine is an ATP antagonist; thus it acts on most, if not all tissues, including the CNS. Another 
proposed mechanism of action is that the arousal of the CNS causes increased mental alertness and 
decreased perception of fatigue (20,39,42,79,127,128,130,132,133). Recent literature has supported the 
proposed ATP mechanism through stimulation of the CNS. For example, Doherty et al(134) 
investigated the effects of caffeine in a three-minute preload test in male cyclists (n=11). The cyclists 
were given 5 mg.kg-1 one hour before exercise, which consisted of two minutes of cycling at 
maximum power output at a constant rate, followed by one minute of “all-out” effort. All cyclists 
post preload had a decreased rate of perceived exertion at 30 seconds, 60 seconds and 120 seconds 
respectively. There was also an increase in mean power output during the last minute of the test. 
The authors suggested that caffeine can alter the perception of effort and thus extend and improve 
performance.  
The third proposed mechanism of action is that caffeine causes alterations in the release and uptake 
of calcium from the sarcoplasmic reticulum, thus acting directly on skeletal muscle, increasing its 
contractility (20,39,42,79,127,128,130,132,133). This mechanism is vaguely described in the literature and thus 
the exact action of caffeine in the body remains elusive. 
 
2.8.2.1.2 Strategies for caffeine use 
Popular methods used in studies to administer caffeine include caffeine capsules or caffeine 
dissolved in solution (133). Other methods of administration include suppositories, intramuscular 
injections and venous infusions (130). Ergogenic studies have used dosages between 2 mg.kg-1 and 9 
mg.kg-1 (79). A double-blind cross-over study by Kovacs et al(135) investigated the effects of three 
different dosages of caffeine. They used male, trained cyclists and triathletes (n=15) in a one-hour 
cycling time trial. The dosages of caffeine used were 2.1 mg.kg-1, 3.2 mg.kg-1 and 4.5 mg.kg-1 
respectively. Even with the lowest dose of caffeine, an increase in performance was observed, with 
the highest dose showing no more benefit compared to the middle dose (135). A dose of 3 mg.kg-1 has 
proved to be effective in increasing endurance, whilst a dose between 3 mg.kg-1 and 6 mg.kg-1 is 




Dosages exceeding 9 mg.kg-1 risk approaching the IOC disqualification limit, which is determined by a 
urine concentration of 12 ug.ml (42,79,130,136). The literature shows that the beneficial effects of 
caffeine on performance can be met at doses that are well below the IOC urinary threshold. An 
athlete’s habitual use of caffeine may alter the dose of caffeine needed for an ergogenic effect to be 
observed (133). Although the ergogenic effects continue to be demonstrated, caffeine was removed 
from the WADA prohibited list in 2004. However, it remains in the Monitoring Programme to closely 
observe its potential misuse in sport (133). 
Readily available sources of caffeine include coffee, tea and soft drinks; however, these are weaker 
sources compared to concentrated caffeine (i.e. in the capsule form) (130). Consuming coffee to 
obtain an ergogenic effect is not the optimal method (42). To exceed the IOC threshold an athlete 
would have to drink six to eight cups of very strong coffee an hour before exercise (42). Caffeine is 
suggested to be consumed one hour before commencing exercise; however, timing of ingestion has 
shown not to be an important factor (133). Ganio et al(133) conducted an extensive systematic review 
and subsequently advised athletes to abstain from habitual caffeine ingestion up to seven days 
before a competition, to maximise the ergogenic effect. 
 
2.8.2.1.3 Current evidence for the effects of caffeine on cycling performance 
A study investigating the effects of caffeine ingestion during short-duration exercise (15 seconds 
cycling) failed to show an improvement in maximum power output, work and fatigue indices (108). 
This finding was later supported by Greer et al(137). The authors also failed to demonstrate an 
improvement in short-duration cycling performance with caffeine ingestion (137). However, recent 
studies have found improved performance after caffeine ingestion in short-duration high-intensity 
exercise (30,61). Wiles et al(138) examined the effects of caffeine ingestion in trained cyclists (n=8) in a 1 
km time trial. The participants were given 5 mg.kg-1 of caffeine one hour before the time trial. 
Results showed that peak power output improved by 75.5 W and performance time by 2.3 seconds. 





Caffeine has also shown to be effective in enhancing endurance in aerobic activities lasting 30 
minutes and longer (131,132,134-136,139). Ivy et al(92) showed a 7.3% greater total power output in a two-
hour cycle test after the ingestion of caffeine. Although the literature shows the ergogenic effect of 
caffeine ingestion on endurance exercise lasting 30 minutes and longer, there are very few studies 
that investigate the effect of caffeine ingestion on ultra-endurance cycling (lasting more than six 
hours or over 100 km). More research specific to ultra-endurance performance effects is necessary. 
The effects of caffeine on performance have been well-established in the literature (138). However, 
the results are variable in terms of the degree of improvements (133). The variability observed may be 
a result of different exercise procedures, the training statuses of the participants, as well as the use 
of different dosages of caffeine (138). 
 
2.8.2.1.4 Health concerns associated with caffeine use 
Compared to the many other ergogenic “drugs” available, the side effects of caffeine are considered 
minimal (103,127). Documented side effects may include irritability, anxiety, restlessness, headaches 
and gastrointestinal disturbances (79,103). The CNS side effects may result in dependency and 
withdrawal (79,103).  The diuretic side effect of caffeine, which may be seen as a problem in endurance 
events, is eliminated by exercise (20). 
Ergogenic effects of caffeine may be beneficial for increasing endurance in training and in 
competition, as well as improving power output and performance in short-duration high-intensity 
exercise, for example, in a time trial (130). There is good evidence to support the ergogenic effects of 
caffeine with the recommended dosages. Table 2.3 provides a summary of relevant experimental 
studies that assessed the ergogenic effects of caffeine ingestion, in both short-term high-intensity 
cycling and endurance cycling (92,131,132,134-141). It is important to note that the majority of these 
studies have been carried out in controlled laboratory environments and not during actual 
competitions or training sessions.  
In summary, caffeine is an effective ergogenic aid for increasing endurance performance, as well as 
improving power output and performance in short-duration high-intensity cycling (98,136-
138,140,141,142,146). Concentrated caffeine capsules and caffeine dissolved in solution are the most 
popular methods of ingestion and means in which to obtain an ergogenic effect (139). The 
recommended dose to produce an ergogenic effect, which will still be below the threshold of the 




Table 2.3: Summary of experimental studies that assessed the ergogenic effects of caffeine on cycling performance.  
Article Study design Sample size (n) Participants Intervention Exercise protocol Results Conclusion 




blind, cross over design 
 
LOE: I 
9 participants  
(males) 
Recreationally active  -6 mg.kg-1 caffeine 
tablets vs. PLA tablets, 
1 h before exercise 
-4 x 30 s Wingate 
sprints, with 4 min rest 
between each sprint 
-No effect on peak PO, 
average power or rate 
of power loss 
-Total PO was the same 
for both tests 
No ergogenic effect of 
caffeine observed on 
repeated bouts of short 
duration HI cycling. 










Trained cyclists -5 mg.kg-1 caffeine 
dissolved in a 250 ml 
lemon solution vs. 250 
ml PLA lemon solution 
vs. C (nothing), 1 h 
before exercise 
-1 km TT -There was an 
improvement in cycling 
performance with 
caffeine ingestion 
compared to PLA and C 
(caffeine vs. PLA vs. 
C):71.1; 73.4; 73.3 min 
(p = 0.002) 
-Peak PO (p = 0.027) 
and average power (p = 
0.007) also increased 
with caffeine compared 
to PLA and C 
There is an ergogenic 
effect of caffeine on 
performance time in 
short duration HI 
exercise. 








(7 males and 2 females) 
 
Trained cyclists -250 mg of caffeine 1 h 
before exercise, 
followed by the 
ingestion of an 
additional 250 mg fed 
at 15 min intervals over 
the first 90 min of the 
exercise vs. PLA 
-2-h isokinetic cycling 
at 80% VO2max 
-PO increased by 7.3% 
with caffeine ingestion 
compared to PLA 
-The caffeine group 
cycled an average of 
90.2 min compared to 
75.5 min in the PLA 
group 
There is an ergogenic 
effect of caffeine on 
endurance cycling 
performance and PO. 
Cox et al
(136) Blinded, placebo-






Highly trained cyclists 
and triathletes 
-6 mg.kg-1 caffeine 1 h 
before (Pre-caf) 
-6 x 1 mg.kg-1  caffeine 
every 20 min (Dur-caf);  
-10 ml.kg–1 Coca-Cola in 
the last 50 min (~1 to 
1.5 mg.kg-1 caffeine vs 
PLA 
-2-h of steady state 
cycling at 70% VO2max 
followed by a 30 min TT 
(CHO fed TT) 
-Improvements in TT 
performance compared 
to PLA were as follows:  
Pre-caf: 3.4% (p = 0.04); 
Dur-caf: 3.1% and 
Coca-Cola: 3.1% 
 
There is an ergogenic 
effect of caffeine on TT 
performance 
at the end of a 2 h 
endurance cycle. 




Table 2.3 (continued): Summary of experimental studies that assessed the ergogenic effects of caffeine on  cycling performance. 











Trained cyclists -1 mg.kg–1, 2 mg.kg–1, 
or 3 mg.kg–1, 1 h before 
exercise vs. PLA 
 
-15 min cycle at 80% 
VO2max, then 4 min of 
active recovery, 
followed by a 15 min  
TT  
-Compared with PLA, 
caffeine doses of 2 
mg.kg-1 and 3 mg.kg-1 
increased performance 
by 4% (p = 0 .02) and 
3% respectively 
There is an ergogenic 
effect of caffeine on TT 
performance.  
(Although the effects 
were ergogenic they 
varied considerably in 
magnitude among 
individual cyclists.) 











Trained cyclists -2.1 mg.kg–1, 3.2 mg.kg1 
and 4.5 mg.kg–1 doses 
vs. PLA; 75 min pre-
exercise and at 20 and 
40 min during TT 
-Cycling TT of about ~1-
h; CHO-fed during 
cycling 
-Compared with PLA 
and the lowest dose of 
caffeine (2.1 mg.kg-1), 
doses of 3.2 mg.kg-1 
and 4.5 mg.kg-1 
increased TT 
performance and work 
output (p < 0.001) 
There is an ergogenic 
effect of caffeine, in 
relatively low doses, 
when added to a CHO–
electrolyte drink in a 1-
h TT. 
 











Trained cyclists -5 mg.kg–1 caffeine 
diluted in 200 ml of 
artificially sweetened 
water vs. PLA 200 ml of 
artificially sweetened 
water, 1 h before 
exercise 
-2 min cycling at 
maximal PO followed 
by a final 1 min ‘all-out’ 
effort, during which as 
much distance as 
possible was to be 
covered 
-RPE (6 to 20 Borg 
scale) were lower in the 
caffeine trial compared 
to PLA (p < 0.05) 
-The average PO during 
the ‘all-out’ effort was 
increased following 
caffeine ingestion 
compared with PLA (p = 
0.05) 
There is an ergogenic 
effect of caffeine, in 
moderate doses, on 
performance time in 
short duration HI 
exercise. 
Beck, Housh, Schmidt, 











Resistance trained -201 mg of caffeine 
tablet (n=17) vs. PLA 
tablet (n=20), 1 h 
before exercise 
-2 x Wingate anaerobic 
tests 
-The caffeine tablet had 
no effect on peak PO or 
average PO 
 
No ergogenic effect of 
caffeine observed in 
short duration HI 
exercise. 






Table 2.3 (continued): Summary of experimental studies that assessed the ergogenic effects of caffeine on cycling performance. 
Bell & Mc Lellan
(132) Randomised, double-




(15 males and 6 
females) (13 caffeine 
users and 8 non-users) 
Regularly active  -5 mg.kg–1of caffeine 
vs. PLA   
(once per week at 
either 1, 3, or 6 h after 
ingestion) 
-6 randomised exercise 
rides to exhaustion at 
80% VO2max 
-Caffeine significantly  
(p < 0.05) improved TTF 
from 24.0 min during 
the PLA trials to 28.8 
min in both users and 
non-users 
-This improvement was 
greater for the non-
users 
-The effect of caffeine 
in the non-users was 
still evident 6 h after 
ingestion  
There is an ergogenic 




magnitude of the 
ergogenic effect of 
caffeine is greater in 
non-users compared 
with users. 








(7 males and 2 females) 
Competitive cyclists -330 mg of coffee 
(caffeine) vs. decaf 
coffee (PLA) 1 h before 
exercise 
-Cycling at 80% VO2max 
until exhaustion 
-Caffeine improved 
TTF: 75.5 min during 
the PLA trial to 90.2 
min in the caffeine trial 
There is an ergogenic 









(6 males and 6 females) 
Trained cyclists -500 ml Red Bull (160 
mg caffeine) vs. 500 ml 
flavoured PLA, 40 min 
before exercise 
-Simulated TT ~1 h 
cycling at 70% VO2max 
-There was a significant 
increase in 
performance (p < 0.01) 
with caffeine compared 
to PLA: 61.5 min 
compared to 64.6 min 
There is an ergogenic 
effect of caffeine on 
endurance exercise 
performance. 




2.8.2.2 Vitamin supplementation 
Vitamins are classified as either water-soluble (Vitamins B and C) or fat-soluble (Vitamins A, D, E and 
K) (11). Water-soluble vitamins are metabolised and excess is excreted in the urine, whereas fat-
soluble vitamins are stored in the liver and metabolised relatively slower, therefore carrying the risk 
of toxicity if large amounts are consumed (11). Athletes often supplement with vitamins with the 
assumption that they can enhance performance (4,11,19,20,64). Huang et al(64) found that the prevalence 
of vitamin supplementation was 65% among elite athletes at the 2000 Sydney Olympics. Cyclists 
demonstrated the highest use of mineral (73%) and nutritional supplementation (100%).  
Popular vitamins include multi-vitamins (consisting mostly of B, A and D), Vitamin C, Vitamin A and 
Vitamin E (11,19,20,64). Vitamin B is proposed to enhance aerobic power by providing enhanced energy 
(20). Vitamin C is an anti-oxidant, which has a number of proposed benefits some of which are based 
on the symptoms of deficiency; decreased immunity, fatigue and weakness (11). Therefore the 
assumed benefits of Vitamin C include enhanced immunity and enhanced aerobic power and thus 
endurance performance (11). Vitamin E is commonly used as it is alleged to decrease the symptoms of 
DOMS (20,42). Currently there is little literature to support supplementation with vitamins, minerals 
and anti-oxidants for athletes following a normal healthy diet (55). Athletes who are on a stringent 
calorie-restricted diet or who are vegan may benefit from vitamin supplementation (20,42,64). The 
ACSM, the American Dietetic Association, and the Canadian Dietetic Association, have all declared 
that athletes do not require vitamin/mineral supplementation if energy intake is sufficient to 
maintain body weight during training or competition (55). 
There is a scarcity of scientific evidence showing benefit of vitamin supplementation on exercise 
performance in endurance athletes (11,20,42,64). Consequently, the intense marketing and promotion of 
vitamin and mineral supplementation surpasses the empirical evidence supporting their use as 






2.8.2.3 Non-steroidal anti-inflammatories, analgesics and cortisone 
2.8.2.3.1 Physiological basis for NSAIDs, analgesics and cortisone use 
The pain relief and anti-inflammatory properties of analgesics and NSAIDs may be seen as an 
appealing modality for cyclists to treat training-related soreness and enhance recovery (15,41). Non-
steroidal anti-inflammatories work by inhibiting the cyclo-oxygenase (COX) enzymes which are 
responsible for synthesising certain modulators of inflammation, specifically prostaglandins (15). 
There are two classes of NSAIDs, which differ according to their inhibition of COX enzymes, either 
COX 1 or COX 2.The COX 2 enzyme has the same pain relieving effects as COX 1, but has a greater 
anti-inflammatory effect (15).  
Analgesics unlike NSAIDs can only reduce pain and not inflammation. The mechanism of action of 
analgesics such as paracetamol is uncertain, however they have demonstrated to act centrally (at 
the CNS) rather than peripherally (at nerve endings) (142). The stronger opioid analgesics (e.g. codeine 
and morphine) are used for both acute and chronic pain. They act on the cerebral opioid receptor 
system, which is involved in setting an individual’s pain threshold as well as controlling pain 
processing (142). 
One of the greatest advances in medicine has been the use of cortisone to suppress inflammation 
(143). Cortisone inhibits the early phase inflammatory reactions as well as the late phase inflammatory 
reactions, and is often used in sport to treat overuse injuries (143).  Since the 1960s, athletes have 
used gluco-corticosteroids (cortisone) to improve performance (144). It is used to ease exercise 
related pain and reduce sensations of tiredness and discomfort (65). Gluco-corticosteroids work by 
increasing gluconeogenesis and the mobilisation of amino acids and fatty acids, thus increasing 
energy production and potentially improving recovery (144). All forms of cortisone are prohibited in 
sport, and a TUE certificate is required if cortisone is needed to treat a diagnosed medical condition 
(144). 
 
2.8.2.3.2 Current evidence for the effects of NSAIDs, analgesics and cortisone use on cycling 
performance 
There is little available literature on the ergogenic effects of NSAIDs and analgesics on sports 
performance in general, and cycling performance specifically. Of the reviewed literature, researchers 
have mainly investigated the effects of NSAIDs on recovery, specifically DOMS after a bout of 
eccentric exercise (15). In cycling, except in some instances of downhill mountain biking, there is very 




Nonetheless, results showed no effect of NSAIDs on muscle soreness or restoration of muscular 
function (15). In fact, Ibuprofen, an over–the-counter anti-inflammatory, blunted the protein 
synthesis response in untrained men after a bout of eccentric exercise (15). Long-term repeated use 
of NSAIDs may therefore negatively affect training adaptions (15,144). 
O’Grady et al(145) examined the effects of diclofenac (NSAID) on objective indices of EIMD in a 
randomized double-blind, placebo-controlled trial (n=54). Diclofenac or a placebo was administered 
twice a day for 27 days. On day 15, participants took part in an exercise protocol of stair climbing to 
induce muscle damage. Muscle samples post-exercise revealed that the diclofenac group had less 
muscle tissue damage than the placebo group (p < 0.002). The authors concluded that NSAIDs can 
significantly reduce objective indices of EIMD. The practicality of what the authors are suggesting: 
pre-administration of NSAIDs to help decrease EIMD, is impossible. The cycling competitive season is 
extended over months, and athletes cannot continue the use of NSAIDs over an entire season. 
Although there is a lack of scientific evidence demonstrating the effectiveness of NSAIDs as an 
ergogenic aid, anecdotal evidence suggests that the prevalence of use is high amongst athletes. At 
the XV Pan-American Games in 2007, 63% of all athletes were reportedly using medication (146). The 
most frequently used type of medication was NSAIDs (146). In-competition use was reported to be 
higher than out-of-competition use (146). The authors proposed that athletes use NSAIDs as ergogenic 
aids to suppress the rate of perceived exertion, therefore prolonging endurance performance (146). 
However, there is a scarcity of sound clinical evidence demonstrating this performance enhancing 
effect of NSAIDs. 
Barlas et al(147) investigated the efficacy of commonly available analgesics on DOMS. Participants 
(n=60) were randomly allocated to one of five experimental groups: control, placebo, aspirin (900 
mg), codeine (60 mg), and paracetamol (1000 mg). DOMS was induced in the elbow flexors through 
a bout of eccentric exercises. There was no evidence of effectiveness in any of the groups, and the 
authors concluded no beneficial effects of analgesic medication in the management of DOMS. Smith 
et al (148) also examined the effect of asprin and acetaminophen (paracetamol) on DOMS after a bout 
of eccentric exercise. There were no significant differences in perception of soreness between the 
groups (asprin, acetaminophen and placebo), and results indicated no effect of these analgesics on 






2.8.2.3.3 Health risks associated with the use of NSAIDs, analgesics and cortisone 
The use of NSAIDs carries the risk of renal, gastrointestinal and cardiovascular health risks, and are 
recommended to be used with caution (15). The continued use may also present clinical implications 
for injury susceptibility in the future (149). Doctors and pharmacists need to be aware of how 
medicines interact with exercise, performance, environment and other medicines to best manage 
athletes under their care (149). 
Analgesics generally have fewer side effects than NSAIDs, but when analgesics are taken excessively 
or with alcohol, they can cause liver and kidney damage (150). Analgesics are present in many over-
the-counter cold and flu medicines, and therefore users may not realise they are taking too much 
and risk overdose. The side effects of opioid analgesics include drowsiness, dizziness, respiratory 
depression, constipation, and urinary retention (150). The continued use of opioid analgesics (e.g. 
codeine) can cause tolerance to the drugs' analgesic effects and may lead to addiction (150). The long-
term use of cortisone has detrimental side effects including osteoporosis, tendon ruptures, joint and 
cartilage degeneration, delayed healing, increased scar formation and delayed muscle regeneration 
(144). 
There is no evidence supporting the use of NSAIDs and analgesics as ergogenic aids in endurance 
cycling performance. Most studies have investigated the effects of these medications on DOMS and 
EIMD after bouts of eccentric exercise. The literature is conflicting and no clear inferences can be 
made from these clinical trials. The evidence for cortisone specifically enhancing endurance 
performance is limited. There is however strong evidence for its ability to supress inflammation. 
 
2.8.2.4 Growth hormone 
It is believed that HGH has been used extensively by athletes since the 1980s for its anabolic and 
lipolytic properties (11,18,127,151-154). With anabolic steroids now more easily detected in doping 
controls, and currently no reliable tests available for HGH, its popularity persists. However, there is 







2.8.2.4.1 Physiological basis for HGH use 
Human growth hormone is a polypeptide hormone that is produced by the anterior pituitary gland 
(104). It was not until the 1950s, when researchers realised that HGH stimulated skeletal, soft tissue, 
bone and cartilage growth (127). Shortly thereafter it was used to treat children and adults with 
growth hormone deficiency and Turners Syndrome. The effects of therapeutic administration were 
dramatically seen, with increases in muscle mass, decreases in fat mass and increases in cardiac 
output and performance (153). It thus developed a reputation for increasing muscular strength, size 
and performance. Its abuse became popular particularly amongst cyclists, swimmers and 
bodybuilders (127,154). At the 1998 Tour de France officials found large amounts of HGH and other 
doping substances being carried by a cycling team and their physiotherapist, signifying misuse within 
the team and among cyclists (127,154). The Festina affair, which was highly publicised, refers to the 
events that followed this finding. They included several doping scandals, investigations and 
confessions by professional cyclists that occurred following the 1998 Tour de France (125,154). 
Human growth hormone stimulates most tissues, including the synthesis of insulin-like growth factor 
one (IGF-1) in the liver (11,18,103,112,127,151-154). The physiological actions of HGH and IGF-1 have an 
anabolic effect on the body. These hormones regulate and increase protein synthesis, whilst insulin 
inhibits protein catabolism, thus increasing muscle mass. The combination also increase fat oxidation 
resulting in a subsequent decrease in body fat mass (11,18,103,112,127,151-154). 
 
2.8.2.4.2 Strategies of use 
Human growth hormone is readily available although it is legally only a prescription drug. It is 
administered either subcutaneously or intramuscularly, generally with a therapeutic dose of 1.5 
mg.day given three times a week (127). The use of black market HGH is a real concern as it is derived 
from cadaveric specimens and runs the risk of Creutzfeldt-Jakob disease in the recipient 
(11,18,103,112,127,151-154). Anecdotal evidence suggests that athletes take up to 20 times the therapeutic 
dose, risking major health concerns (11,18,103,112,127,151-154). 
 
2.8.2.4.3 Current evidence for the effects of HGH on cycling performance 
Recent clinical trials have yet to demonstrate the ergogenic effect of HGH on sports performance 
(11,18,103,112,127,151-154). Yarasheski et al(155) showed that even when IGF-1 levels were doubled in healthy 





Future studies need to investigate the effects of “stacking”, the combined use of anabolic steroids 
and HGH on enhancing performance, a practice used by many athletes. The difficulty however lies in 
obtaining ethical approval for a suitable study, as there are many ethical issues involved in a study of 
this nature. 
The side effects of HGH are well documented in the literature, causing acromegaly, hypothyroidism, 
diabetes mellitus, water retention and cardiomyopathies (11,18,103,112,127,151-154). The skeletal changes 
that occur with acromegaly are irreversible and the artificial administration of HGH may affect 
normal growth metabolism (13). In the absence of scientific evidence, the use of HGH as an ergogenic 
aid to enhance performance cannot be advocated in healthy individuals. Despite this, it is listed as a 
banned substance by WADA. 
 
2.8.3 Physiological aids 
Blood transfusions, EPO and anabolic steroids will be discussed under physiological ergogenic aids. 
These ergogenic aids will be reviewed as appropriate considering their physiological basis for use, 
strategies for use in cycling, current evidence for the effects of their use on cycling performance and 
the health risks associated with their use.  
Athletes started blood doping with autologous and homologous transfusions in the 1970s and 1980s 
with the desire of increasing oxygen transport capacity (13,156). It was especially popular among 
endurance athletes, mainly cyclists and runners. Oxygen is carried to dependent tissues, being that 
of peripheral tissues and muscles, in two ways; dissolved in plasma (3%) or bound to haemoglobin 
(97%) (157). Haemoglobin is found within red blood cells (RBC) and is the most important component 
of oxygen transportation in blood (157,158). The amount of haemoglobin in the body is consistent with 
the oxygen requirements and consumption by dependent tissues (158). As the demand for oxygen 
increases with exercise, the oxygen-carrying capacity is adjusted to satisfy the increase in demand 
(158). 
Maximum aerobic capacity can be defined as the maximum amount of oxygen that is consumed 
during exercise (159). There is a strong relationship between VO2max and haemoglobin mass (the total 
amount of haemoglobin in the body), which is independent of age and sex (159). Maximum aerobic 
capacity is directly related to the delivery and utilization of oxygen, and therefore improvements in 
the oxygen transport ability may have the potential to increase VO2max and thus enhance athletic 
performance (159). The oxygen-carrying protein, haemoglobin, is imperative for success in endurance 
exercise. The goal of blood doping in endurance sport, is to increase the haemoglobin mass and 




This ergogenic effect can either be achieved by direct infusion of whole blood or inducing 
erythropoiesis (127,158,159). Due to the large effect these practices have shown on oxygen transport, 
both are banned by WADA (159). 
 
2.8.3.1 Blood transfusions 
Administration of packed RBC is used therapeutically in patients with anaemia, and in patients who 
have lost large amounts of RBC in accidents or as a result of surgery (103,158). Transfusions may be 
either autologous or homologous. An autologous transfusion is when blood is donated by an 
individual and then their same blood is re-infused, whereas homologous transfusion is the infusion 
of a donor’s blood (158).  
 
2.8.3.1.1 Strategies for blood transfusions in cycling 
The procedure for autologous transfusion usually involves withdrawing one to four units of blood 
(one unit = 450 ml). Bone marrow is stimulated as a result of the withdrawal of blood, which 
stimulates RBC formation (156,157). Transfusions are done a number of weeks before a competition or 
event, thus allowing time for the RBC mass to restore to baseline value. Once the blood is withdrawn 
it is centrifuged, separating plasma from RBC. The plasma is then re-infused immediately and the 
RBC can either be refrigerated at 4o C (lasting four to five weeks) or frozen at -80o C (lasting several 
years) (156). The RBC is then re-infused one to seven days before a competition (157,160). The ergogenic 
effect of blood transfusions is well documented, and both haemoglobin and haematocrit levels can 
increase by 20% when the procedure is properly executed (156,157). There is, however, a period of 
reduced performance following blood withdrawal, when the RBC count is low and bone marrow 
stimulation is being induced (161). 
 
2.8.3.1.2 Current evidence for the effects of blood transfusions on cycling performance 
Many studies have been conducted to determine the effect of RBC infusions at rest and during 
exercise. A recent review by Ekblom(162) found that RBC infusion increased haemoglobin values 
above the norms and consequently improved VO2max, as well as athletic performance as measured 
by an increase in time to exhaustion. Gledhill(163) reviewed numerous studies on the effects of blood 
doping, and found that re-infusion of 900 ml to 1350 ml improved the oxygen carrying capacity of 
blood, and VO2max by 4% to 9% 




The transfusion of blood does not come without its risks. Homologous transfusions carry the risk of 
transmission of blood borne infectious diseases, as well as transfusion reactions (127,158). This practice 
is also undesirable as RBC have a long lifespan (three to four months). As a result blood samples 
taken months after a transfusion can still be detected producing a positive doping test (158). With the 
high risks associated with transfusion, as well as the time, intricacies and related storage issues, 
athletes and coaches have looked at other means of supplying the same ergogenic benefit with less 
risk (158). Thus RBC transfusion has largely been replaced by Recombinant Human Erythropoietin 
(rHuEpo) (11,127,158). 
 
2.8.3.2 Erythropoietin  
2.8.3.2.1 Physiological basis for EPO use 
The primary regulator of RBC production is EPO. Endogenous EPO is largely synthesized in the 
kidneys and is produced in correspondence to the amount of oxygen in the blood. Erythropoietin 
production results in the synthesis of RBC within the bone marrow in a process called erythropoiesis, 
as well as an increasing haemoglobin and haematocrit (11,127,158). In 1985 rHuEpo became 
commercially available when the gene code of EPO was cloned (127,158). 
Low doses of rHuEpo increase bone marrow production and thus increase the number of RBC, 
haemoglobin and haematocrit, as with traditional blood doping (transfusions) (160). RHuEpo can be 
administered either subcutaneously or intravenously, with the half-life being relatively shorter when 
given intravenously (157). A number of scandals in international competitions have highlighted the use 
of exogenous EPO. Its abuse as an ergogenic aid by elite endurance athletes is estimated to be 3% to 
7%, although some estimate a much higher prevalence, especially among cyclists (157,165). 
 
2.8.3.2.2 Current evidence for the effects of EPO on cycling performance 
Many clinical trials have proved the ergogenic effect of rHuEpo on performance, measured by time 
to exhaustion on a cycle ergometer (166). Ekblom and Burglund(167) were the first to carry out a clinical 
trial. They injected 20 IU.kg-1 to 40 IU.kg-1 of rHuEpo three times per week, over six weeks, and found 
an increase in haemoglobin and VO2max, which lasted as long as two weeks after the last injection.
 
Lundby et al(166) injected rHuEpo over 15 weeks in healthy recreational males (n=8), and also found 
an increase in haemoglobin (11.6%) as well as an increase in VO2max. Audran et al
(168) examined the 
effects of rHuEpo by injecting 50 IU.kg-1 subcutaneously in trained athletes (n=9), in an incremental 




Maximal aerobic capacity increased by 9% and power output by 7%. Audran et al(168) also showed 
that the ergogenic effects of rHuEpo lasted several days after the last dose, as did Ekblom and 
Burglund(167). Lippi et al(157) had similar results to the aforementioned studies with rHuEpo 
administration increasing haemoglobin, haematocrit and VO2max. 
Lippi et al(157) also found that the effects of rHuEpo lasted longer, with values only returning to 
baseline one month after the last dose. A double-blinded study conducted by Parissotto et al(169) 
found similar results to all of the above mentioned studies, with a 7% to 12% increase in 
haemoglobin mass and a 6% to 7% increase in VO2max. The literature clearly demonstrates the 
ergogenic effect of rHuEpo on endurance performance by increasing oxygen transportation and 
availability. Table 2.4 provides a summary of relevant experimental studies that assessed the 
ergogenic effects of blood doping on cycling performance (166,168-171).  
In addition to rHuEpo there are a number of other methods that are being used to increase 
haemoglobin, oxygen transportation and performance (160,161,172). There are several EPO analogues 
available (79). Darbepoetin is one such example, which is used medically in the treatment of chronic 
renal failure (79). Darbepoetin has a longer half-life than rHuEpo and thus can be administered less 
often, however it is easier to detect (103,161). Potential side effects of rHuEpo and EPO analogues may 
include hypertension, thromboembolic events and seizures. Increased thromboembolic events occur 
as there is an increase in viscosity of the blood due to an increase in the number of packed RBC 
(18,103,157,159,173). 
The ergogenic effects of blood doping through blood transfusions and EPO are well documented 
(164,168-171). Due to the high risks of blood transfusions and the intricacies involved, the popularity of 
EPO has increased (164,169). Recombinant human erythropoietin increases haemoglobin levels, 






Table 2.4: Summary of experimental studies that assessed the ergogenic effects of blood doping on cycling performance.  
Article Study design Sample size (n) Participants Intervention Exercise protocol Results Conclusion 
Thomsen et al







Healthy volunteers -PLA group (saline) vs. 
rHuEPO (60 IU.kg-1) of 
rHuEpo 
-First 2 weeks, one 
injection every second 
day; 
-Third week, three 
injections on three 
consecutive days;  
-Week 4 to 13, one 
injection every week 
-The protocol was done 
pre-trial, at 4 weeks 
and at 11 weeks:  
-Incremental bike ride 
until fatigue  at VO2max 
followed by, 
-TTF at a given percent 
of the maximum 
attained work-load 
during the incremental 
exercise test  
-At 11 weeks there was 
an additional TTF trial 
-With rHuEpo 
treatment , VO2max 
increased by 9.1 % and 
8.1% in week 4 and 11 
respectively (p < 0.05) 
(no changes in the PLA 
group) 
-TTF in the rHuEpo 
treatment group was 
increased by 54.0 % 
and 54.3% after 4 and 
11 weeks of treatment 
(p < 0.05)   
rHuEpo significantly 




rHuEpo provides an 
ergogenic effect by 
prolonging submaximal 












-5,000 IU of rHuEpo 
was injected during the 
first 2 weeks, one 
injection every second 
day;  
-three injections on 3 
consecutive days in the 
third week; and 
-Week 4 to 15, one 
injection every week 
-Cycle to fatigue with 
incremental increases 
in load 
-Tests were completed 
before rHuEpo 
administration (pre-
rHuEpo), as well as 
after week 13 
-rHuEpo increased Hb 
by 11.6% and VO2max 
increased by 300 ml 
-Maximal workload was 
also significantly 
increased from pre- to 
post rHuEpo 
administration  
(p < 0.05) 
rHuEpo exerts its main 
effect on VO2max 
through an increase in 
RBC mass. The 
ergogenic effect of 
rHuEpo on VO2max can 
be explained through 
the enhancement of 
the oxygen-carrying 
capacity of blood. 














LOE: I  
20 participants 
(males) 





-5,000 IU of rHuEPO 
(n=10) vs. PLA (n=10) 
three times weekly for 
30 days 
-Participants were 
followed for a period of  
4 weeks thereafter 
-Cycle test: TTF with an 
incremental workload 
maintaining a cadence 
of 85 rpm to 95 rpm 
-VO2max increased by 7% 
post rhEPO 
administration (p  = 
0.001) (no change in 
PLA group) 
-TTF  increased from 
12.8 min at baseline to 
14.0 min 1 day post-
treatment in the 
rHuEPO group  
(p < 0.0001) 
VO2max and TTF were 
significantly increased 
for up to 3 weeks post-
administration, which 
indicates an ergogenic 
effect on endurance 
performance. 
This study also showed 
a performance 
advantage for at least 2 
weeks longer without 
than any indication of 
rHuEPO use in blood 
samples. 
Parisotto et al








(22 males and 5 
females) 
Healthy volunteers -5 weeks of preliminary 
training followed by 25 
days of rHuEPO (n=18) 
vs. PLA (saline) (n=9) 
administration  
-50 IU.kg-1 (3 x week) 
-Total Hb mass and 
VO2max were 
determined 1 week 
prior to rHuEPO 
administration, within 
3 days after the last 
injection and at the end 
of wash-out (on a 
treadmill or cycle 
ergometer) 
-Relative to baseline 
the rHuEPO group 
showed a significant 
increase (p < 0.05) 7% 
to 12% in Hb mass (PLA 
group unchanged) 
-VO2max increased by 6% 
to 7% from baseline in 
the rHuEPO group 
This study shows an 
ergogenic effect of 
rHuEPO administration 
in enhancing sporting 
performance, lasting up 
to 4 weeks after 
cessation of use. 




(7 males and 2 females) 
Trained athletes -rHuEpo administered 
(50 IU.kg-1) for 26 days 
-Incremental exercise 
cycle test to fatigue 
-The tests were 




values and the first 
week after the last drug 
intake 
-VO2max and PO were 
significantly higher 
after 26 days of rHuEpo 
administration than at 
baseline 
Repeated doses of 
rHuEpo administered 
to normal athletes 
stimulated 
erythropoiesis, 
therefore providing an 
ergogenic effect in 
cycling performance. 




2.8.3.4 Anabolic steroids 
Since 1935, when testosterone was first discovered, many derivatives of testosterone have been 
synthesized and developed to improve its efficacy (174). Testosterone can have both androgenic and 
anabolic effects. Growth of the male reproductive system and secondary sexual characteristics is a 
result of the androgenic effects, whereas increased protein synthesis is a result of the anabolic 
effects of testosterone (174). 
 
2.8.3.4.1 Physiological basis for anabolic steroid use 
The widespread use of anabolic-androgenic steroids (AAS) manifests from the myotrophic action, 
resulting in enhanced muscle size, strength, power and thus performance (66,144,174). Anabolic-
androgenic steroids are effective in three principal ways (174). Firstly, AAS increase protein synthesis 
in skeletal muscle at a cellular level. The AAS bind to androgen receptors, which in turn stimulates 
gene transcription and the production of mRNA, ultimately inducing protein synthesis (174). Secondly, 
AAS block the catabolic effects of gluco-corticosteroids during intense and stressful training or 
competition (174). Lastly, the ingestion and injection of AAS results in states of ecstasy and diminished 
feelings of fatigue (174). Subsequently, athletes using AAS can train more frequently and at the 
required intensity, as recovery between training sessions and from competition is increased (174). 
Anabolic-androgenic steroids are mostly used by athletes in power sports (e.g. weightlifting). 
However, anecdotally they are reported to be used among a number of other sporting codes in 
which athletes seek to improve strength and appearance (66). The exact quantification of the effect of 
AAS on performance is not possible to evaluate. A double-blind study would be ethically impossible 
(66). The mechanisms of action of AAS are well understood and the numerous side effects, although 
variable are well documented (66). Possibly the key motive for its use amongst cyclists would be to 
allow for more intensive training by increasing the rate of recovery (65). 
The use of AAS is not limited to professional athletes. Recently there has been an increase in use 
amongst young athletes and non-athletes alike; trying to improve body physique and recreational 
sporting performance (174). Anabolic-androgenic steroids are easily available on the black market and 
in training centres. As a result it is a highly accessible drug and therefore one of the most commonly 
misused drugs in sport (66,144,174). Most athletes using AAS either do so using the “stacking” method 
(using two or more AAS) or “cycling” method (a six to ten week cycle of use, followed by a similar 




The main side effects of AAS include cardiovascular risk factors (increased blood pressure and 
cholesterol levels), acne, increased body hair, aggressive behaviour, irritability, mood disorders, 
sleeplessness and decreased fertility (66,144,174). The prevalence of use of AAS among cyclists is 
unknown and generally based on anecdotal evidence and speculation.  
Anabolic steroids are effective for increasing muscle size, power and strength when an athlete is 
involved in a resistance training programme. Anabolic steroids do not improve VO2max, but may have 
the potential to improve endurance performance by increasing power output (13). Evidence 
supporting the effectiveness of AAS as an ergogenic aid in endurance cycling performance is limited. 
 
2.9 INSTRUMENTATION TO DETERMINE THE USE OF ERGOGENIC AIDS 
It is difficult to know the extent of doping; worldwide it is a controversial area of sports medicine 
(8,9,103). Only a handful of studies have reported the incidence of doping amongst cyclists (7-9). 
Methods of data collection have included anonymous self-reported paper questionnaires and 
personal interviews (6,7,9). 
One of the major biases to consider when administering a questionnaire or conducting an interview 
is social desirability. This refers to the tendency by respondents to give more socially desirable 
answers to questions; “faking good” (175). This generally involves giving answers that make a good 
impression or conceal sensitive information (175). Less distortion of social desirability was found in 
computerised questionnaires compared to paper-based questionnaires and interviews (176). This was 
especially seen when participants could backtrack to questions and were alone when completing the 
questionnaire. When anonymity was assured, participants also gave reduced social desirability 
distortion with computerised questionnaires compared to paper-based questionnaires and 
interviews (176). This was particularly seen when sensitive information or personal behaviour was 
being assessed (176). The presence of another person in the form of a test administrator or 
interviewer may obviate assertions of anonymity. Participants may be inclined to have a greater 





The presence of a test administrator or interviewer may reduce neutrality and provoke evaluation 
apprehension. However, interviews are still used to gather this highly sensitive information of 
doping and ergogenic aid use. The advantage of interviews is that they reduce non-responses and 
allow for more elaborate answers (175). Petroczi(7) investigated doping behaviour and attitudes 
through a series of psychological tests and self-reported questionnaires in college athletes (n=174). 
Due to the sensitivity of the subject Petroczi(7) emphasized that there was a high rate of under-
reporting. 
Over the years there has been an increase in the number of studies using internet and email to 
collect data for research. However the response rates of internet studies are decreasing causing 
doubt in this method of data collection (177). Sheehan(177) reported a mean response rate of 36.8% for 
email surveys, while Cook, Heath and Thompson(178) suggested that a response rate of 25 to 30% 
from email surveys is more likely. The response rates to email and online surveys may have a 
number of potential influences (177,179). 
With regards to survey length, the literature is conflicted and more research is required to make 
direct inferences (177). With the increase in the amount of online survey research being conducted, 
the number of requests sent to individuals to complete surveys has increased (177). As a result 
individual’s attitudes may be unfavourable towards surveys, which may lower response rates (177). 
Poorer response rates may also be related to the participant’s perception of the mail as “junk mail” 
or that the email contains a virus (179). Participants’ concerns regarding confidentiality of data and 
privacy may too decrease response rates (180). Evans and Mathur(179) suggest clearly defined policies 
of confidentiality and statements as to what data will be used for to help decrease possible refusal of 
participation.  
Research has identified the benefits of email surveys over paper surveys, particularly with regards to 
cost, flexibility and speed efficiency (177,178,180). The internet allows for online surveys to be speedily 
distributed nationally or internationally within a short time period (179). Online surveys are very 
flexible as they accommodate for customised language selection, as well as allowing participants to 
view only questions applicable to them (179). Online surveys also provide researchers with the 
opportunity of manipulating questions. Questions are manipulated to ensure participants answer 
the questions before being able to advance, which assists in decreasing non-responses (179). The 
quality and success of a survey depends not only on a sufficient sample size, but also on fully 
completed responses (180). The low cost of data collection also allows for greater sample sizes, 




The use of questionnaires as a study method may be considered weak. It is recommended in the 
literature that combinations of quantitative measures are employed, for example biomedical tests, 
interviews and questionnaires (181). The purpose of a descriptive study is to discover information 
about a specified population. It provides information on the magnitude of a problem within a 
defined population. Descriptive research is often the starting point of other research, as it provides 
information on what to further investigate, how to further investigate it and helps to formulate 
testable hypotheses (182).  
Considering the sensitive nature of the topic under investigation, an online questionnaire was 
developed to collect data as defined in the literature and as stated in the aim of this study as set out 
in Section 1.2.2 (page 2). It was highlighted earlier that the risk of under-reporting in questionnaires 
is one of the limitations of a study of this nature. However, information gathered through 
anonymous self-administered questionnaires has demonstrated to be reliable (6). A key variable 
effecting data collection and data quality are assurances of anonymity and confidentiality (175,176). 
This has shown to be enhanced through the use of questionnaires compared to interviews (176). The 
use of a questionnaire to collect data has the benefits of reduced costs, time and most importantly 
for this study, a larger sample size. Interviews are highly time consuming, require specific skills by 
the interviewer, are expensive and generally can only reach a small sample size. An online 
questionnaire was used specifically for the reasons as stated above, and the suggestion from Evans 
and Mathur(179) related to clearly defined policies of confidentiality and transparency for the data 
was employed in this study.  
 
2.8 SUMMARY OF THE LITERATURE 
With the mounting popularity of cycling in South Africa, and the increasing emphasis on athletic 
performance, it is unlikely that the use of ergogenic aids will decrease (2,19). Cyclists and coaches are 
consistently looking for that competitive edge, and it is often found that athletes will be “ten steps 
ahead” of science when it comes to the next best ergogenic aid (153). Important components of 
endurance cycling include training, fatigue and recovery. Consideration of the potential factors 
limiting training and natural performance enhancement may suggest that ergogenic aids are not 
restricted to professionals. 
Factors influencing the prevalence of ergogenic aids amongst athletes depend on three sport specific 
elements, namely: the type of sport, whether it is a team or individual sport, and whether the sport 




Current literature has revealed that the most frequently used ergogenic aids among cyclists are 
sports drinks, vitamins, amino acids, caffeine, PRO, and NSAIDs (6,57). 
Across the literature, it has been shown that there is difficulty in quantifying the degree to which 
doping practices are common (66). The use of both legal and illegal/banned ergogenic aids is generally 
concealed behaviour. This limits findings of true incidence rates (66,8,9). This surreptitious behaviour 
makes it hard to present clear evidence on the short term and long term adverse health effects of 
specific ergogenic aids (66). The consumption of a variety of products by athletes also makes it hard to 
provide clear evidence for the adverse health effects (66). 
There are well-documented roles for CHO, caffeine, blood transfusions and EPO in enhancing 
performance in endurance cycling. An ergogenic effect was also observed in short duration high-
intensity cycling performance mimicking time trials, with these aids. The evidence supporting the 
benefit of other popular ergogenic aids on cycling performance was equivocal and inconclusive. A 
major limitation across the literature was the lack of standardised exercise protocols when 
investigating the true effect of specific ergogenic aids on cycling performance. Future research must 
develop standardised measurement outcomes and protocols that stimulate real life competitions, so 
that studies can be compared and sound inferences can be made.  
The prevalence of use and practices in South African cyclists are unknown and yet to be examined. 
Research is needed to gain information and knowledge as to which ergogenic aids South African 
cyclists are using, before we can investigate beliefs and knowledge of doping. Research of this 
nature is needed to understand the magnitude of doping, as well as the actual intake of nutritional 
and pharmacological ergogenic aids. In addition, the intake of legal ergogenic aids may increase the 
likelihood of subsequent doping (6). Effective anti-doping strategies should be planned and based on 
the consideration of a possible relationship between frequency and usage patterns of all ergogenic 
aids (1). This study will provide the first step in gathering information on usage patterns of ergogenic 
aids in South African cyclists. For all aforementioned reasons, this study and future studies are 
strongly warranted and needed to help bridge the gap between science and cycling.  
Therefore the aim of this study was to describe the use of ergogenic aids in South African cyclists 
during training and competition. For this purpose, usage patterns of both legal and illegal/banned 





CHAPTER 3: THE USE OF ERGOGENIC AIDS IN CYCLISTS 
3.1 INTRODUCTION 
Athletes often use ergogenic aids in an attempt to improve performance and address the negative 
stresses resulting from high intensity exercise (15,16,183). There are a number of different types of 
ergogenic aids, of which the pharmacological and physiological aids have received the most 
attention in cycling over the last decade (17,18). Within the three broad categories of nutritional, 
pharmacological and physiological ergogenic aids there are both legal and illegal/banned substances. 
The banned substances are those mostly classified under physiological ergogenic aids and include 
anabolic steroids, blood transfusions, EPO, HGH and cortisone (11). 
The estimated prevalence of ergogenic aid use amongst international athletes across “all sports” 
ranges from 46% to 100% (6,53,55,64). However, these data are generic rather than focused specifically 
on cycling. There are few studies reporting the prevalence of use specifically within cycling. A 10.3% 
to 17.5% prevalence of doping was reported by one study that included cyclists from a recreational 
level of participation to an international level (10). It is difficult to determine the scale of ergogenic 
practices, due to the sensitive nature of the research (66). It is therefore thought that the prevalence 
is much higher than that reported in the literature. The use of ergogenic aids in South African cyclists 
has not been determined. A good understanding of prevalence of use of ergogenic aids and factors 
influencing choices is necessary to facilitate safe participation in sport, to promote drug-free sport, 
to identify educational needs, and the needs of other forms of interventions. 
Therefore the current survey was performed to assess information regarding the current use (last 12 
weeks) of nutritional, pharmacological and illegal/banned ergogenic aids amongst South African 
cyclists. The aim and specific objectives of this dissertation have been described in Section 1.2.2 





3.2.1 Study design  
The study had a descriptive correlational design. Participants were recruited through electronic 
correspondence and cycling-specific media platforms. All participants were required to provide 
informed consent prior to completing the questionnaire (Appendix I).  
 
3.2.2 Participants 
3.2.2.1 Inclusion criteria 
Participants included male and female cyclists between 18 and 65 years of age.  Participants were 
required to meet at least one of the following criteria to be included in the study: a minimum of two 
years history of competitive cycling*; a minimum average mileage of 80 km.wk-1; cycling for at least 
six months out of 12 months in a year; and/or the completion of at least three cycling races in the 
last six months (34).  
 
3.2.2.2 Exclusion criteria 
Novice cyclists were excluded from the study.  Participants with diabetes mellitus, eating disorders 
and any metabolic disorders were also excluded from the study, because these conditions may have 
limited or influenced nutritional choices (88). Participants who failed to complete more than 30% of 
the questionnaire were excluded from the study. By failing to complete more than 30% participants 
did not reach Section C: the use of ergogenic aids (page 9 of the online questionnaire). In addition, 
participants who did not provide informed consent on FluidSurveys© were not able to access the 
questionnaire, and were thus excluded from the study.   
  
                                                          
*
Competitive cycling was defined according to the following race times; (i) Cape Argus Pick ‘n Pay Cycle Tour 
(109 km): male-sub 3h15m, female-sub 3h30m, (ii) Momentum 94.7 Cycle Challenge (94.7 km): male-sub 





3.2.2.3 Sample size determination 
In the absence of more definitive data regarding the use of ergogenic aids by cyclists, the prevalence 
of supplement use in athletes was used to calculate the required sample size for the study.  An 
expected frequency of 60% was selected based on previous studies, which report the incidence of 
supplement use of between 45% and 85% (180,184).  If the worst expected frequency was 55%, with 
confidence intervals (CI) of 80%, 90% and 95%, the required sample size was 140, 211 or 276 
participants respectively.  It is recognised that response rates for questionnaire-based studies are 
often less than 56% (185). Therefore to ensure sufficient statistical power approximately 552 
participants needed to be recruited for this study.  A total of 467 questionnaires were returned of 
which 260 were excluded from final analyses. The details for exclusion are discussed further in 
Section 3.3.1 (page 74). The final sample size for this study was 207 participants. 
 
3.2.2.5 Recruitment 
A web-based search for contact details of cycle clubs, shops and online forums in South Africa was 
performed. Google was searched using the keywords: “cycling”, “South Africa”, “cycling clubs”, 
“cycling shops” and “cycling forums”. Club chairman’s and cycle shop managers were informed 
electronically or telephonically of the study, and permission was requested to distribute the link and 
study information on mailing lists or in club newsletters (Appendix II). The cycling clubs and shops 
were sent two email reminders over the time the questionnaire was available on FluidSurveys© (22 
April 2013 to 18 August 2013). Table 3.1 reflects the provincial distribution of cycling clubs and shops 
(n=58) that were contacted regarding the study. In addition, five online media platforms hosted the 
questionnaire link for the entire duration of the study. The five forums included: The hub 
(www.thehubsa.co.za), Warthog Google Group (warthogs-mtb-sa@googlegroups.com), Bicycling 
Magazine (www.bicycling.co.za), Cycle lab Facebook (www.facebook.com/pages/Cycle-Lab/) and 
Cycle Lab Western Cape twitter (@CycleLabWC). The researcher sent reminders to the media 










Table 3.1: Summary of the provincial distribution of cycling clubs and shops (n=58) that were contacted. 
Province Number of clubs and shops contacted 
Western Province n=22 (38.0%) 
Gauteng n=9 (15.5%) 
Free State n=1 (1.7%) 
KwaZulu-Natal n=13 (22.4%) 
Limpopo n=2 (3.4%) 
Mpumalanga n=4 (7.0%) 
Eastern Cape n=5 (8.6%) 
Northern Cape n=1 (1.7%) 
North West n=1 (1.7%) 
Total n=58 (100.0%) 
 
Based the on poor response rate to the above two recruitment methods, the recruitment method 
was amended after two months. Ethics approval for the amendment was obtained from the 
University of Cape Town, Faculty of Health Sciences Human Research Ethics Committee (HREC). 
Participants were also then recruited from a database of race participants who completed a previous 
cycling questionnaire regarding race goodie bags from the Cape Argus Pick ‘n Pay Cycle Tour.  
Participants voluntarily gave their contact details and residing province to this database, and gave 
unrestricted permission to be contacted about cycling-related events or activities. The list consisted 
of 3378 national and international email contacts. One hundred and twenty one participants were 
excluded as they were international cyclists. Of the remaining 3257 contacts, approximately 20 
emails per 100 sent were unsuccessful, due to failed deliveries. Therefore, approximately 2605 
cyclists were contacted individually with the link requesting their participation in the study. The 





3.2.3 Measurement instrument 
3.2.3.1 Ergogenic aids questionnaire 
A self-developed questionnaire was designed to obtain information regarding the use of ergogenic 
aids in cyclists during training and competition, as well as to determine cyclists’ pattern of use and 
the perceived effect of ergogenic aids (Appendix III).  The prologue to the questionnaire included 
participant information, informed consent and training screening questions (inclusion criteria). 
Participants were excluded from the study if they did not give informed consent or meet the training 
criteria. The questionnaire comprised of three sections following the prologue. Section A assessed 
demographic information and included a brief medical screening. Participants were excluded from 
the study if they had any medical disorders. Section B assessed training and competition history, and 
Section C investigated the current use of ergogenic aids in cyclists. Section C was based on 
commonly reported ergogenic aids used in cycling in current literature (9,17), as well as WADA’s 
prohibited list (62). The ergogenic aids which the questionnaire included were both legal and illegal 
substances.  Table 3.1 and Table 3.2 provide a summary of the questions asked in Section A and 
Section B of the questionnaire respectively.  Table 3.3 provides a summary of questions asked in 
Section C for each ergogenic aid. Participants were required to complete all parts of Section A and 
Section B. In Section C, participants were required to indicate which ergogenic aids they were 
currently using (over the last 12 weeks) from a list provided. The list of ergogenic aids were not 
categorised into groups, they were listed in a random order. Based on participants’ individual 
selection, the online questionnaire automatically redirected participants to detailed questions 
regarding the self-reported ergogenic aids.  
The questionnaire was posted online via FluidSurveys©. FluidSurveys© is a Canadian-developed 
online questionnaire software programme, which enables users to develop surveys to collect and 
analyse data. Participants were able to access the questionnaire via a link 
(http://fluidsurveys.com/surveys/ergogenic_aids/copy-the-use-of-ergogenic-aids-by-
cyclists/langeng/)*. FluidSurveys© provided easy to use steps, allowing participants to answer all 
required and relevant sections, whilst skipping irrelevant sections.  The questionnaire was available 
in English and Afrikaans. The questionnaire was forward-and back-translated to ensure content, 
technical and semantic equivalence.  The ethical issues relating to the privacy, confidentiality and 
anonymity of data collected in this study are discussed in Section 3.2.6 (page 72). 
                                                          
*
It is not possible to access the questionnaire via this link anymore, as the FluidSurveys
©
 account was closed 




Table 3.1: Summary of the Training Screening Section, and Section A of the questionnaire. 
Prologue: training screening 
(If participants did not meet the training inclusion criteria they were excluded from the study.) 
Q.1 Please indicate for which criteria you qualify for below: 
A.1 Have been cycling competitively for at least two years 
A.2 Currently cycle a minimum of 80 km.wk-1 
A.3 Cycle for at least six months out of the year 
A.4 Have participated in at least three cycling races/events in the last six months 
A.5 Not applicable (N/A) 
Section A: demographic information 
Q.1 Gender 
Q.2 Age 
Q.3 Height (m) 
Q. 4 Weight (kg) 
Q.5 Highest level of education 
medical screening 
(If participants had any of these medical disorders they were excluded from the study.) 
Q.1 Do you suffer from any of the following conditions? 
A.1 Diabetes Mellitus  
A.2 Any metabolic disorder (specify) 





Table 3.2: Summary of Section B of the questionnaire. 
Section B: training and competition history 
(As applicable over the last 12 week period.) 
Q.1 Type of event/s you participate in? 
Q.2 Which is your preferred event? 
Q.3 Are you currently cycling competitively? 
Q.4 How many years have you been cycling competitively? 
Q.5 In which year did you start competitive cycling? 
Q.6 On average how many times do you cycle per week? 
Q.7 On average how many hours do you cycle per week? 
Q.8 On average how many kilometers do you cycle per week? 
Q.9 How many of your rides per week would you classify as hard rides (>75% HRmax)? 
Q.10 How many one-day events have you completed in the last 12 weeks? 
Q.11 How many multi-day events have you completed in the last 12 weeks? 
Q.12 What is your best race time for the following races (list provided), and when did you achieve this time (year)?  
Q.13 How many days after a race (80 km to 100 km) would you resume normal training? 






Table 3.3: Summary of Section C of the questionnaire. Note: the shaded blocks represent the questions which were asked for each ergogenic aid. The un-shaded blocks 
indicate that the question was not asked for that particular ergogenic aid. 
Section C: Ergogenic aids 





















































































































When do you use it?                  
How many years have 
you been using it? 
                 
How do you administer 
it? 
                 
How many times a year 
do you use it? 
                 
Do you have help 
administering it? 
                 
Does it improve your 
performance? 
                 
How do you think it 
works? 





Table 3.4 (continued): Summary of Section C of the questionnaire. Note: the shaded blocks represent the questions which were asked for each ergogenic aid. The un-

























































































































                 
Which product do you 
use most frequently? 
                 
What do you use it 
for?(therapeutic 
reasons/performance) 
                 
How soon after training 
or competition do you 
start ingesting it? 
                 
Do you eat a specific 
amount according to 
your body mass? 
                 
What form of CHO are 
you ingesting? 





Table 3.4 (continued): Summary of Section C of the questionnaire. Note: the shaded blocks represent the questions which were asked for each ergogenic aid. The un-





















































































































If you use refined* CHO, 
please indicate which 
kind. 
                 
If you use nutrient 
dense CHO, please 
indicate which one. 
                 
What form of PRO are 
you ingesting? 
                 
If you use liquid PRO, 
please indicate which 
kind. 
                 
If you use lean PRO, 
please indicate which 
one. 
                 
  
                                                          
*




Table 3.4 (continued): Summary of Section C of the questionnaire. Note: the shaded blocks represent the questions which were asked for each ergogenic aid. The un-





















































































































How would you best 
describe your 
preparation leading up 
to a race (5 days)? 
                 
How many tablets per 
dose? 
 
                 
How many doses per 
day? 
 
                 
How many days will you 
continue to take it for? 
                 
Please rank your top 
three sources of 
information influencing 
your use of it? 





3.2.3.2 Validity of the ergogenic aids questionnaire 
A panel of three experts, with special interests in cycling, reviewed the questionnaire to ensure 
content and construct validity. The expert validators were selected based on their expertise and 
reputation in the field of endurance sport. The validation panel consisted of a sports physician and 
South African cycling coach, a sports dietician, and a sports physiotherapist. Once ethical approval 
was granted, the validators were contacted requesting their assistance in validating the 
questionnaire (Appendix IV). The validators were requested to comment on the relevance and 
importance of the questions and whether the questions were clear and easy to understand. In 
addition, the validators were requested to give input regarding potential questions or sections that 
had not been included, and that may contribute to addressing the study objectives. The validators 
were asked to complete the review of the questionnaire within a four-week period.  All three 
experts returned the questionnaires. The researcher and supervisors reviewed and consolidated the 
feedback from the three validators, and compiled an updated version of the questionnaire. 
Feedback was predominantly related to aspects of language simplification of questions as well as the 
inclusion of contact details for the researcher, supervisors and the HREC. There was no conflicting 
feedback from the validation panel. The panel of experts all indicated that the questionnaire was 
thorough and covered all components of the study objectives. The revised questionnaire was sent 
back to the validators for final approval before the feasibility study.  
 
3.2.3.3 Feasibility of the ergogenic aids questionnaire 
Feasibility of the questionnaire was established with a feasibility study that consisted of seven 
cyclists who met the inclusion criteria for the study. The participants were required to comment on 
the comprehension of the questions and the ease of completion of the online questionnaire. All 
seven participants completed the questionnaire successfully, making multiple or numerically ranked 
selections where applicable. Feedback was obtained from all participants regarding the 
comprehension of the questionnaire and the potential difficulty in navigating through the online 
questionnaire. Changes as a result of feedback mostly included technical aspects concerned with the 
online survey programme itself. Firstly, the automatic redirecting of participants to more detailed 
questions regarding the use of ergogenic aids had to be corrected. Participants were only required to 
answer questions on their self-reported use of ergogenic aids. Secondly, participants had to rank 
their top three sources of information associated with their use of any particular ergogenic aid. This 
ranking question had to be revised so that each number could only be selected once to accurately 




The final change was the inclusion of metric measurements (ml) concerning fluid intake before, 
during and after competitions. Participants’ responses from the feasibility study were not included 
for data analysis of the main study.  
 
3.2.4 Procedure 
Once the questionnaire was validated and the feasibility study completed, participants were 
contacted through electronic or telephonic correspondence informing them of the purpose of the 
study, and requesting their participation. Respective cycling clubs, shops, media platforms and 
individual participants were then emailed the link to the questionnaire available on FluidSurveys© 
(Appendix II). Only participants that indicated that they understood the study information and were 
willing to take part in the survey (informed consent) were able to progress to the next stage of 
completing the questionnaire. Participants who did not meet the training criteria after giving 
informed consent were excluded from the study. Participants were asked to self-report medical 
history in a screening question, before accessing Section B and Section C of the questionnaire. 
Participants who were excluded based on screening information (training criteria and medical 
history) were redirected to an exit window within the online survey. No personal information was 
requested to ensure the anonymity of participant responses. On completion of the questionnaire, 
participants were thanked for their time and response. Cycling clubs and shops were sent two email 
reminders over the time the questionnaire was “live” on FluidSurveys© (22 April 2013 to 18 August 
2013). Reminders to the media platforms were sent, ensuring the questionnaire link was reposted 
twice in each forum over the duration of the study.  
 
3.2.5 Statistical analyses 
Statistical analyses were performed using Statistica software (StatSoft, Inc. 2004) STATISTICA (Data 
analysis software system, version 11, www.statsoft.com). Pearson’s chi-square measures of 
association and percentages were used for categorical data, for example; gender, level of education, 
competitiveness, preferred cycling event and the self-reported use of ergogenic aids.  Independent t-
tests were used for all numerical data. Numerical data presented as the mean and standard 
deviation (X ± SD) were age, stature, body mass and body mass index (BMI). Average weekly 
mileage, number of training rides per week and the number of recovery days taken after an event 




Forward stepwise analyses in IBM SPSS Statistics (version 21, 2012) were performed to predict the 
probability of participants using a specific ergogenic aid. The predictor (independent) variables were 
age, BMI, education, preferred cycling event, cycling competitively, average weekly mileage (km.wk-
1), number of times a participant cycled per week (frequency) and the number of recovery days post 
competition (80 km to 100 km). 
The predictor variables were coded as seen in Table 3.5. Regression analyses were performed on all 
ergogenic aids except for illegal/banned aids due to the small response rate relating to the use of 
these aids. All variables were entered simultaneously, CIs were 95% and statistical significance was 
accepted as p < 0.05. All of the forward stepwise regression tables show the odds ratio (Exp(B)), p-
values, 95% CIs and the Wald test for each of the predictors. The Wald test is used to test the 
significance of the variable based on the sample estimate (186). 
 
Table 3.5: Predictor variables coded for forward stepwise regression analyses. 
Predictor variable Coded 1 Coded 0 
Age (years) ≥40 ≤39 
BMI ≥25 18.2 to 24.9 
Education ≥Grade 12 ≤Grade 11 
Preferred event Road cycling Mountain biking 
Cycle competitively Yes No 
Km.wk-1 ≥120 ≤119 
Frequency per week ≥4 ≤3 
Recovery days post competition ≤three days ≥Four days  
 
3.2.6 Ethical considerations 
The study was performed in accordance with the principles of the Declaration of Helsinki (Seoul 
version, 2008*.  The study was submitted and approved by the Faculty of Health Sciences Human 
Research Ethics Committee, University of Cape Town (HREC REF: 255/2012) (Appendix V).  Ethics 
approval was obtained prior to the commencement of any research-related activities.  Participants 
were required to give informed consent before taking part in the study.    
                                                          
*
The researcher is aware that there is a new version of the Declaration of Helsinki (Brazil, 2013); however the 




The first page of the online questionnaire provided the participants with information regarding: the 
purpose of the study; the risks and benefits of the study; how privacy, confidentiality and anonymity 
would be maintained; voluntary participation and the right to withdraw from the study at any time 
while completing the online questionnaire (Appendix I). 
Participants were required to check a box indicating that they understood the study information and 
were willing to take part in the survey to progress to the next stage of completing the questionnaire.  
Participants that did not provide consent were unable to access the questionnaire and were 
automatically redirected to an exit window on the questionnaire site. Once participants had 
completed the questionnaire they could not withdraw consent. Participants’ responses could also 
not be withdrawn once submitted. The online questionnaire was completely anonymous.  This was a 
feature of FluidSurveys© software design that was purposefully selected for this study. As a result all 
referring uniform resource locators (URLs) and internet protocol (IP) addresses of respondents were 
hidden.  It was therefore not possible for responses to be traced back to individual respondents.  
Once all the responses were received and the online survey was closed, responses were numerically 
coded. The data were strictly confidential, and only the principal researcher and primary supervisor 
had access to the data. There were no hard copies of the data. All data were securely stored on one 
password-protected laptop.  
 
3.2.6.1 Risks to the participants 
There were no risks to the participants, as no physical testing was carried out. Due to the sensitive 
nature of the questionnaire inquiring the use of both legal and illegal ergogenic aids, information 
obtained from the questionnaires was not forwarded to any regulatory body, such as the South 
African Institute for Drug-Free Sport (SAIDS) and South African cycling. This was clearly stated in the 
participant information sheet on the first page of the online questionnaire.  
 
3.2.6.2 Benefits to the participants 
There were no direct benefits to participants for taking part in this study. It was not possible to 
provide participants with feedback about the study due to the completely anonymous nature of the 
questionnaire. A small minority of participants contacted the researcher independently stating that 




Online Bicycling Magazine also requested feedback about the study with intention to write a feature 
story. Feedback to those participants who were interested in the results and to the online Bicycling 




The questionnaire was available on FluidSurveys© from the 22 April 2013 until 18 August 2013. Four 
hundred and sixty-seven responses were received. Figure 3.1 shows a summary of the study sample. 
Of all the responses received, 78 did not qualify for the study. Participants did not qualify as a result 
of not providing informed consent, failing to meet the training and medical screening criteria or they 
did not use the ergogenic aids listed. A further 182 participants were excluded, although having 
qualified, as they did not complete more than 30% of the questionnaire. By failing to complete more 
than 30%, participants did not reach Section C: the use of ergogenic aids (page 9 of the online 
questionnaire). Therefore a total of 207 participants qualified and were included in the analyses.  
The average completion time was 28.5 ± 32.2 minutes for males and 20.5 ± 11.7 minutes for 
females.  There was no significant difference in completion time between male and female 
participants. Although the questionnaire was available in both English and Afrikaans, no Afrikaans 














   
 
Figure 3.1: Summary of the study sample. 
Note:  
¥: Not qualified: the online questionnaire terminated due to the nature of the participants’ response. They either did not meet the inclusion criteria or were excluded on 
the basis of medical screening.  
β: Complete/ Incomplete questionnaires: if participants’ did not complete more than 30% of the questionnaire, it was considered incomplete. By failing to complete more 
than 30%, participants did not reach Section C: the use of ergogenic aids (page 9 of the online questionnaire).  
α: Incomplete questionnaires: the page number indicates the last part of the questionnaire that the participant completed. 







Did not give informed 
consent (n=8) 
 




Did not use any of the 
ergogenic aids 
included in the 
questionnaire (n=24) 
Did not pass the medical screening 
(n=20) 
Diabetes mellitus (n=5) 
Metabolic disorder (n=11) 
Eating disorder (n=3) 
Metabolic and eating disorder (n=1) 










 Questionnaire background 
(n=44) 
Pg 2 Inclusion criteria (n=38) 
Pg 3 Demographic data (n=11) 
Pg 4 Medical screening (n=1) 
Pg 5 Training & race history (n=6) 
Pg 6 Training & race history (n=67) 
Pg 7 Fluid intake (n=10) 
Pg 8 Ergogenic aids 1) (n=2) 
Pg 9 Ergogenic aids 2) (n=4) 
 
 
Fully completed but 
some missing data  
(n=13) 
 





3.3.2 Descriptive characteristics 
The descriptive characteristics of all participants included in the analysis (n=207) are shown in Table 
3.6 and Table 3.7 respectively. There were no significant differences in age, stature, body mass, BMI 
and level of education between male and female participants.  
 
Table 3.6: Descriptive characteristics of male (n=177) and female (n=30) participants. Data are expressed as 






Age (years) 45.1 ± 11.7 42.1 ± 10.1 
Stature (m) 1.8 ± 0.1 1.7 ± 0.1 
Body mass (kg) 82.5 ± 11.1 64.1 ± 10.4 
BMI 25.6 ± 3.2 23.4 ± 3.2 
 
Table 3.7: Level of education of male (n=177) and female (n=30) participants. Data are expressed as number 
of responses (n) and percentages (%). 






PhD 3 (1.5%) 1 (0.5%) 4 (2.0%) 
Masters 40 (19.3%) 4 (1.9%) 44 (21.3%) 
Honours 35 (16.9%) 5 (2.4%) 40 (19.3%) 
Diploma 41 (19.8%) 10 (4.8%) 51 (24.6%) 
Undergraduate 40 (19.3%) 5 (2.4%) 45 (21.7%) 
Grade 12 17 (8.2%) 5 (2.4%) 22 (10.6%) 
Grade 10 1 (0.5%) 0 (0.0%) 1 (0.5%) 






3.3.3 Training and competition history 
There were no significant differences in participation in competitive cycling or preferred cycling 
events between male and female participants (Table 3.8).  
 
Table 3.8: Competitive history and preferred cycling event of male (n=177) and female (n=30) participants. 







 Cycle competitively* 
Yes 80 (38.6%) 12 (5.8%) 92 (44.4%) 
No 97 (46.9%) 18 (8.7%) 115 (55.6%) 
 Preferred cycling event 
Road 107 (51.7%) 20 (9.6%) 127 (61.3%) 
Mountain biking 69 (33.3%) 9 (4.4%) 78 (37.7%) 
Time trial 1 (0.5%) 1 (0.5%) 2 (1.0%) 
 
There were no significant differences in average weekly mileage (km.wk-1) or the number of times 
participants cycled per week between males and females. The majority of participants cycled four 
times a week, averaging 80 km.wk-1 to 120 km.wk-1. Please refer to Appendix VI for weekly training 
data tables. 
 
3.3.3.1 Performance levels 
De Pauw et al(34) recently developed a performance classification system for cyclists based on 
physiological parameters and training status. As physiological parameters were not assessed in this 
study, a modified version of De Pauw et al(34) classification system (Table 3.9), was used to evaluate 




                                                          
*
 Competitive cycling was defined according to the following race times; (i) Cape Argus Pick ‘n Pay Cycle Tour 
(109 km): male-sub 3h15m, female-sub 3h30m, (ii) Momentum 94.7 Cycle Challenge (94.7 km): male-sub 









 PL 1 PL 2 PL 3 PL 4 PL 5 







Km.wk-1 - <60 km 60 to 290 km >250 km >500 km 
Number of times 
cycle per week 
- - ≥3 >3 >5 
Note: “-”: not assessed; PL: performance level. 
 
If performance level was assessed according to average weekly mileage only (Appendix VI), none of 
the participants fell into performance levels one and two. Eighty-eight percent (80.3%, n=183) of 
participants were classified at performance level three (trained cyclists); 12.2% (n=25) at 
performance level four (highly trained cyclists); and 0.5% (n=1) at performance level five 
(professional cyclists).  
If performance level was assessed according to the average number of times participants cycled per 
week only (Appendix VI), 21.8% (n=45) of participants who cycled only once or twice a week were 
not classified according to De Pauw et al(34), or can be predicted to be classified at performance level 
one or two. Twenty percent (20.3%, n=42) were classified at performance level three (trained 
cyclists); 46.3% (n=96) at performance level four (highly trained cyclists); and 11.6% (n=24) at 
performance level five (professional cyclists). 
Considering the two training parameters and where the majority of the participants were placed, 
average weekly mileage categorised the participants of this study as trained cyclists whereas average 
weekly frequency of training, categorised the participants as highly trained cyclists. The participants 





There were no significant differences in the number of recovery days for both types of competitive 
events between males and females (Table 3.10 and Table 3.11). The majority of the participants had 
two to three days recovery after a single day race (58.0%, n=120) and multi-stage race (16.4%, n=34) 
respectively. 
 
Table 3.10: Average number of recovery days of male (n=177) and female (n=30) participants after a single 
day event (80 km to100 km). Data are expressed as number of responses (n) and percentages (%). 








1 day 33 (15.9%) 7 (3.4%) 40 (19.3%) 
2-3 days 101 (48.8%) 19 (9.2%) 120 (58.0%) 
4-5 days 21 (10.1%) 3 (1.5%) 24 (11.6%) 
6-7 days 10 (4.8%) 1 (0.5%) 11 (5.3%) 
8-10 days 6 (2.9%) 0 (0.0%) 6 (2.9%) 
>11 days 6 (2.9%) 0 (0.0%) 6 (2.9%) 
 
Table 3.11: Average number of recovery days of males (n=177) and females (n=30) participants after a multi-
stage event. Data are expressed as number of responses (n) and percentages (%). 








1 day 7 (3.4%) 1 (0.5%) 8 (3.9%) 
2-3 days 29 (14.0%) 5 (2.4%) 34 (16.4%) 
4-5 days 25 (12.1%) 7 (3.4%) 32 (15.5%) 
6-7 days 17 (8.2%) 2 (1.0%) 19 (9.2%) 
8-10 days 5 (2.4%) 0 (0.0%) 5 (2.4%) 
11-12 days 5 (2.4%) 0 (0.0%) 5 (2.4%) 
13-14 days 2 (1.0%) 0 (0.0%) 2 (1.0%) 
>15 days 3 (1.5%) 0 (0.0%) 3 (1.5%) 





3.3.4 Type of ergogenic aids used 
All ergogenic aids were categorised into three groups for the presentation of the results and 
discussion section of this dissertation. The three groups included nutritional ergogenic aids (sports 
drinks/gels, CHO, PRO, amino acids, creatine, and electrolytes); pharmacological ergogenic aids 
(caffeine, Vitamin B*, NSAIDs, and analgesics); and illegal/banned ergogenic aids (anabolic steroids, 
HGH, and cortisone) (11). The ergogenic aid listed as “other” (n=15) was excluded from further 
analysis, as participants had to self-report what “other” included, which made it difficult to 
categorise. 
The ergogenic aids used by participants are shown in Figure 3.2. Nutritional ergogenic aids were 
used by 42.0%; pharmacological ergogenic aids by 23.4%, and illegal/banned ergogenic aids by 0.8% 
of participants.  The highest self-reported ergogenic aid used within each of the groups (nutritional, 











                                                          
*
The researcher is aware that Vitamin B can be classified as either a nutritional or pharmacological ergogenic 




























































































































Self-Reported Use of Ergogenic Aids
 






There were no significant differences in the use of ergogenic aids between males and females (Table 
3.12). Four participants (all males) used illegal/banned ergogenic aids. They included anabolic 
steroids, HGH and cortisone. Participants in this study did not use blood transfusions and EPO. The 
average number of ergogenic aids used by participants in this study was 3.1 (649 total instances/207 
total sample size) (187). Among all the ergogenic aids, sports drinks/gels had the highest reported use 
(90.8%, n=188), followed by CHO and PRO (56.5%, n=117), caffeine (44.9%, n=93) and electrolytes 
(40.1%, n=83). 
 
Table 3.12: Use of ergogenic aids in male (n=177) and female (n=30) participants. Data are expressed as 








Total number of 
participants using 
the aid Yes No Yes No 
Sports 
drinks/gels 
163 (78.7%) 14 (6.8%) 25 (12.1%) 5 (2.4%) 188 (90.8%) 
Nutritional (CHO 
and PRO) 
101 (48.8%) 76 (36.7%) 16 (7.7%) 14 (6.8%) 117 (56.5%) 
Amino acids 30 (14.5%) 147 (71.0%) 2 (1.0%) 28 (13.5%) 32 (15.5%) 
Creatine 15 (7.3%) 162 (78.2%) 0 (0.0%) 30 (14.5%) 15 (7.3%) 
Electrolytes 70 (33.8%) 107 (51.7%) 13 (6.3%) 17 (8.2%) 83 (40.1%) 
Caffeine 81 (39.1%) 96 (46.4%) 12 (5.8%) 18 (8.7%) 93 (44.9%) 
Vitamin B 45 (21.7%) 132 (63.8%) 10 (4.8%) 20 (9.7%) 55 (26.6%) 
NSAIDs 24 (11.6%) 153 (73.9%) 6 (2.9%) 24 (11.6%) 30 (14.5%) 
Analgesics 13 (6.3%) 164 (79.2%) 3 (1.5%) 27 (13.0%) 16 (7.8%) 
Anabolic 
steroids 
1 (0.5%) 176 (85.0%) 0 (0.0%) 30 (14.5%) 1 (0.5%) 
HGH 2 (1.0%) 175 (84.5%) 0 (0.0%) 30 (14.5%) 2 (1.0%) 
Cortisone 2 (1.0%) 175 (84.5%) 0 (0.0%) 30 (14.5%) 2 (1.0%) 
Blood 
transfusions 
0 (0.0%) 177 (85.5%) 0 (0.0%) 30 (14.5%) 0 (0.0%) 
EPO 0 (0.0%) 177 (85.5%) 0 (0.0%) 30 (14.5%) 0 (0.0%) 






3.3.5 Pattern of use of ergogenic aids 
3.3.5.1 Nutritional aids 
The pattern of use of nutritional ergogenic aids are shown in Figure 3.3, Figure 3.4 and Figure 3.5 
respectively. Table 3.13 (page 92) shows the percentage distribution of when all the ergogenic aids 
were reportedly used.  The majority of the participants used sports drinks/gels (48.7%, n=91), CHO 
(34.9%, n=38) and electrolytes (30.1%, n=25) before/during training and competition respectively. 
The majority of participants used PRO (28.6%, n=2) equally before training and competition, after 
training and after training and competition. Amino acids (28.1%, n=9) and creatine (33.3%, n=5) 
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3.3.5.2 Pharmacological aids 
Figure 3.6 and  
Figure 3.7 show when pharmacological ergogenic aids were used by participants. The majority of 
participants used caffeine (40.9%, n=38) and Vitamin B (45.5%, n=25) before training and 
competition. Non-steroidal anti-inflammatories (66.7%, n=20) and analgesics (43.8%, n=7) were 
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3.3.5.3 Illegal/banned aids 
Figure 3.8 shows when the illegal/banned ergogenic aids were used. Anabolic steroids were reported 
to be used by one participant before/during competition. Human growth hormone (n=1) was 
reportedly used before training and competition, while cortisone (n=2) was only used when 
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Before training & competition
Before training
number of responses
Pattern of Use: Illegal/Banned Ergogenic Aids
 





Table 3.13 summarise the pattern of use of all categories of ergogenic aids.  
 








































































































Before training 2.1% 1.8% 0.0% 3.1% 0.0% 1.2% 8.6% 9.1% 6.7% 0.0% 0.0% 0.0% 0.0% 
Before training 
& competition 





0.5% 9.2% 0.0% 0.0% 13.3% 4.8% 3.2% 9.1% 0.0% 6.3% 0.0% 0.0% 0.0% 
During training 1.1% 0.0% 0.0% 6.3% 0.0% 1.2% 2.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
During training 
& competition 
19.3% 10.1% 0.0% 0.0% 6.7% 19.3% 4.3% 1.8% 3.3% 0.0% 0.0% 0.0% 0.0% 
During 
competition 
7.5% 6.4% 0.0% 3.1% 0.0% 12.0% 9.7% 1.8% 3.3% 18.8% 0.0% 0.0% 0.0% 
Before & 
during training 








Table 3.13 (continued): Summary of the self-reported pattern of use of ergogenic aids by cyclists. Data are expressed as percentages (%). 
 






























































































12.8% 13.8% 0.0% 6.3% 0.0% 8.4% 17.2% 25.5% 10.0% 12.5% 100.0
% 
0.0% 0.0% 
After training 0.0% 0.0% 28.6% 0.0% 20.0% 7.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
After training & 
competition 
0.0% 0.9% 28.6% 12.5% 6.7% 1.2% 1.1% 0.0% 3.3% 0.0% 0.0% 0.0% 0.0% 
After 
competition 
0.0% 0.0% 0.0% 15.6% 0.0% 2.4% 0.0% 0.0% 0.0% 6.3% 0.0% 0.0% 0.0% 
Only if 
stiff/injured 





3.3.6 Details of the ergogenic aids used 
3.3.6.1 Nutritional aids 
Table 3.14 and Table 3.15 show detailed information regarding the nutritional ergogenic aids that 
were used by participants. Sports drinks (61.3%, n=114) were used more regularly than gels (6.4%, 
n=12). Refined (35.2%, n=75) and dense (35.7%, n=76) CHO were mostly consumed. Of the refined 
and dense CHO consumed, sports drinks (37.4%, n=101) and pasta/potato (28.6%, n=75) were the 
most popular. Carbohydrates (60.2%, n=59) were mostly ingested within 30 minutes of finishing 
training or a competition. Liquid PRO (40.0%, n=6) was the most popular form of PRO used. Of the 
liquid and lean PRO, milk (44.5%, n=4) and eggs (35.7%, n=5) were consumed the most. Protein 
(57.1%, n=4) was mostly ingested within 30 minutes of finishing training or a competition. The 
majority of participants (58.0%, n=18) used both whey and BCAA. Electrolytes (59.5%, n=47) were 






Table 3.14: Details regarding the self-reported use of sports drinks/gels and CHO. Data are expressed as 
number of responses (n) and percentages (%). 
Which product do you use more frequently: Sports drinks or gels? Number of responses (n) 
Sports drinks 114 (61.3%) 
Gels 12 (6.4%) 
Both 60 (32.3%) 
How soon after training or competition do you ingest 
carbohydrates? 
 
Within 30 minutes of finishing 59 (60.2%) 
Within two to four hours of finishing 17 (17.3%) 
>six hours of finishing 1 (1.0%) 
Within no specific time period 3 (3.1%) 
I do not ingest carbohydrates after training or competition 18 (18.4%) 
What form of carbohydrate do you ingest?  
Refined 75 (35.2%) 
Dense 76 (35.7%) 
Supplement 56 (26.3%) 
Other 6 (2.8%) 
What type of refined carbohydrate do you ingest?  
Sports drinks 101 (37.4%) 
Soft drinks 30 (11.1%) 
Sweets 25 (9.3%) 
Gels 50 (18.5%) 
Sports bars 61 (22.6%) 
Other 3 (1.1%) 
What type of dense carbohydrate do you ingest?  
Bread 63 (24.1%) 
Cereal 53 (20.2%) 
Pasta/potato 75 (28.6%) 
Rice 31 (11.8%) 
Fruit 37 (14.1%) 




Table 3.15: Details regarding the self-reported use of PRO, amino acids and electrolytes. Data are expressed 
as number of responses (n) and percentages (%). 
How soon after training or competition do you ingest protein?  
Within 30 minutes of finishing 4 (57.1%) 
Within two to four hours of finishing 1 (14.3%) 
>six hours of finishing 1 (14.3%) 
Within no specific time period 1 (14.3%) 
I do not ingest protein after training or competition 0 (0.0%) 
What form of protein do you ingest?  
Liquid 6 (40.0%) 
Lean 5 (33.3%) 
Powder 3 (20.0%) 
Other 1 (6.7%) 
What type of liquid protein do you ingest?  
Milk 4 (44.5%) 
Liquid meal replacement 2 (22.2%) 
Body building protein powder 3 (33.3%) 
Skim milk powder 0 (0.0%) 
Other 0 (0.0%) 
What type of lean protein do you ingest?  
Skinless chicken 4 (28.6%) 
Fish 3 (21.4%) 
Eggs 5 (35.7%) 
Low fat yogurt 2 (14.3%) 
Other 0 (0.0%) 
Which amino acid product do you use most frequently?  
BCAA 6 (19.4%) 
Whey 6 (19.4%) 
Both  18 (58.0%) 





Table 3.15 (continued): Details regarding the self-reported use of PRO, amino acids and electrolytes. Data 
are expressed as number of responses (n) and percentages (%). 
How soon after training or competition do you ingest electrolytes?  
Within 30 minutes of finishing 47 (59.5%) 
Within two to four hours of finishing 12 (15.2%) 
>six hours of finishing 0 (0.0%) 
Within no specific time period 11 (13.9%) 
I do not ingest electrolytes after training or competition 9 (11.4%) 
 
3.3.6.2 Pharmacological aids 
Table 3.16 shows detailed information regarding the pharmacological ergogenic aids that were used 
by participants. Participants mostly consumed caffeine (54.5%, n=67) through coffee. The NSAID and 
analgesic dosages used were similar. The majority of participants took two tablets per dose (NSAIDs 
53.5%, n=15 and analgesics 73.3%, n=11); one dose per day (NSAIDs 40.8%, n=11 and analgesics 




Table 3.16: Details regarding the self-reported use of caffeine, NSAIDs and analgesics. Data are expressed as 
number of responses (n) and percentages (%). 
What form of caffeine do you use? Number of responses (n) 
Coffee 67 (54.5%) 
Capsules 10 (8.1%) 
Red Bull 7 (5.7%) 
Chocolate 9 (7.3%) 
Other 30 (24.4%) 
How do you administer NSAIDs?  
Orally 26 (89.7%) 
Intravenously 1 (3.4%) 
Both 2 (6.9%) 
Number of NSAID tablets taken per dose?  
One 12 (42.9%) 
Two 15 (53.5%) 
Three 1 (3.6%) 
Four 0 (0.0%) 
Number of NSAID doses per day?  
One 11 (40.8%) 
Two 10 (37.0%) 
Three 6 (22.2%) 
Four 0 (0.0%) 
Numbers of days, NSAIDs are taken for?  
One 11 (39.3%) 
Two to three days 10 (35.7%) 
One-week 1 (3.6%) 
As long as I feel I need too 5 (17.8%) 





Table 3.16 (continued): Details regarding the self-reported use of caffeine, NSAIDs and analgesics. Data are 
expressed as number of responses (n) and percentages (%). 
Number of analgesic tablets taken per dose?  
One 2 (13.3%) 
Two 11 (73.3%) 
Three 1 (6.7%) 
Four 1 (6.7%) 
Number of analgesic doses per day?  
One 8 (53.3%) 
Two 6 (40.0%) 
Three 1 (6.7%) 
Four 0 (0.0%) 
Numbers of days, analgesics are taken for?  
One 9 (60.0%) 
Two to three days 3 (20.0%) 
One-week 0 (0.0%) 
As long as I feel I need too 3 (20.0%) 
 
3.3.6.3 Illegal/banned aids 
Table 3.17 shows detailed information regarding the illegal/banned ergogenic aids that were used by 
participants. Human growth hormone and cortisone were both reported to be administered 
intravenously. Participants used medical support personnel to help administer both HGH and 





Table 3.17: Details regarding the self-reported use of HGH and cortisone. Data are expressed as number of 
responses (n) and percentages (%). 
How do you administer human growth hormone? Number of responses (n) 
Orally 0 (0.0%) 
Intravenously 2 (100.0%) 
Do you use human growth hormone for therapeutic purposes or 
performance enhancing purposes? 
 
Therapeutic 1 (50.0%) 
Performance 1 (50.0%) 
Do you have help administering human growth hormone?  
General practitioner 0 (0.0%) 
Physiotherapist 0 (0.0%) 
Medical support personal 1 (50.0%) 
Team mate 1 (50.0%) 
Other 0 (0.0%) 
How do you administer cortisone?  
Orally 0 (0.0%) 
Intravenously 2 (100.0%) 
Do you use cortisone for therapeutic purposes or performance 
enhancing purposes? 
 
Therapeutic 1 (50.0%) 
Performance 1 (50.0%) 
Do you have help administering cortisone?  
General practitioner 1 (50.0%) 
Physiotherapist 0 (0.0%) 
Medical support personal 1 (50.0%) 
Team mate 0 (0.0%) 




3.3.7 Perceived effect of ergogenic aids 
3.3.7.1 Nutritional aids 
Figure 3.9 and Figure 3.10 show the perceived effect of nutritional ergogenic aids. Table.3.18 
summarises participants’ perception of effect of ergogenic aids used, expressed as percentages (%).  
Most participants perceived that sports drinks/gels (81.1%, n=150), CHO and PRO (75.0%, n=6), and 
electrolytes (60.8%, n=48) increased endurance and time to fatigue. Amino acids (53.3%, n=16) and 
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Perception of Effect: Sports Drinks/Gels & CHO/PRO
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Perception of Effect: Amino Acids, Creatine & Electrolytes
 




3.3.6.2 Pharmacological aids 
Figure 3.11 and Figure 3.12 show the perceived effect of pharmacological ergogenic aids. Most 
participants believed that caffeine (50.0%, n=46) and Vitamin B (34.6%, n=18) increased endurance 
and time to fatigue. Non-steroidal anti-inflammatories (71.4%, n=20) and analgesics (53.3%, n=8) 
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Perception of Effect: Caffeine & Vitamin B
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Perception of effect: NSAIDs & Analgesics
 




3.3.6.3 Illegal/banned ergogenic aids 
Figure 3.13 shows the perceived effect of illegal/banned ergogenic aids. Anabolic steroids were 
perceived to increase endurance and time to fatigue as well as increase strength and power. Human 
growth hormone was perceived to decrease stiffness, however one participant (of two only) was 
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Perception of Effect: Illegal/Banned Ergogenic Aids
 




Table.3.18 below summarises participants’ perception of effect of all categories of ergogenic aids.  
 


























































































13.0% 25.0% 51.6% 23.1% 34.2% 0.0% 15.4% 35.7% 13.3% 0.0% 0.0% 50.0% 
Decrease stiffness 10.3% 12.5% 25.8% 19.2% 25.3% 1.1% 1.9% 71.4% 53.3% 0.0% 50.0% 50.0% 
Increase endurance and 
time to fatigue 
81.1% 75.0% 22.6% 26.9% 60.8% 50.0% 34.6% 3.6% 13.3% 50.0% 0.0% 0.0% 
Increase strength and 
power 
29.2% 37.5% 32.3% 15.4% 7.6% 14.1% 9.6% 0.0% 6.7% 50.0% 0.0% 0.0% 
Increase muscle mass 0.5% 25.0% 45.2% 7.7% 2.5% 1.1% 1.9% 0.0% 0.0% 0.0% 0.0% 0.0% 
Other 8.6% 0.0% 3.2% 3.8% 12.7% 9.8% 23.1% 3.6% 20.0% 0.0% 0.0% 0.0% 
Unsure 9.7% 0.0% 9.7% 3.8% 7.6% 30.4% 26.9% 17.9% 13.2% 0.0% 50.0% 0.0% 




3.3.7 Participants’ perceived effect of ergogenic aids on performance 
Figure 3.14 shows the perceived effect of ergogenic aids on performance.  Responses were grouped 
according to whether participants believed that the ergogenic aid improved their performance; and 
if they had to stop using the ergogenic aids, whether their performance would deteriorate 
respectively.  Responses have been presented as three domains, namely: “yes/yes”, where 
participants responded positively to both questions; “yes/no”, where participants thought that 
although the aid improved their performance, their performance would not deteriorate if they 
stopped using the aid; and “no/no”, where participants responded negatively to both questions.  
The majority of participant’s (71.0% to 87.5%) using nutritional ergogenic aids where grouped in the 
“yes/yes” domain. Sports drinks/gels (6.5%, n=12), amino acids (12.9%, n=4), creatine (23.1%, n=3) 
and electrolytes (5.1%, n=4) had participants in the “yes/no” domain. Sports drinks/gels (8.1%, 
n=15), CHO and PRO (12.5%, n=1), amino acids (16.1%, n=5) and electrolytes (19.0%, n=15) had 
participants in the “no/no” domain.  
Of the pharmacological ergogenic aids caffeine (34.8%, n=32), Vitamin B (34.6%, n=18), NSAIDs 
(39.3%, n=11) and analgesics (60.0%, n=9) had participants in the “yes/yes” domain. Caffeine (37.0%, 
n=34) and Vitamin B (36.5%, n=19) had more participants in the “yes/no” domain. Non-steroidal 
anti-inflammatories (57.1%, n=16) had the majority of participants in the “no/no” domain. 
The one participant who reported using anabolic steroids was grouped in the “yes/yes” domain. The 
participants who used HGH (n=2) and cortisone (n=2) both had one participant grouped in the 























































































































Perceived Effect of Ergogenic Aids on Performance
 
Figure 3.14: Participants’ perceived effect of ergogenic aids on performance. 
 




3.3.8 Sources of information influencing the use of specific ergogenic aids 
Less than 12% of participants sought information from research articles as their primary source of 
information. Participants using ergogenic aids mainly obtained information from “questionable” 
resources, such as self-experimentation (51.7%), fellow cyclists (13.7%), books/magazines (8.6%), 
coaches/trainers (7.0%), the internet (5.5%), and adverts (2.3%) as their primary source (59). 
 
3.3.8.1 Nutritional aids 
Participant’s primary source of information influencing the use of all nutritional ergogenic aids 
(sports drinks/gels 50.5%, n=92; CHO and PRO 85.7%, n=6; amino acids 30.0%, n=9; creatine 45.5%, 
n=5; and electrolytes 54.5%, n=42) was self-experimentation (Figure 3.15 and Figure 3.16). Fellow 
cyclists were the second most influential source for sports drinks/gels (25.9%, n=43), CHO and PRO 
(57.1%, n=4) and electrolytes (33.8%, n=25). The third most influential sources of information across 
all the nutritional ergogenic aids (n=5) were adverts (n=3), books/magazines (n=2) and research 






























Source of Information: Sports Drinks/Gels & CHO/PRO
 











































Source of Information: Amino Acids, Creatine & Electrolytes




3.3.8.2 Pharmacological aids 
Participant’s primary source of information influencing the use of all pharmacological ergogenic aids 
(caffeine 46.7%, n=42; Vitamin B 42.6%, n=20; NSAIDs 76.0%, n=19; and analgesics 80.0%, n=12) was 
self-experimentation (Figure 3.17 and Figure 3.18). The second most influential source for caffeine 
(25.9%, n=21) was fellow cyclists, whereas for NSAIDs (30.4%, n=7) and analgesics (36.4%, n=4) it 
was research articles. The third most influential sources of information across all the 



































Source of Information: Caffeine & Vitamin B
 






























Source of Information: NSAIDs & Analgesics
 





3.3.8.3 Illegal/banned ergogenic aids 
Participant’s primary source of information influencing the use of all the illegal/banned ergogenic 
aids (anabolic steroids n=1, HGH n=1, and cortisone n=1) was self-experimentation (Figure 3.19).  
Research articles (n=1), books/magazines (n=1), the internet (n=1) and fellow cyclists (n=1) were 
found to be the second most influential sources of information. The third most influential source of 















































Source of Information: Illegal/Banned Ergogenic Aids
 





3.3.9 Regression analyses of factors influencing the use of specific ergogenic aids 
Forward stepwise regression analyses were performed to predict the probability of participants 
using a specific ergogenic aid. The predictor (independent) variables were age, BMI, education, 
preferred cycling event, cycling competitively, average weekly mileage (km.wk-1), number of times a 
participant cycled per week (frequency) and the number of recovery days post competition (80 km 
to 100 km). The predictor variables were coded in Table 3.5 Section 3.2.5 (page 71). This study was 
unable to identify predictive factors for the use of sports drinks/gels, Vitamin B and NSAIDs.  The 
non-significant regression analyses are presented in Appendix VII. 
 
3.3.9.1 Nutritional aids 
a) Carbohydrates and PRO 
In Table 3. preferred type of event (p = 0.04) and the average weekly mileage (p = 0.03) were 
significant factors influencing the use of CHO and PRO. Road cyclists were half as likely (Exp(B) = 
0.52) to use CHO and PRO compared to mountain bikers. Furthermore, participants who cycled more 
than 120 km.wk-1 were 2.28 times more likely to use CHO and PRO than those who cycled less than 


















 1.25 0.64   0.22 
Age  
 1.59 0.17 0.83 3.06 1.92 
BMI 
 0.82 0.53 0.45 1.52 0.39 
Education 
 1.06 0.90 0.43 2.62 0.02 
Preferred 
cycling event 0.52 0.04* 0.28 0.96 4.44 
Cycle 
competitively 1.21 0.59 0.61 2.37 0.29 
Km.wk-1 













In Table 3.20, preferred type of event (p = 0.003) and the number of recovery days post competition 
(p = 0.02) were significance factors influencing the use of electrolytes.  Road cyclists were 
approximately a third (Exp(B) = 0.39) less likely to use electrolytes compared to mountain bikers. 
Participants who recovered for less than three days after a competition were nearly three times 
more likely (Exp(B) = 2.65) to use electrolytes than those that recovered for more than four days. 
 













 0.34 0.04   4.20 
Age  
 1.85 0.07 0.95 3.61 3.29 
BMI 
 1.03 0.94 0.53 1.97 0.01 
Education 
 0.77 0.61 0.29 2.05 0.27 
Preferred 
cycling event 0.39 0.003* 0.21 0.72 8.94 
Cycle 
competitively 1.61 0.19 0.79 3.26 1.71 
Km.wk-1 













c) Amino acids 
There was a tendency for competitive cycling to be predictive of the use of amino acids (p = 0.07); 
however this difference was not significant (Table 3.21). This may be due to the small amount of 
participants who reported using amino acids (n=32), which would correspond to the large CI 
observed (0.93 - 6.30).  
 













 0.10 0.00   10.21 
Age  
 1.77 0.19 0.76 4.11 1.75 
BMI 
 1.20 0.69 0.50 2.83 0.16 
Education 
 0.43 0.29 0.09 2.03 1.14 
Preferred 
cycling event 0.56 0.15 0.25 1.24 2.04 
Cycle 
competitively 2.42 0.07 0.93 6.30 3.26 
Km.wk-1 















There was a tendency for average weekly mileage (km.wk-1) to be predictive of the use of creatine (p 
= 0.08); however this difference was not significant (Table.3.22). As with amino acids, the small 
amount of participants reportedly using creatine (n=15) could cause this tendency. The large CI 
observed (0.86 - 17.64) would correspond to the small sample size. 
 













 0.02 0.00   14.63 
Age  
 2.67 0.11 0.79 9.01 2.50 
BMI 
 1.68 0.39 0.51 5.56 0.73 
Education 
 2.36 0.23 0.58 9.58 1.45 
Preferred 
cycling event 1.84 0.33 0.54 6.29 0.94 
Cycle 
competitively 1.04 0.95 0.29 3.72 0.00 
Km.wk-1 
















3.3.9.2 Pharmacological aids 
a) Caffeine 
In Table 3., age had a significant effect (p = 0.04) on the use of caffeine. The likelihood of someone 
older tha 40 years of age using caffeine were double that of someone younger than 39 years of age. 
Participants who cycled more than 120 km.wk-1 were twice as likely to use caffeine compared to 
those participants who cycled less than 119 km.wk-1 (p = 0.06); however this was not significant. 
 













 0.55 0.21   1.55 
Age  
 1.99 0.04* 1.04 3.82 4.32 
BMI 
 0.85 0.60 0.45 1.58 0.28 
Education 
 1.17 0.73 0.47 2.94 0.12 
Preferred 
cycling event 0.62 0.13 0.34 1.14 2.35 
Cycle 
competitively 1.81 0.09 0.92 3.56 2.97 
Km.wk-1 














In Table 3., the preferred cycling event had a significant effect (p = 0.02) on the use of analgesics. 
Road cyclists were 11.55 times more likely to use analgesics compared to mountain bikers. Although 
this factor was significant the CI was very large (1.45 - 91.98); therefore this result should be 
interpreted with caution. 
 













 0.01 0.00   12.02 
Age  
 1.60 0.43 0.50 5.13 0.62 
BMI 
 1.47 0.50 0.48 4.52 0.45 
Education 
 2.01 0.34 0.49 8.31 0.92 
Preferred 
cycling event 11.55 0.02* 1.45 91.98 5.34 
Cycle 
competitively 1.04 0.96 0.29 3.68 0.00 
Km.wk-1 












3.3.10 Summary of results 
In summary, the participants in this study used an average of three ergogenic aids. Nutritional 
ergogenic aids were used by 42.0%; pharmacological by 23.4% and illegal/banned by 0.8% of the 
participants.  Sports drinks/gels, CHO and PRO, caffeine and electrolytes were the most commonly 
used ergogenic aids. 
Nutritional ergogenic aids (80.0%) were used mostly for both training and competition. Of the 
pharmacological ergogenic aids, caffeine and Vitamin B were mostly used for training and 
competition, whereas NSAIDs (66.7%) and analgesics (43.8%) were only used when participants were 
stiff and/or injured. The illegal/banned ergogenic aids were mostly used (66.6%) for competition. 
Cortisone was not reported to be used in training and competition. 
The majority of the participants (58.3%) perceived that the seven ergogenic aids (sports drinks/gels, 
CHO and PRO, electrolytes, caffeine, Vitamin B, and anabolic steroids) increased endurance and time 
to fatigue. Thirty-three percent (33.3%) of participants perceived that the four ergogenic aids 
(NSAIDs, analgesics, HGH, and cortisone) decreased stiffness. Seventeen percent (16.7%) of 
participants perceived that the two ergogenic aids (amino acids and cortisone) decreased cellular 
damage and that the two ergogenic aids (creatine and anabolic steroids) increased strength and 
power. Participant’s primary source of information influencing the use of all ergogenic aids (n=12) 
listed was self-experimentation. Less than 12.0% of participants sought information from research 
articles as their primary source of information. 
Preferred cycling event, average weekly mileage, age and the number of recovery days were factors 
found to significantly influence the use of ergogenic aids. Road cyclists were less likely to use CHO 
and PRO (p = 0.04) and electrolytes (p = 0.003), but they were 11.55 times more likely to use 
analgesics (p = 0.02) compared to mountain bikers. Participants who cycled more than 120 km.wk-1 
(p = 0.03) were more likely to use CHO and PRO, and those that recovered for less than three days 
were more likely to use electrolytes (p = 0.02). Participants older than 40 years of age were twice as 






The purpose of this study was to describe the use of ergogenic aids in South African cyclists during 
training and competition. The discussion follows the order of presentation of the results in Section 
3.3 (page 74). The literature has determined that investigating the use of ergogenic aids, both legal 
and illegal, is challenging due to the sensitive nature of the topic (127,188-192).  The diverse prevalence 
of use and lack of evidence, especially within the sport of cycling, can be attributed to the fact that 
doping and or the use of ergogenic aids, is illicit and most often concealed behaviour (8,9,66). 
 
3.4.1 Participants 
3.4.1.1 Sample size 
The total sample size of this study was 207 participants, which provided a statistical power of 
approximately 90%. It must be recognised that over 2600 potential participants were emailed 
individually requesting their participation in the study along with the questionnaire link. A total of 58 
cycling clubs and shops were contacted nationwide requesting the advertisement of the study in 
their respective newsletters. Five popular cycling media platforms also advertised the study link 
online. A total of 467 potential participants responded, which was narrowed down to 207 
participants following a protocol of exclusion criteria. It is not possible to calculate a response rate 
for this study, based on the methods of distribution of the questionnaire and also the anonymity. 
The anonymity of the online questionnaire prevented the researcher from seeing the total number 
of people that accessed the link but that did not start the survey. 
Low response rates are commonly reported in studies that investigate supplement use in athletes.  
Petroczi and Naughton(187) investigated the use of nutritional supplements among athletes over 18 
years old sent out 2995 surveys to randomly selected participants via sports councils, and received 
874 responses. Of those responses, only 520 met their criteria for further analysis. Brissonneau and 
Ohl(188) on the genesis and effect of French anti-doping policies in cycling, tried interviewing any 
professional cyclist between the years of 1960 and 2000 on doping behaviour. Of all the professional 
cyclists through those years, only 20 individuals were willing to take part in their study. Investigating 
the use of ergogenic aids both legal and illegal is challenging (127,188-192). The literature has shown that 
athletes are reluctant to discuss their use of performance-enhancing products, particularly of illegal 
substances. Previous studies’ response rates have shown to be similar to the seemingly low response 




The sample size of studies that investigated the use of ergogenic aids varied widely across the 
literature (190). The difference in sample size was largely dependent on whether the studies were 
sport-specific or not. Studies targeting “all sports” had larger sample sizes of between 257 to 1810 
athletes (64,187,190,193), whereas those specific to cycling had between eight and 70 participants 
(40,159,163).  Former studies that were sport-specific (power-lifters, n=26 and skiers, n=67) also had 
smaller sample sizes (112,184). It is recognised that a larger sample size would have allowed for a more 
generalised representation of the South African cycling community. 
 
3.4.1.2 Descriptive characteristics 
There were no significant differences in age, body mass, stature, BMI and level of education 
between male and female participants. Participants were well-educated, with 88.9% having at least 
a tertiary school education. Only 30 participants were female. This finding might reflect different 
levels of participation in sport, but may be due to other factors related to the use of ergogenic 
aids.The mean age of participants was 44 years of age, suggesting that more adults over the age of 
40 are participating in cycling. There are no previous studies in South African cyclists to compare 
data, however Australia demonstrated a similar pattern of cycling for age and gender, indicating 
fewer women and older adults cycling (194). 
Most studies that investigated the use of performance enhancing substances amongst cyclists 
exclusively used male participants (5,9,188,191,193). Previous studies that investigated the use of 
performance-enhancing substances among “all sports” included female participants 
(7,64,66,114,184,187,190,193). The inclusion of females in this study is novel and would have allowed for a 
more generalised observation of the use of ergogenic aids across a cycling population, rather than a 
gender-specific observation. This study attempted to explore use in females but a larger sample size 
would have been needed. Sub-group analysis was only performed on descriptive characteristics, 
training and competition history and the type of ergogenic aids used. There were no significant 
differences between male and female participants across all the sub-group analyses. A consistent 
pattern of considerably lower rates of cycling amongst females has been shown in self-reported 
surveys (195). A survey by the Australian Sports Commission found that females participated in cycling 
half as much as males (194,195).  There is a lack of evidence regarding nutritional intake, and 




Previous studies have used younger cyclists between 18 and 27 years old (5,9,188,191). Where former 
professionals were included in the same age group, the focus was on their career (184,187,189). This 
study did not exclude participants based on age, and showed results across a broader cycling 
population (18 to 65 years old). 
 
3.4.2 Training and competition history 
More than forty-four percent (44.4%) of the participants cycled competitively. The majority of 
participants preferred road cycling (61.3%) compared to mountain biking (37.7%).  Previous studies 
have not included mountain biking in their investigation of the use of performance enhancing 
substances (ergogenic aids) in cyclists (5,9,17,188,191). In general, road and track cycling are the most 
common disciplines reported in cycling literature (173). A major limitation of studies investigating the 
relative characteristics of cycling and the effects of ergogenic aids on cycling performance, is the lack 
of consensus regarding the calibre of cyclists used or observed (66). In an attempt to classify the 
participants in this study, a modified version of De Pauw et al(34) performance classification system 
was used. Participants were classified as ranging between trained and highly trained. 
Studies that have investigated the use of performance-enhancing substances amongst cyclists used 
pre-professional, currently professional, or former professional cyclists only (5,9,17,188,191). Studies that 
used trained or highly trained participants were not specific to cycling (7,187,190,193). Previous studies 
have not investigated the use of performance enhancing substances in this calibre of cyclists 
specifically. This makes a direct comparison of results of different studies difficult. 
The majority of the participants took two to three days to recover after a single day race and multi-
stage race respectively. Cycling competitions are generally high-intensity in nature, and the 
literature states that the higher the intensity of the exercise bout, the longer the length of the 
recovery period needed (183). It may be assumed then that a longer recovery period would be needed 
after a multi-stage race compared to a single day race, which was not found in this study. Recovery 
must be individualised and match the specific stress (i.e. single day race versus multi-stage race) to 
maximise the adaptations due to physical training (183).  
 
3.4.3 Type of ergogenic aids used 
The prevalence of doping varies widely across studies (193). A review of self-reported studies between 
1980 and 1996, estimated a 3% to 5% prevalence of doping for children and adolescents and 5% to 




Petroczi(7) carried out a questionnaire-based study on highly trained male college athletes (“all 
sports”, n=174), which included past and current use of performance enhancing substances (both 
legal and illegal). Results showed a 7.5% current use of illegal drugs and a 2.5% current use of legal 
performance enhancing substances (7). 
The true incidence of doping is thus difficult to define in cycling, as most studies are not specific to 
cycling (66). Participants used an average of three ergogenic aids in this study (649 total instances/207 
total sample size) (187). If compared to the results in the Petroczi and Naughton (187) in 2008, the result 
from this present study, namely, 3.2 (number of instances/total sample size) for the average number 
of ergogenic aids, was similar. 
Nutritional ergogenic aids were used by 42.0% of participants; pharmacological ergogenic aids by 
23.4% of participants and illegal/banned ergogenic aids by 0.8% of participants. Sports drinks/gels 
CHO and PRO, caffeine and electrolytes were the most commonly used ergogenic aids. Moran et 
al(193) conducted a study using high performance athletes (n=375) older than 18 years old. Results 
demonstrated that 11% of the athletes self-reported to have knowingly used illegal substances to 
improve performance. These results were similar to those estimated by Laure(196), although Moran et 
al(193)  included both recreational substances and performance-enhancing substances. When the use 
of recreational drugs (cannabis and alcohol) was removed, only 2.2% of the athletes admitted to 
using drugs to specifically enhance performance. This reported prevalence is comparable to the 2.8% 
adverse analytical findings across all sporting codes tested in the South African (Bloemfontein) 
laboratory in 2012 (197). It is also comparable to the SAIDS 2011/2012 annual report, which found a 
2.7% adverse analytical finding across 35 sporting codes (192). More specific to cycling, the Union 
Cyclistse Internationale (UCI) reported a 1.1% rate of adverse analytical findings in 2012 (197). This 
was the most comparable statistic to the findings in this study of 0.8% self-reported use of 
illegal/banned substances. 
 
3.4.3.1 Nutritional ergogenic aids 
Of the nutritional ergogenic aids listed, sports drinks/gels (90.8%), CHO and PRO (56.5%) and 
electrolytes (40.1%) were used for the most part, followed by amino acids (15.5%) and creatine 
(7.3%). There was no significant difference between gender and the use of nutritional ergogenic 
aids, although the majority of male participants used amino acids, while creatine was used 




Nutritional practices of cyclists are aimed at improving training adaptations and competition 
performance (4). Carbohydrates represent an important fuel for both these components of cycling (4). 
Burke(4) found that male cyclists generally exceeded the estimated intake of PRO for athletes who 
were highly trained. 
There is not much data on the prevalence of using CHO and PRO for the specific purpose of 
enhancing performance. Research has shown that CHO ingestion can delay the onset of fatigue 
during prolonged cycling and thus provide an ergogenic effect through enhanced endurance 
performance (75,92,95,97). The evidence for the consumption of electrolytes to enhance performance 
and improve recovery is lacking (126). In spite of this, a large percentage of participants reported using 
electrolytes. Previous studies have not investigated the prevalence of electrolytes among cyclists, so 
the findings of this study cannot be compared to previous findings. Lentillon-Kaestner and Carstairs(9) 
interviewed young elite cyclists (n=8), with the aim to identify and understand the use of legal and 
illegal performance enhancing substances. All participants reported using performance enhancing 
products, and a wide variety of products was used. The nutritional products included amino acids, 
CHO and PRO (9). There was also a high reported use of nutritional supplements among the cyclists.  
The risk of taking nutritional supplements is high, as they often lead to inadvertent doping. 
Supplements may contain illegal substances which are not acknowledged on their label (9). The 
world’s largest supplement testing laboratory in Europe carried out a survey (HFL Sports Science 
2013 European Supplement contamination survey) on 114 products from the top 24 supplement 
brands across Europe. Supplements tested included energy products, protein shakes, gels, powders, 
liquids and tablets. A 10% contamination rate was found, with capsules and tablets having the 
highest incidence of contamination (192). The Cologne laboratory also carried out a survey of 
nutritional supplements which included vitamins, minerals, PRO, amino acids and creatine, 
purchased from 13 different countries. Altogether, 14.8% of the supplements tested contained 
illegal substances and a further 10% produced adverse analytical findings (42). These two surveys 
highlight the risk involved in using nutritional supplements, not just for cyclists but for all athletes 
alike. 
Petroczi and Naughton(187) described a 36.1% self-reported use of creatine among 520 high-
performance athletes. Although the percentage is higher than this current study (7.3%), they had a 
much larger sample size which included athletes from “all sports”. Cyclists only represented 8.7% of 
their total sample size. Similar to this study, the authors found that creatine was typically associated 
with males across all age groups. In contrast to the findings of this study, they found that athletes 




3.4.3.2 Pharmacological ergogenic aids 
Of the pharmacological ergogenic aids listed, caffeine (44.9%) and Vitamin B (26.6%) were used the 
most, followed by NSAIDs (14.5%) and analgesics (7.8%). Del Coso, Munoz and Munoz-Guerra(198) 
investigated the use of caffeine by athletes after its removal from the WADA list in 2004. Urine 
samples from 2004 to 2008 were used after official national and international competitions 
(n=20,686). More than seventy percent (73.8%) of the urine samples contained caffeine; cycling had 
the second highest levels of urine caffeine concentration. This figure was considerably higher than 
the reported use of caffeine by athletes (23.7%) in a previous study done in 2008. This did not differ 
signficantly, however, from Van Thuyne et al(199) who found that 74% of urine samples tested 
between 1993 and 2002 contained caffeine. This suggests that the use of caffeine has not changed in 
sports since its removal from the WADA list. Del Coso, Munoz and Munoz-Guerra(198) found no 
significant difference between males and females. The endurance sports, i.e. the triathlon, cycling 
and rowing, had the highest urine caffeine excretion after competition, suggesting that caffeine is 
used before and/or during competition (198). After the removal of caffeine from the WADA prohibited 
list, an increase in the use of caffeine might have been expected (198). The authors hypothesised that 
the former urinary threshold for doping (12 ug.ml-1) was not restrictive enough to control the use of 
caffeine amongst athletes for the specific purpose of enhancing performance. The literature has 
evidently demonstrated that the beneficial effects of caffeine on performance can be met at doses 
that are well below the IOC urinary threshold (127,132,136). 
Multivitamins have been reported to be used by 70.7% of athletes (187). Previous studies have found 
that Vitamin C, multivitamins, mineral products, and caffeine are most commonly used by cyclists 
(6,9). This is despite the lack of evidence for them enhancing performance (caffeine excluded). Most 
athletes have reported to take multivitamins (which include Vitamin B) for general reassurance and 
to avoid possible deficiencies (20). 
The use of NSAIDs and analgesics is relatively unknown amongst cyclists. Most of the studies specific 
to cycling did not give reference to the use of these medications (9,17,188,191). Huang, Johnson and 
Pipe(64) investigated the use of medication by Canadian athletes at the Atlanta (1996) and Sydney 
(2000) Olympic Games. Non-steroidal anti-inflammatories were the most commonly used 
medication at both games amongst athletes, with cycling being one of the sports in which a high 




There was an overall prevalence of 33% in Atlanta and 38% in Sydney. This is much higher than the 
findings in this study, although it is a representation of athletes across “all sports” (64). Laraschi et al(6) 
was the one study specific to cycling in which the use of prescription drugs was reportedly a 
common occurrence among young elite cyclists, specifically the use of NSAIDs. 
 
3.4.3.3 Illegal/banned ergogenic aids 
A total of four participants in this study self-reported to be doping. Human growth hormone (1.0%), 
cortisone (1.0%) and anabolic steroids (0.5%) were used; EPO and blood transfusions were not 
reported to be used by any of the participants in this study. According to the WADA 2012 report, out 
of all the Olympic sports, cycling had the third highest number of samples analysed- football and 
athletics respectively had the highest number of samples analysed (197). Three South African cyclists 
in the 2011/2012 year tested positive for illegal/banned substances and were subsequently 
prosecuted (192). Two of the cyclists tested positive for anabolic steroids and one for stimulants (192). 
Although this may seem similar to the current study’s results on reported doping, there are some 
important points to consider. Firstly, surveys of this nature present limitations of under-reporting, 
and secondly, potentially far more cyclists are doping, but are for various reasons undetected 
(5,9,66,127,187-191,193,198). In addition, SAIDS drugs-test cyclists’ considered to be “professional”, whereas 
the participants in this study represented a different calibre of cyclists, who are not generally flagged 
for drug testing.  
Recent studies have evaluated the incidence of anabolic steroids in various age groups and across 
various sports and sporting levels (127,144,174). Although the exact incidence varies between all studies 
and across different groups, there is great concern regarding the increase in prevalence, especially 
amongst high school students (127). The approximate prevalence of anabolic steroid use among 
cyclists is unknown and most evidence is based on anecdotal data. 
The literature suggests that HGH is abused by numerous cyclists; however, a prevalence rate has not 
been documented to the knowledge of this researcher (154). Lentillon-Kaestner, Hagger and 
Hardcastle(5) recognised that of the cyclists interviewed in their study, there was a consistent 
reference to EPO, HGH and cortisone with regards to doping. Evidence for cyclists using HGH has 
generally emerged from media reports on the positive testing of professional cyclists. The Festina 
team scandal was one such highly publicised event, in which the cyclists and the physiotherapist 




Though only 1.0% (n=2) of participants admitted to using cortisone in this study, research has 
previously reported the frequent use of cortisone in cycling through the misuse of TUE certificates to 
improve performance (5,9,17). The South African Institute of Drug-Free Sport reported receiving 13 
TUE certificates during the 2011/2012 year from cycling specifically. Rowing and swimming had the 
highest incidence of TUE certificates (192). It was not clear from the data of this study whether the 
participants using cortisone had TUE certificates or not.  
In this study EPO and blood transfusions were not reported to be used. This finding is congruent with 
the literature. Among the cycling studies, the use of EPO and blood transfusions was minimal. The 
high costs and difficulties in obtaining the substances and instruments, along with the intricacies 
involved in the administration and the storage of the products were restricting factors (5,9). Lentillon-
Kaestner, Hagger and Hardcastle(5) found that EPO was used more at a professional level, as a result 
of these usage constraints. The participants of this study were only classified as trained/highly 
trained cyclists, which may potentially be the reason that the results of this study had no reported 
use of EPO and blood transfusions. The misuse of EPO as an ergogenic aid has been projected to 
range between 3% and 7% in elite endurance athletes (“all sports”) (157). There is a considerable 
amount of clinical evidence supporting the ergogenic benefits of EPO on endurance performance as 
a result of the increases in haemoglobin, haematocrit and VO2max 
(157,166,168-171). 
Since all the doping scandals, regulations and preventative actions have been increased (5). Across 
the studies reviewed, there was consensus that the sport has evolved since 1998 (Festina team 
scandal) and doping is now less of an organised team practice and rather a more individualised deed 
(5,9,17,188-191,193). Although cycling, as a sport, is scrutinised and stigmatised in the media to be “the 
doping sport”, WADA, SAIDS and the UCI are finding low rates of adverse analytical findings. This 
finding can be seen as similar to the low percentage of participants in this study who admitted to 
doping. It can be argued that, as doping is now perhaps more individualised, and cycling is subjected 
to close scrutiny (cycling had the third highest amount of tests analysed by WADA in 2012)(197), those 
cyclists that are doping, are more cunning and secretive about their behaviour, making true 
incidence rates hard to obtain. The Festina Affair might thus actually have been a catalyst for more 
sophisticated doping regimes as evidenced by iconic individuals and popular teams over the last 
decade. 
Of the self-reported use of illegal/banned ergogenic aids in this study, all were from male 
participants. In general this proved non-significant in this study, an epidemiological review by 
Laure(196) found similar results. Across all the reviewed studies, males displayed higher usage of 




Moran et al(193) also found that males had a more positive attitude towards doping compared to 
females. There is literature available that provides insight into the differences in use of ergogenic 
aids and gender, however whilst acknowledging the theories put forward, no clear theory has yet to 
predict doping behaviour related to gender type (189). 
 
3.4.4 Pattern of use and perceived effects 
Research investigating the tactical strategies employed by athletes is lacking, especially amongst 
cyclists, as to when certain ergogenic aids are used. Through clinical trials, the literature has 
described and recommended when and how particular ergogenic aids should be taken to obtain the 
maximum performance enhancing benefits (66,75,103,133,146).  
 
3.4.4.1 Nutritional ergogenic aids 
Eighty percent (80%) of the nutritional ergogenic aids were used for both training and competition 
(Section 3.3.5, page 83). The majority of participants believed that sports drinks/gels, CHO and 
electrolytes worked by increasing endurance and time to fatigue. The literature has demonstrated 
the ergogenic effect of CHO on endurance performance by increasing time-to-fatigue (75,92,95,97). 
Carbohydrates are recommended to be consumed three to six hours before an event, and during 
exercise that lasts longer than 90 minutes (66,72,75,76,78). Whether CHO is consumed in the liquid (sports 
drinks/gels) or solid form, the ergogenic benefit is not affected (80). 
Amino acids and creatine were used more frequently before training and competition. Amino acids 
were perceived to decrease cellular damage and creatine to increase strength and power. A 
relationship can be made as to when creatine was most used and its perceived effect. As for amino 
acids it may have been assumed that participants would consume them after training and 
competition to enhance recovery. A possible explanation may be the use of unreliable information 
resources used by participants. 
 
3.4.4.2 Pharmacological ergogenic aids 
Caffeine and Vitamin B were mostly used before training and competition, which correlated to the 
participants’ perception that they increased endurance and time-to-fatigue. This finding also relates 





The literature suggests that caffeine be ingested one hour before exercise for maximum benefit (133). 
Coffee, tea and soft drinks are considered weaker sources of caffeine compared to concentrated 
caffeine (capsule) (130). Yet participants reported using caffeine mostly through the consumption of 
coffee. Currently there is little literature to support supplementation with vitamins, minerals and 
anti-oxidants for athletes following a normal healthy diet. There is also little scientific evidence 
showing any benefit of vitamin supplementation on exercise performance in endurance athletes 
(11,20,42,64). As seen from the results, Section 3.3.8 (page 112) a very low percentage of participants 
actually sought information from reliable resources. This may influence the pattern of use as seen 
above. 
Non-steroidal anti-inflammatories and analgesics were used mainly when participants were stiff 
and/or injured, which correlates to the perceived effect of decreasing stiffness. This may suggest 
that participants were using them to enhance the recovery process after a bout of intensive training 
or competition. It does not, however, indicate whether participants were using these medications 
during exercise, which is of concern because of the potential interactions that may occur with 
exercise and the use of medication. Despite the lack of scientific evidence demonstrating ergogenic 
effects of vitamins, NSAIDs and analgesics on sports performance, 48.8% of the participants in this 
study reported using these products. 
 
3.4.4.3 Illegal/banned ergogenic aids 
The illegal/banned ergogenic aids were mostly used (66.6%) for competition. Cortisone was not 
reported to be used in training or competition, but only when participants felt stiff and/or were 
injured. The illegal/banned ergogenic aids had more than one commonly perceived effect of which 
one included “unsure”. This may suggest that knowledge about these ergogenic aids is poor. This is 
concerning since, firstly, there is poor evidence supporting their effect on endurance performance, 
and secondly, because of the consequential health effects related to their use (11,18,66,103,144,174). 
 
3.4.5 Perceived effects on performance 
Fifty-eight percent (58%) of participants perceived that the ergogenic aids used increased endurance 
and time to fatigue. Thirty-three percent (33.3%) of participants perceived that they decreased 





All the cyclists in the Lentillin-Kaestner and Carstairs(9) study expected the methods and substances 
that they used would have beneficial effects on their performance. They had, however, not 
quantified or evaluated them. Athletic performance may be improved by expectancy effects (200). 
Eighty-nine percent (89%) of athletes surveyed professed positive effects from ergogenic aids on 
their performance (200,201). Of all the ergogenic aids listed in this study, besides for creatine and 
anabolic steroids, a percentage of participants were grouped in the “no/no” domain (Section 3.3.7, 
page 110). This is an interesting observation, which raises questions as to what the motivation is 
behind the continued use of a substance. The intense marketing and promotion of products may 
drive the continued use, or athletes continue to use substances out of habit. Eight percent (8%) of 
participants in a previous study reported “common habit” as a reason for doping (6). Another theory 
suggests that athletes become psychologically dependent on a substance. If participants have taken 
the substance previously and had a good race, there is then a notion of belief that they must always 
take it, because without it they are unlikely to do well again (9). Future research needs to investigate 
the motivation for the use of specific ergogenic aids in order to better understand the athletes’ 
intentions and behaviour. 
 
3.4.6 Sources of information 
Cycling has been described in the literature as being a “coherent community built on shared ideals” 
(17). This description of cycling aptly relates to the findings in this study, highlighting the impact 
fellow cyclists have on each other’s behaviour due to the tight nit nature of the sport (especially 
road cycling).  
 
Participants using ergogenic aids mainly obtained information from “questionable” resources, such 
as self-experimentation (51.7%) and fellow cyclists (13.7%) (59). Reliable resources, such research 
articles were used by less than 12.0% of participants. Results on the pattern of use and perceived 
performance effects (Section 3.3.5, page 83 and Section 3.3.7, page 101) are in line with findings in 
the literature showing that the sources of information used by participants were mainly non-medical 
(6). Information provided by fellow cyclists, books/magazines, coaches/trainers, the internet and 
adverts does not mean it is based on scientific research; therefore the advice may be inaccurate or 
inappropriate (55). The use of a substance based on fictional information, along with the influence of 




For example; self-experimentation and fellow cyclists were the two most influential sources for the 
use of caffeine. Seventy-two percent of participants used coffee as a means to enhance performance 
despite research clearly stating that it is not the ideal method to obtain an ergogenic effect (42).  
Research articles were found to be the second most influential source of information for the 
reported use of creatine, Vitamin B, NSAIDs, analgesics and all the illegal/banned substances. This 
finding is surprising as research based on scientific trials has demonstrated very little evidence for 
these ergogenic aids, especially in endurance cycling (4,15,20,42,64,65,121,126,144). Interest in ergogenic aids 
may stem from the large amount of media attention given to doping in cycling (5,9). Primary sources 
of information for the participants of the Lentillain-Kaestner and Carstairs(9) study included fellow 
cyclists (former professionals), books about doping and the internet. The more experienced cyclists 
were reported to be the most influential in promoting the use of illegal/banned substances to other 
cyclists (9). The temptation for doping was also greater when the young cyclists spent time with 
fellow cyclists who were doping (5,9). Lentillon-Kaestner, Hagger and Hardcastle(5) found that since all 
the doping scandals in the media, team staff and doctors have backed off from placing pressure on 
professional cyclists to dope. In contrast; Schnieder(17) found that coaches, managers, doctors and 
masseurs had a substantial influence on the use of illegal/banned performance enhancing 
substances at the professional cycling level.  
 
3.4.7 Factors predicting the use of ergogenic aids analyses 
3.4.7.1 Descriptive characteristics 
Del Coso, Munoz and Munoz-Guerra(198) found that athletes over 30 years of age had significantly 
higher levels of urine caffeine concentration compared to athletes younger than 20 years of age. 
This supports the significant association between age and the use of caffeine as found in this study. 
Participants older than 40 years old were twice as likely to use caffeine than participants younger 
than 39 years old. The authors hypothesised a number of reasons for the relationship between age 
and the use of caffeine (198). Firstly, the ingestion of tea and coffee may increase with age, although 
there are no scientific data confirming this. Secondly, the sports-speciality may be related to age. 
This is supported by Rissel, Munro and Bauman’s(194) finding of a greater number of older adults who 
are cycling compared to the number of younger adults. Thirdly and finally, perhaps the increased 
caffeine consumption in older athletes is an attempt to negate the decline in physiological 
capabilities related to the natural aging process itself (198). All of the reasons above are mere 




The level of education did not play a significant role in influencing the use of specific ergogenic aids 
amongst participants. Of the previous studies reviewed, not one had investigated the relationship 
between level of education and the likelihood of using performance enhancing products (5,9,17,188,191). 
 
3.4.7.2 Cycling discipline 
Road cyclists were half as likely to use CHO and PRO and approximately a third less likely to use 
electrolytes compared to mountain bikers. Mountain biking generally entails off-road terrain, 
characterised by dirt and gravel roads as well as narrow trails and open fields. It typically involves a 
large proportion of uphill climbing followed by technical descents (202). Lee et al(202) found that 
mountain bikers were lighter and significantly leaner than road cyclists when they compared 
physiological characteristics.  
This is surprising when considering the associations found in this study. As a result of the factors 
discussed in Section 2.2.2 (page 6), it may be assumed that mountain bikers are more weight 
conscious due to the excessive mountainous terrain. Limited feeding time whilst cycling may also be 
expected in mountain bikers due to the technical skills the sport requires (202). Perhaps as a result of 
the nature of the sport, mountain biking could be considered a more demanding endurance sport 
compared to road cycling, and thus ingestion of fuel in the form of CHO, PRO and electrolytes is 
greater in order to sustain energy levels and resist fatigue (202). 
Road cyclists were almost 12 times more likely to use analgesics compared to mountain bikers. The 
large confidence interval however, strongly suggests that this finding be interpreted with caution. As 
such no, further discussion regarding this underlying association in this study is warranted. No 
previous study, to our knowledge, has investigated the difference between nutritional intake and 
characteristics in road cyclists and mountain bikers. Thus a comparison of the associations found in 
this study between the two cycling disciplines is impossible.   
 
3.4.7.3 Training factors 
Participants who cycled more than 120 km.wk-1 were 2.28 times more likely to use CHO and PRO 
than those who cycled less than 119 km.wk-1. The higher the demands of training the higher the 
energy demand on the body, and thus the more fuel the body needs to sustain energy levels, 
optimise training and enhance performance. This association is supported by literature relating 




Participants who recovered for less than three days after a competition were nearly three times 
more likely to use electrolytes than those that recovered for more than four days. The majority of 
the participants (77.3%) took less than three days recovery post competition (80 km to 100 km). This 
association found between the use of electrolytes and enhanced recovery (as fewer number of 
recovery days were taken), is supported by the literature. Fallowfield et al(85) were the first to 
demonstrate that the ingestion of a CHO-electrolyte drink after exercise enhances recovery.  
Interestingly, the most common perceived effect of electrolytes (60.8%) was that they improve 
endurance and time to fatigue. Furthermore, electrolytes were mostly reported to be consumed 
before/during training and competition. These findings contradict the subsequent notion that 
participants were using electrolytes to enhance the recovery process. The top two sources of 
information influencing the decision to use electrolytes were self-experimentation and fellow 
cyclists. Participants did not obtain information from trustworthy scientific sources; hence the 
reasons associated with the use of electrolytes were not correlated to the literature. 
The main predictor variable influencing the use of specific ergogenic aids was preferred cycling event 
(road or mountain biking). While a participant’s competitiveness did not reach significance, the p-
values had a tendency to approach significance more often when compared to other variables. 
Laure(10) demonstrated a 4.8% prevalence of doping at a recreational level and 10.8% prevalence in 
competition. It was proposed that the level of competition influenced doping behaviour. At a 
national and international level of competition, 17.5% declared doping compared to 10.3% at local 
competitions. However, this study was not specific to cycling and different sports are considered to 
have different doping cultures (10). Athletes of all levels will be driven to improve and reach higher 
levels of achievement (66). The literature has shown that the use of illegal/banned ergogenic aids 
does not only exist at the professional level of cycling (5,9,66). Athletes at the recreational level are no 
longer competing against themselves for self-fulfilment, they are competing against someone else 
and there is inevitably always someone better, faster or stronger (66). Perhaps it is this which drives 
curiosity for alternative means to improve performance. 
If it can be assumed that all elite cyclists train as smartly and as intensely as they possibly can, then it 
can be assumed that all recreationally competitive (trained/highly trained) cyclists do too. The 
difference is that at the recreational level most athletes are working full time. The frequency and 
duration of training may thus be limited, potentially further influencing the use of performance 





3.4.8 Limitations of the study 
The prevalence of ergogenic aid use and doping in the literature has mainly been measured through 
questionnaires of self-reported use, interviews with athletes, questionnaires about use by other 
athletes and the number of positive doping test results (7,64,66,114,184,187-191,193). All methods of 
measurement to determine the prevalence of ergogenic aid use and specifically doping will present 
limitations as discussed in Section 2.9 (page 55) (127,187-191,193).  
While the sample size was adequate, and larger than most studies (5,9,170,188,191), once sub-group 
analyses were performed for gender and the specific ergogenic aids, the numbers may not have 
been large enough to provide adequate statistical power. It is recognised that the researcher could 
have potentially recruited more participants for the study through reminder emails, with an apology 
if participants had completed the questionnaire already. Reminders were only sent to cycling clubs, 
shops and media platforms. A larger sample size would have allowed for better representation of 
the South African cycling population. Due to the voluntary nature of the questionnaire the study 
sample may represent bias. Individuals who volunteer to participate in a study are often different 
from non-volunteers. Volunteers often tend to be more concerned about their health and more 
motivated (182). 
The study’s sample may represent bias towards “responders”. Emails requesting participation in the 
study were sent to prospective participants from a database of individuals who had responded to a 
previous cycling questionnaire. Thus there was an increased likelihood that they would respond to 
this questionnaire. It can be argued that the topic of the questionnaire was completely different to 
this study and that individuals presumably gave their contact details because they had a chance of 
winning something. The participants of this study were well informed that there were no direct 
benefits for completing this study’s questionnaire. 
The study’s sample may also represent bias towards cyclists in the Western Cape. The majority of 
cycling clubs and shops contacted (38%) were situated in the Western Cape. The extent to which this 
bias exists is speculative as the questionnaire was completely anonymous, and there was no way of 
determining where participants resided. This study also did not clearly define a population. A more 
stringent level of competitiveness, gender and/or age group definition for inclusion would have 
potentially improved the ability to compare and relate findings with previous studies; however this 
would have reduced the generalisability of the study findings.  
In an attempt to secure the participants’ trust and increase credibility of the questionnaire data, the 
following steps were taken, which were in line with those taken in previous studies of the same 




Firstly, the aim of the research, and what the data was going to be used for, was clearly outlined on 
the opening page of the online questionnaire. Secondly, all participants were informed that their 
responses were completely anonymous, that IP addresses could not be traced, and that responses 
would not be sent to any testing authorities. Given the sensitivity of the information received from 
participants, this was essential to communicate (5). Thirdly, participants were informed that they 
were able to stop and/or exit the online questionnaire at any point without sanction or prejudice, 
before providing their informed consent.  
Furthermore in an attempt not to bias potential participants, the questionnaire had a customised 
language selection. Participants were also able to complete the questionnaire easily as they only 
viewed questions which were applicable to them (179). In an effort to decrease non-responses and 
missing data, most questions were manipulated to ensure participants answered the questions 
before advancing forward (179). 
 
3.4.9 Summary and recommendations 
Results of this study show that trained and/or highly trained cyclists use an average of three 
ergogenic aids, and that nutritional ergogenic aids are the most commonly used aids. Sports 
drinks/gels had the highest reported use, followed by CHO and PRO, caffeine and electrolytes. Four 
participants self-reported to be doping with anabolic steroids, HGH and/or cortisone. 
This is the first study, to this researcher’s knowledge, that investigated the pattern of use of 
ergogenic aids in cyclists. The pattern of use was variable; however 75% of the ergogenic aids listed 
were mostly used in training and competition. The two main predictor variables influencing the use 
of specific ergogenic aids were preferred cycling event and average weekly mileage. The findings on 
pattern of use and perceived performance effects, suggest inappropriate use and poor 
understanding of many of the ergogenic aids used. The misconceptions and inaccuracies correlate to 
the “questionable” information resources used by participants (85). 
There are two novel aspects of this study. This is the first study that has investigated the type and 
pattern of use of ergogenic aids in South African cyclists.  This study also has the largest sample size 
investigating the use of ergogenic aids in cycling. Future studies should continue to include more 
female cyclists and mountain bikers. The inclusion of females and mountain bikers will allow for a 
more generalised observation of the use of ergogenic aids across a cycling population, rather than a 
gender specific or discipline specific observation. As discussed in Section 3.4.1.2 (page 129) this 
study attempted to explore use in females and different disciplines but a larger sample size is 




A major issue regarding the investigation of the use of ergogenic aids in the literature is that studies 
have included and categorised aids differently. Standardised classifications of ergogenic aids will 
enable researchers compare findings between studies (53). 
Based on the findings of this study, it is evident that the consumption of nutritional and 
pharmacological ergogenic aids is high and often concomitant. Educational interventions are needed 
in South Africa to ensure cyclists are appropriately informed about the use of ergogenic aids. This 
highlights the importance of regulatory authorities (e.g. SAIDS) to take responsibility in ensuring that 
cyclists are informed about legal ergogenic aids, rather than monitoring and censoring use of 
illegal/banned aids only. Recently SAIDS advertised the implementation of a proactive anti-doping 
and education programme targeted at professional and youth football players on the risks 
associated with sports supplements use (192). A programme similar to this, targeting cyclists and 
educating them on the use of legal ergogenic aids is recommended. The collaboration of SAIDS and 
Cycling South Africa on an initiative such as this would perhaps make funding more feasible. 
It may be challenging as an individual cyclist to enter a sporting discipline where there are 
anecdotes, misconceptions and inaccurate information regarding efficaciousness of ergogenic aids.  
More research is needed to obtain an in-depth understanding of knowledge, attitudes and 
behaviours regarding the use of ergogenic aids. This information can be used to assess the value of 
current interventions, as well as to support the need for strong educational initiatives to positively 




CHAPTER 4: SUMMARY AND CONCLUSION 
Cycling is largely an endurance event which pushes cyclists to exhaustion and fatigue in both training 
and competition (3). Ergogenic aids are misused to address the metabolic disturbances that may 
result from high intensity training and competition, in an attempt to improve performance and 
enhance recovery (15,16). There is widespread use of nutritional and pharmacological ergogenic aids 
despite the poor evidence for their ergogenic effect on cycling performance (64). Anecdotal evidence 
far precedes scientific evidence in relation to the benefits of using most ergogenic aids (6,11). This has 
contributed to inappropriate use of ergogenic aids seen in this study amongst cyclists and therefore 
an increased risk of health related side-effects (12). 
The overall aim of this study was to describe the use of ergogenic aids in South African cyclists during 
training and competition. Based on the evidence provided in this dissertation, the study objectives 
as described in Section 1.2.2 (page 2) may be answered as follows: 
(1) To obtain information on ergogenic aid use in male and female South African cyclists, 
with regard to the type of ergogenic aids used, and the pattern of use during training 
and competition. 
 
In this study, participants used an average of three ergogenic aids, indicating that ergogenic aids are 
used in combinations (158). Concomitant use of ergogenic aids can be dangerous as a result of 
interactions causing undesired health related side-effects (6,187). Nutritional ergogenic aids were used 
the most, followed by pharmacological ergogenic aids. The reported use of illegal/banned 
substances was low, and may not provide an accurate reflection of the current practice.  Of all the 
ergogenic aids listed sports drinks/gels had the highest self-reported use, followed by CHO and PRO, 
caffeine and electrolytes. Four participants reported the use of anabolic steroids, HGH and/or 
cortisone. Additional ergogenic aids that were used by participants in descending order included; 
Vitamin B; amino acids; NSAIDs; analgesics and creatine. 
There was a variable pattern of use for all categories of ergogenic aids however they were used 
throughout training and competition. The majority of participants reportedly used NSAIDs, 
analgesics and cortisone only when they were stiff and/or injured. The limitation is that this does not 
reflect whether participants are using these aids during exercise.  The variable pattern of use may 
reflect inadequate understanding of the proposed mechanisms of action of many of the ergogenic 






(2) To determine South African cyclists’ perception of the effect of ergogenic aids. 
 
The majority of participants (58.3%) perceived that the ergogenic aids used increased endurance and 
time to fatigue. Thirty-three percent of participants perceived that they decreased stiffness, 17% 
perceived that they decreased cellular damage and increased strength and power. The 
illegal/banned ergogenic aids had more than one commonly perceived effect. This suggests that 
knowledge about these ergogenic aids is poor, which is concerning as participants were continuing 
to use them. Participants in this study had misconceptions regarding the effect of ergogenic aids. 
Participants’ perceived effects of many of the ergogenic aids did not correlate to the effects shown 
in the literature but rather to anecdotal evidence. Consequently these misconceptions might lead to 
the ineffective and dangerous use of aids during cycling training and competition. 
 
(3) To determine the sources of information influencing South African cyclists’ use of 
ergogenic aids. 
 
Self-experimentation and fellow cyclists were determined to be influential sources of information in 
the decision-making process regarding the use of specific ergogenic aids. Less than 12.0% of 
participants ranked research articles as their primary source of information. This raises even more 
concern given the observation that the participants of this study had good instruction levels (88.9% 
with at least a tertiary degree) (6). The variable pattern of use and misconceptions of perceived 
performance effects observed in the findings might be consequential to the non-medical sources of 
information used by participants.  
Research articles were found to be the second most influential source of information for the 
reported use of creatine, Vitamin B, NSAIDs, analgesics and all of the illegal/banned substances.  This 
was interesting, as some of the perceived effects did not correlate to the literature. This discrepancy 
might exist as a “research article” was not defined for participants. Participants might have read 
expert opinions on the internet and believed that those were research articles.  The source of 
information needs to be clearly explored to understand where cyclists are getting their information. 




It is unsafe for athletes to use ergogenic aids without a full evaluation and understanding of the 
associated benefits and risks (12). Educational interventions are needed to enable cyclists to be 
appropriately informed about the use of ergogenic aids. 
 
(4) To explore the socio-demographic and training factors that may predict the use of 
ergogenic aids, such as age, level of education and training and competition history. 
 
There was a significant association between the use of caffeine and age, with a higher prevalence of 
use in participant’s older than 40 years of age. This is an interesting observation which may be linked 
to the psycho-stimulant effects of caffeine (203). Caffeine has been found to increase alertness and 
quicken reaction time (203). Older adults may feel an increased need for these effects compared to 
younger participants. Appropriately, road cycling requires the skill of drafting that necessitates 
concentration and mountain biking presents technical terrains requiring quick reaction times. There 
was a significant association between mountain biking and the use of CHO and PRO and electrolytes. 
Due to the large amount of climbing and technical aspects of mountain biking, it takes much longer 
to cover the same distance of that on the road. This would explain the increased use of nutritional 
ergogenic aids observed in mountain bikers. Carbohydrates and PRO were also significantly 
associated with increased average weekly mileage (more than 120 km.wk-1). This suggests that 
participants who trained more consumed more nutritional aids. The nutritional requirements of an 
athlete increase as training duration, frequency and intensity increase (86). The number of recovery 
days taken after a competition was also significantly associated with the use of electrolytes. Those 
participants using electrolytes took fewer number of recovery days. The literature is conflicting 
regarding the ability of electrolytes to enhance performance (126). The use of a CHO-electrolyte drink 
however has shown beneficial effects on recovery time (82,85). 
Based on the findings of this study it is recommended that SAIDS and Cycling South Africa 
collaborate to review current strategies of anti-doping and programmes within the “I Play Fair” 
concept. The results of this study show that there is a high prevalence of use of legal ergogenic aids, 
with very little understanding of the beneficial effects and potential risks. The information resources 
used are mainly non-medical and inaccurate, propagating misconceptions with the cycling 
community.  Educational initiatives focusing on the use of nutritional and pharmacological ergogenic 
aids are needed to ensure safe and appropriate use amongst cyclists and to facilitate maximum 
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QUESTIONNAIRE BACKGROUND AND INFORMED CONSENT 
(Template of the online version: page one of the questionnaire) 
Thank you for taking the time to complete this questionnaire which would greatly add to the body of 
knowledge and literature regarding the use of performance and recovery products by cyclists. 
This survey will take 40 minutes to complete (maximum) 
Please follow the instructions carefully. 
Sections A and B are compulsory. In Section C, please answer only the questions relevant to you. 
Each questionnaire will be coded (allocated a number) to ensure confidentiality and anonymity.  
We understand the need for extreme sensitivity as some of the questions below entail information 
surrounding illegal/banned substances. We take confidentiality and anonymity very seriously. The 
information collected will only be used for research purposes. All referring URL’s and IP addresses of 
respondents are hidden and therefore cannot be traced by any means. 
 Information obtained from the questionnaires will not be provided to any regulatory body, such as 
SAIDS and Cycling South Africa.  
 
Please tick (√) the appropriate box to indicate your answer when filling out the questionnaire. 
Please complete sections A, B and C  




Section B: Training and Race history (over the last 12 weeks) 
Section C: Use of performance and recovery products (as CURRENTLY applicable) 
If you have any questions you would like answered before completing this questionnaire please feel 
free to contact the following people: 
Ashleigh Hansen (Principle Investigator)............ash_hansen10@hotmail.com 
Dr Theresa Burgess (Supervisor).............theresa.burgess@uct.ac.za 
Professor Andrew Bosch (Co-Supervisor)......andrew.bosch@uct.ac.za 
Professor Mike Lambert (Co-Supervisor).....mike.lambert@uct.ac.za 
Any questions or concerns regarding your rights as research participants please contact: 
Human Research Ethics Committee (HREC REF: 255/2012)....marc.blockman@uct.ac.za 
Participation in this study is voluntary. 
You have the right to withdraw from this study at any time without reason or prejudice. 
You will be required to indicate informed consent by ticking the appropriate box below. 
Please note that by accepting the option to participate in the study you are providing your informed 
consent. 
This will then lead you to the questionnaire. 
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Tel: +27 (0) 21 406 6401/ 6428/ 6628/ 6534 
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Dear Prospective participant 
MASTERS THESIS RESEARCH: THE USE OF ERGOGENIC AIDS IN CYCLISTS 
I am a Masters of Philosophy in Sports Physiotherapy student at the University of Cape Town, 
Division of Physiotherapy. I am conducting a study, as part of my degree, to investigate the use of 
ergogenic aids by cyclists. This study has been given ethics approval by the University of Cape Town, 
Faculty of Health Sciences Human Research Ethics Committee (HREC REF: 255/2012).  
It is well known that athletes seek out ergogenic aids to enhance sporting performance. Ergogenic 
aids can be defined as “any means of enhancing energy utilisation, including energy production, 
control, and efficiency”. Ergogenic enhancing practices include well acknowledged techniques of 
carbohydrate loading prior to an event, use of supplements such as creatine, caffeine and multi-
vitamins as well as the use of growth hormone and blood doping.  
There is little available literature on the use of ergogenic aids by cyclists.  The purpose of this study is 
to gain a greater understanding of the current practices of cyclists as well as their rationale for the 
use of specific practices. Identification of practices employed combined with current scientific 
evidence of the efficacy; risks and benefits may help change behaviour and influence safe 




The questionnaire will include questions on training and race history as well as the use and 
knowledge of ergogenic aids. No personal information or email addresses will be captured as part of 
the data. Information obtained from the questionnaires will not be provided to any regulatory body, 
such as the South African Institute for Drug-Free Sport (SAIDS) and Cycling South Africa. All 
information is strictly confidential and for statistical purposes only. Please open the link below to 
access the survey: 
http://fluidsurveys.com/surveys/ergogenic_aids/copy-the-use-of-ergogenic-aids-by-
cyclists/langeng/ 
This study is being supervised by Dr Theresa Burgess of the division of Physiotherapy, University of 
Cape Town as well as Professor Mike Lambert and Professor Andrew Bosch, from the Sports Science 
Institute of South Africa.  
If you have any questions about the study please feel free to contact any of the individuals listed 
below. 
Researcher:  Ms Ashleigh Hansen           0795281588; ash_hansen10@hotmail.com 
Supervisor:  Dr Theresa Burgess  theresa.burgess@uct.ac.za  
Co-Supervisors: Professor Mike Lambert mike.lambert@uct.ac.za  
                              Professor Andrew Bosch andrew.bosch@uct.ac.za 
If you have any concerns or questions regarding your rights or welfare as a research participant, 
please contact Professor Marc Blockman (Chairperson, Faculty of Health Sciences Research and 










The use of ergogenic aids in cyclists
*
 
IN ORDER TO QUALIFY FOR PARTICIPATION YOU MUST: 
Please indicate for which criteria you qualify for below. 
-You can tick more than one box. 
-Competitive cycling was defined according to the following race times; (i) Cape Argus Pick ‘n Pay 
Cycle Tour (109 km): male-sub 3h15m, female-sub 3h30m, (ii) Momentum 94.7 Cycle Challenge (94.7 
km): male-sub 2h45m, female- sub 3h00m, and/or (iii) Amashova Durban Classic (106 km): male-sub 
3h00m, female- sub 3h15. 
 Have been cycling competitively for at least two years 
 Currently cycle a minimum of 80 km per week 
 Cycle for at least 6 months out of the year 





Please answer the questions below. 
GENDER  Male 
 Female 
 
AGE (years) _________ 
HEIGHT (m) _________  
WEIGHT (kg)  _________ 
HIGHEST LEVEL OF EDUCATION  Grade 10 
 Grade 11 
 Grade 12 (Matric) 
                                                          
*This is originally an online questionnaire, which has subsequently been converted to a word document 












Do you suffer from any of the following conditions? 
-Please tick the appropriate box/es below. 
 Diabetes Mellitus 
 Any metabolic disorder (please specify) ______________________ 




TRAINING AND RACE HISTORY  
Please indicate which type of event/s you participate in? 
-You can tick more than one box below. 
 Road 
 Mountain (MTB) 
 Track 
 Time trial 









Please COMPLETE the relevant questions below as applicable over the last 12 week period. 
Are you currently cycling competitively? 
Competitive cycling was defined according to the following race times; (i) Cape Argus Pick ‘n Pay Cycle Tour 
(109 km): male-sub 3h15m, female-sub 3h30m, (ii) Momentum 94.7 Cycle Challenge (94.7 km): male-sub 




How many years you have been cycling competitively? 
________ 
In which year did you start competitive endurance cycling? 
________ 
How many times on average do you cycle per week? (looking at the last 12 weeks) 
________ 
How many hours on average do you cycle per week? (looking at the last 12 weeks) 
________ 

























How many of your rides per week would you classify as hard rides? (>75% heart rate maximum) 
________ 
How many (1 day) races have you completed, in the last 12 weeks? 
________ 
How many multi-stage/day events have you completed in the last 12 weeks? 
________ 
What is your best race time for the following races and when did you achieve this time (year)? 
 Time (hours; minutes) Year 
Cape Argus Pick ‘n Pay Cycle Tour  ________________ ________ 
Momentum 94.7 Cycle Challenge   ________________ ________ 
Amashova Durban Classic  ________________ ________ 
Double Century  ________________ ________ 
Reeds Chevrolet Ninty Niner  ________________ ________ 
Die Burger  ________________ ________ 
Franchhoek valley Delta Trap  ________________ ________ 
Pick 'n Pay Mountain Bike Challenge  ________________ ________ 
Napier Patasfees MTB (60 km)  ________________ ________ 
MTN National Marathon series #3 Tulbagh  ________________ ________ 
MTN National Marathon series #5 Wellington gravel travel  ________________ ________ 
How many days after a race (80 km to 100 km) would you resume normal training? 





















Please answer the questions below. 
How would you best describe your fluid intake during an endurance (80 km to 100 km) race/event? 
-Please indicate by ticking the box/es below.-You can tick more than one box. 
 Drink to thirst 
 Drink as much as tolerable 
 Drink according to a pre-determined drinking schedule 
 Drink to prevent weight loss 
 Drink a bottle per an hour (750 ml) 
 I do not drink 
 Other: Please specify ______________________ 
What percentage of your fluid intake will consist of these beverages during a race/event? 


















































What is your preferred drink of choice the hour leading up to a race/event? 
 Water 




What is your estimated total fluid intake during a race/event (80 km to 100 km)?  
 100 ml-200 ml 
 201 ml-300 ml 
 301 ml-400 ml 
 401 ml-500 ml 
 501 ml-600 ml 
 601 ml-700ml 
 701 ml-800 ml 
 801 ml-900 ml 
 901 ml-1000 ml 
 1.1 L-1.5 L 
 1.6 L-2 L 
 >2.1 L 
What is your drink of choice during a race/event (80 km to 100 km)? 
 Water 




What is your estimated total fluid intake after a race? 
30-minutes  100 ml-200 ml 









 301 ml-400 ml 
 401 ml-500 ml 
 501 ml-600 ml 
 601 ml-700 ml 
 701 ml-800 ml 
 801 ml-900 ml 
 901 ml-1000 ml 
 1.1 L-1.5 L 
 1.6 L-2 L 
 2.1 L-2.5 L 
 2.6 L-3 L 
 >3 L 
 N/A 
 
6-hours  100 ml-200 ml 
 201 ml-300 ml 
 301 ml-400 ml 
 401 ml-500 ml 
 501 ml-600 ml 
 601 ml-700 ml 
 701 ml-800 ml 
 801 ml-900 ml 
 901 ml-1000 ml 
 1.1 L-1.5 L 
 1.6 L-2 L 
 2.1 L-2.5 L 
 2.6 L-3 L 
 >3 L 
 N/A 
 
24-hours  100 ml-200 ml 
 201 ml-300 ml 
 301 ml-400 ml 




 501 ml-600 ml 
 601 ml-700 ml 
 701 ml-800 ml 
 801 ml-900 ml 
 901 ml-1000 ml 
 1.1 L-1.5 L 
 1.6 L-2 L 
 2.1L-2.5 L 
 2.6 L-3 L 




What is your preferred drink of choice after a race? 
 Water 




Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of fluids (Please note that there can only be ONE of each number) 
1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 







PERFORMANCE AND RECOVERY PRODUCTS 
Ergogenic aids are any products or means of increasing or improving performance and recovery in 
sport. Athletes frequently use a variety of products to help improve their performance. Examples 
may include: caffeine, carbo-loading, specific drinks (Energade, Cytomax, PVM, Powerade, USN, 
Coca-Cola, etc.), vitamin supplementation (injections or tablets), nutritional supplementation (whey 
protein), blood doping, growth hormone, creatine, anabolic steroids, cortisone and gels. We would 
like to determine what products South African cyclists are ingesting or using; when they are doing 
so, and how they believe it works for them. The study is purely for research purposes and statistics. 
We would like to re-iterate that information obtained from the questionnaires will not be provided 
to any regulatory body, such as SAIDS and Cycling South Africa. 
PLEASE ANSWER THE QUESTIONS BELOW AS CURRENTLY APPLICABLE TO YOU OVER THE LAST 12 
WEEKS.   
Do you use performance or recovery products to improve your cycling? 
 Yes 
 No 
Which performance and recovery products do you use?  -Please indicate by ticking the box/es 
below. 
-You can tick more than one box. 
 Caffeine 
 Blood transfusions 
 Creatine 
 Vitamin B 
 Sports drinks/gels 
 Amino acids 
 Erythropoietin (EPO) 
 Anabolic steroids 
 Nutritional: carbo-loading and or protein 




 Analgesics (e.g. Paracetemol) 
 Electrolytes 
 Growth hormone 
 Corticosteroids (cortisone) 
 Other: Please specify ______________________ 
 N/A 
 
Performance and recovery product: 
CAFFEINE 
Please answer the questions below regarding your use of caffeine. 
When do you use caffeine OR a caffeine containing substance as a performance or recovery 
product?-Please indicate by ticking the box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 





How do you ingest caffeine for the specific purpose of improving performance or recovery? -Please 
specify the quantity/amount that you take in the text box provided.-You can tick more than one box. 
 Coffee ______________________ 
 Capsules ______________________ 
 Red Bull ______________________ 
 Chocolate ______________________ 
 Other: please specify ______________________ 
Do you feel caffeine improves your performance? 
 Yes 
 No 
In your opinion how do you think caffeine works as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box.       
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use caffeine, your performance would deteriorate?       
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of caffeine (Please note that there can only be ONE of each 
number) 
1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    




Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
 
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
BLOOD TRANSFUSIONS 
Please answer the questions below regarding your use of blood doping. 
How do you administer blood doping? 
 Intravenously 
 Other: please specify ______________________ 


















Do you have help administering this performance and recovery product from either of the following 
people?-Please indicate by ticking the box/es below.-You can tick more than one box. 
 General Practitioner (GP) 
 A physiotherapist 
 Medical support personal 
 Team mate 
 Other: please specify ______________________ 
Do you feel that blood doping improves your performance? 
 Yes 
 No 

























In your opinion how do you think blood doping works as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use blood doping, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of blood doping (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    






Performance and recovery product: 
CREATINE 
Please answer the questions below regarding your use of creatine. 
When do you use creatine as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
Do you feel creatine improves your performance? 
 Yes 
 No 
In your opinion how do you think creatine works as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 






Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of creatine (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
VITAMIN B 
Please answer the questions below regarding your use of Vitamin B. 
When do you use Vitamin B as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 





Do you feel Vitamin B improves your performance? 
 Yes 
 No 
In your opinion how do you think Vitamin B works as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 







Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of Vitamin B (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
SPORTS DRINKS/GELS 
Please answer the questions below regarding your use of sports drinks/gels. 
Which product do you use most frequently? 
 Sports drinks 
 Gels 
 Both 
When do you use sports drinks/gels as a performance or recovery products?-Please indicate by 
ticking the box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 




 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
Do you feel sports drinks/gels improve your performance? 
 Yes 
 No 
In your opinion how do you think sports drinks/gel work as performance or recovery products?-
Please indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use sports drinks/gels, your performance would deteriorate?       
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of sports drinks/gels (Please note that there can only be ONE of 
each number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    




If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
AMINO ACIDS (BCAA/WHEY) 
Please answer the questions below regarding your use of amino acids. 
In what form are you using amino acids?-Please indicate by ticking the box below. 
 Branched Chain Amino Acids (BCAA) 
 Whey 
 BCAA and Whey 
 Other: please specify ______________________ 
When do you use amino acids as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
Do you feel amino acids improve your performance? 
 Yes 
 No 
In your opinion how do you think amino acids work as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 




 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use amino acids, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of amino acids (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
ERYTHROPOIETIN (EPO) 
Please answer the questions below regarding your use of EPO. 
Do you use EPO for.... 
 Therapeutic use :please specify ______________________ 




If you are using EPO for therapeutic purposes please skip this subsection and move forward to the 
next relevant subsection. If you are using EPO for performance and recovery purposes please answer 
the rest of the questions below. 
When do you use EPO as a performance or recovery product?-Please indicate by ticking the box/es 
below.-You can tick more than one box.       
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
Do you have help administering this performance and recovery product from either of the following 
people?-Please indicate by ticking the box/es below.-You can tick more than one box. 
 General Practitioner (GP) 
 A physiotherapist 
 Medical support personal 
 Team mate 
 Other: please specify ______________________ 

























Do you feel that EPO improves your performance? 
 
 
In your opinion how do you think EPO works as a performance or recovery product?-Please indicate 
by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 










Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of EPO (Please note that there can only be ONE of each number) 
1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
ANABOLIC STEROIDS 
Please answer the questions below regarding your use of anabolic steroids. 

























When do you use anabolic steroids as a performance or recovery product?-Please indicate by ticking 
the box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
Do you feel anabolic steroids improve your performance? 
 Yes 
 No 
In your opinion how do you think anabolic steroids work as a performance or recovery product?-
Please indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 




 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use anabolic steroids, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of anabolic steroids (Please note that there can only be ONE of 
each number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
NUTRITION: CARBOHYDRATES AND PROTEIN 
Do you use carbohydrates as a performance and recovery aid? 
 Yes 
 No 
If you ticked YES please answer all the questions below. If you ticked NO please click the NEXT 






When do you use carbohydrates as a performance or recovery product?-Please indicate by ticking 
the box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
How soon after training or a race do you start ingesting carbohydrates? 
 Within 30 minutes of finishing 
 Within 2-4 hours of finishing 
 >6 hours of finishing 
 Within no specific time period 
 I don't ingest carbohydrates after training or a race 
Do you try to eat/drink a specific amount of carbohydrates calculated according to your body 
mass per day, whilst training? 
 Yes 
 No 
If you ticked YES in the above question, then what formula are you using and/or how many extra 






What form of carbohydrates are you ingesting?-Please indicate by ticking the box/es below.-You can 
tick more than one box. 
 Refined (sports drinks/sweets/coke/sugars) 
 Nutrient dense (pasta/rice/potato/bread) 
 Supplementation (powder) 
 Other: please specify ______________________ 
If you ticked REFINED carbohydrates in the above question, then please indicate which product type 
you use most.-Please indicate by ticking the box/es below.-You can tick more than one box. 
 Sports drinks (Energade/Powerade/Game) 
 Soft drinks (Coke) 
 Sweets (Jelly babies) 
 Gels 
 Sports bars (energy bars/Jungle oats bar) 
 Other: please specify ______________________ 
If you ticked NUTRIENT DENSE carbohydrates in the above question, then please indicate which 














Do you use protein as a performance and recovery aid? 
 Yes 
 No 
If you ticked YES please answer all the questions below. If you ticked NO please click the NEXT 
button at the bottom of the page 
When do you use protein as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
How soon after training or a race do you start ingesting protein? (with or without carbohydrates) 
 Within 30 minutes of finishing 
 Within 2-4 hours of finishing 
 >6 hours of finishing 
 Within no specific time period 
 I don't ingest protein after training or a race 




If you ticked YES in the above question, then what formula are you using and/or how many extra 





What form of protein are you ingesting?-Please indicate by ticking the box/es below.-You can tick 
more than one box. 
 Liquid (milk/meal replacement powder) 
 Lean protein (chicken/meat/eggs/fish) 
 Body building protein powder 
 Other: please specify ______________________ 
If you ticked LIQUID protein in the above question, then please indicate which product type you use 
most? -Please indicate by ticking the box/es below.-You can tick more than one box. 
 Milk 
 Liquid meal replacement 
 Body building protein powder 
 Skim milk powder 
 Other: please specify ______________________ 
If you ticked LEAN protein in the above question, then please indicate which product type you use 
most. -Please indicate by ticking the box/es below.-You can tick more than one box. 
 Skinless chicken 
 Fish 
 Eggs 
 Low fat yogurt 
 Other: please specify 
 ______________________ 
How would you best describe your preparation (5 days prior) leading up to a race?-Please indicate by 
ticking the box/es below.-You can tick more than one box. 
 Increased water intake 3 to 5 days prior to the race/event 
 Change to a high carbohydrate diet 3 to 5 days prior to the race/event 
 Carbo-load the night before the race/event 
 I do not change anything 
 Other: please specify ______________________ 






In your opinion how do you think nutrition (carbohydrates and/or protein) works as a performance 
or recovery product? -Please indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 




Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of nutrition (carbohydrates and/or protein) (Please note that there 
can only be ONE of each number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    






Performance and recovery product: 
NSAIDs (e.g VOLTAREN) 
Please answer the questions below regarding your use of NSAIDs. 
How do you administer your NSAIDs? 
 Intravenously 
 Orally 
 Other: please specify ______________________ 
When do you use NSAIDs as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 






















If taken orally, on average how many days will you continue to take NSAIDs for? 
 1 day 
 2-3 days 
 One week 




Do you feel NSAIDs improve your performance? 
 Yes 
 No 
In your opinion how do you think NSAIDs works as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 





Do you feel that if you did not use NSAIDs, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of NSAIDs (Please note that there can only be ONE of each number) 
1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
If you selected other in the above question: please specify below. 
  
 
Performance and recovery product: 
Analgesics “pain killers” (e.g PARACETAMOL) 
Please answer the questions below regarding your use of pain killers. 
When do you use pain killers as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 




 During training rides 
 During races/events 
 Other: please specify ______________________ 
















On average how many days will you continue to take pain killers for? 
 1 day 
 2-3 days 
 One week 
 As long as I feel I need too 
 5 
 6 







In your opinion how do you think pain killers work as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use pain killers, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of pain killers (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    







Performance and recovery product: 
ELECTROLYTES (e.g REHYDRATE) 
Please answer the questions below regarding your use of electrolytes. 
When do you use electrolytes as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
How soon after training or a race do you start ingesting electrolytes? 
 Within 30 minutes of finishing 
 Within 2-4 hours of finishing 
 >6 hours of finishing 
 Within no specific time period 
 I don't ingest electrolytes after training or a race 
Do you try to consume a specific amount of electrolytes? 
 Yes 
 No 







What type of electrolytes are you ingesting? -Please indicate by ticking the box/es below.-You can 
tick more than one box. 
 Pre-mixed sports drinks 
 Mixable powders 
 Capsules/tablets 
 Other: please specify ______________________ 
Do you feel electrolytes improve your performance? 
 Yes 
 No 
In your opinion how do you think electrolytes work as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use electrolytes, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of electrolytes (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    




Research articles    
Other    
If you selected other in the above question: please specify below. 
  
Performance and recovery product: 
GROWTH HORMONE 
Please answer the questions below on your use of growth hormone. 
Do you use growth hormone for therapeutic (a diagnosed medical condition) purposes or as a 
performance and recovery product? 
 Therapeutic purpose (please specify condition) ______________________ 
 Performance and recovery product 
What type of growth hormone do you use? 
  
How do you administer growth hormone? 
 Intravenously 
 Other: please specify ______________________ 
Do you have help administering this performance and recovery product from either of the following 
people?-Please indicate by ticking the box/es below.-You can tick more than one box. 
 General Practitioner (GP) 
 A physiotherapist 
 Medical support personal 
 Team mate 
 Other: please specify ______________________ 

























When do you use growth hormone as a performance or recovery product?-Please indicate by ticking 
the box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 







In your opinion how do you think growth hormone works as a performance or recovery product?-
Please indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use growth hormone, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of growth hormone (Please note that there can only be ONE of 
each number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    






Performance and recovery product: 
CORTICOSTEROIDS (CORTISONE) 
Please answer the questions below on your use of cortisone. 
Do you use cortisone for therapeutic (a diagnosed medical condition) purposes or as a performance 
and recovery product? 
 Therapeutic purpose (please specify condition) ______________________ 
 Performance and recovery product 
How do you administer corticosteroids? 
 Intravenously 
 Other: please specify ______________________ 
Do you have help administering this performance and recovery product from either of the following 
people?-Please indicate by ticking the box/es below.-You can tick more than one box. 
 General Practitioner (GP) 
 A physiotherapist 
 Medical support personal 
 Team mate 
 Other: please specify ______________________ 

























When do you use cortisone as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 







In your opinion how do you think cortisone work as a performance or recovery product?-Please 
indicate by ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 
 Other: please specify ______________________ 
Do you feel that if you did not use cortisone, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of cortisone (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    






Performance and recovery product: 
OTHER (please specify below) 
Please answer the questions below. 
Performance and recovery product used: 
  
When do you use this product as a performance or recovery product?-Please indicate by ticking the 
box/es below.-You can tick more than one box. 
 Before every training ride (1-2 hours) 
 Only if the training ride is going to be particularly long or hard 
 Before every race/event (1-2 hours) 
 Only if the race/event is going to be particularly long or hard 
 Every day no matter what training or race is planned 
 Only when I am injured 
 Only when I am stiff and tired 
 During training rides 
 During races/events 
 Other: please specify ______________________ 
In your opinion how do you think it works as a performance or recovery product?-Please indicate by 
ticking the box/es below.-You can tick more than one box. 
 Increases muscle mass 
 Increases lean muscle mass 
 Increases endurance and time to exhaustion/fatigue 
 Increases strength and power performance 
 Decreases cellular damage 
 Decreases stiffness 
 Unsure 





Do you feel that if you did not use it, your performance would deteriorate? 
 Yes 
 No 
Please rank your TOP THREE sources of information below, on their importance on 
formulating/influencing your use of this product (Please note that there can only be ONE of each 
number) 1-being the most influential and 3-being the least influential 
 1 2 3 
Coach/trainer    
Fellow cyclists    
Books/magazines    
Internet    
Adverts    
Self-experimentation    
Research articles    
Other    
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Dear Prospective validator (insert individuals name) 
REQUEST FOR ASSISTANCE: VALIDATION OF THE QUESTIONNAIRE TITLED 
“USE OF ERGOGENIC AIDS IN CYCLISTS” 
I am an MPhil (Sports Physiotherapy) student at the University of Cape Town, and am writing to you 
to request assistance with the validation of an ergogenic aids questionnaire. 
It is well known that athletes seek out ergogenic aids to enhance sporting performance. Ergogenic 
aids can be defined as “any means of enhancing energy utilisation, including energy production, 
control, and efficiency”. Ergogenic enhancing practices include well acknowledged techniques of 
carbohydrate loading prior to an event, use of supplements such as creatine, caffeine and multi-
vitamins to the use of growth hormone and blood doping.  
There is little available literature on the use of ergogenic aids by cyclists.  The purpose of this study is 
to gain a greater understanding of the current practices of cyclists as well as their rationale for the 
use of specific practices. Identification of practices employed combined with current scientific 
evidence of the efficacy; risks and benefits can help change behaviour and influence safe 
participation in sport. 
Accordingly, I propose to investigate the use of ergogenic aids by cyclists.  The study has been given 
ethics approval by the University of Cape Town, Faculty of Health Sciences Human Research Ethics 




As a recognised medical doctor /dietician/physiotherapist, with expertise in the field of sports and 
exercise science, I therefore wish to request your assistance with the validation of the content of the 
questionnaire.  Please could you review the questionnaire in order to ensure that the questions are 
clear and easy to understand, and that the questions adequately assess use and knowledge of 
ergogenic aids by cyclists. 
 
Your feedback will be valuable and greatly appreciated. I have attached the questionnaire; if 
possible, please could you return any feedback on or before 20 November 2012. Please contact me 
should you have further questions.   
My contact details are as follows: 
Ashleigh Hansen:  
Ash_hansen10@hotmail.com 
Mobile:       0795281588 
 
Thank you for your time and supporting research in the field of Sports Physiotherapy. 
Kind Regards 
Ashleigh Hansen 
BSc. Physiotherapy (UCT) 
Supervisor:   Dr Theresa Burgess  theresa.burgess@uct.ac.za 
Co-Supervisors:  Professor Mike Lambert mike.lambert@uct.ac.za 







Table 3.25 and Table 3.36 show the training history of male and female participants. There was no 
significant difference between average weekly mileage and male and female participants. 
Table 3.25: Average weekly mileage (km) covered by male (n=177) and female (n=30) participants. Data are 
expressed as number of responses (n) and percentages (%). 






81-100 55 (26.5%) 12 (5.8%) 67 (32.3%) 
101-120 19 (9.1%) 2 (1.0%) 21 (10.1%) 
121-140 14 (6.7%) 3 (1.5%) 17 (8.2%) 
141-160 15 (7.2%) 3 (1.5%) 18 (8.7%) 
161-180 8 (3.8%) 4 (1.9%) 12 (5.8%) 
181-200 12 (5.8%) 1 (0.5%) 13 (6.3%) 
201-220 14 (6.7%) 2 (1.0%) 16 (7.7%) 
221-240 7 (3.4%) 0 (0.0%) 7 (3.4%) 
241-260 8 (3.8%) 2 (1.0%) 10 (4.8%) 
261-280 2 (1.0%) 0 (0.0%) 2 (1.0%) 
281-300 7 (3.4%) 0 (0.0%) 7 (3.4%) 
301-320 6 (2.9%) 0 (0.0%) 6 (2.9%) 
321-340 2 (1.0%) 0 (0.0%) 2 (1.0%) 
341-360 3 (1.4%) 1 (0.5%) 4 (1.9%) 
361-380 0 (0.0%) 0 (0.0%) 0 (0.0%) 
381-400 2 (1.0%) 0 (0.0%) 2 (1.0%) 
401-420 2 (1.0%) 0 (0.0%) 2 (1.0%) 
421-440 0 (0.0%) 0 (0.0%) 0 (0.0%) 
441-460 0 (0.0%) 0 (0.0%) 0 (0.0%) 
461-480 0 (0.0%) 0 (0.0%) 0 (0.0%) 
481-500 0 (0.0%) 0 (0.0%) 0 (0.0%) 





Table 3.26: Average number of times male (n=177) and female (n=30) participants cycle per week. Data are 









1 15 (7.3%) 3 (1.5%) 18 (8.8%) 
2 23 (11.1%) 4 (1.9%) 27 (13.0%) 
3 34 (16.4%) 8 (3.9%) 42 (20.3%) 
4 49 (23.6%) 8 (3.9%) 57 (27.5%) 
5 34 (16.4%) 5 (2.4%) 39 (18.8%) 
6 19 (9.1%) 2 (1.0%) 21 (10.1%) 
7 1 (0.5%) 0 (0.0%) 1 (0.5%) 
8 0 (0.0%) 0 (0.0%) 0 (0.0%) 
9 1 (0.5%) 0 (0.0%) 1 (0.5%) 






Regression analyses of factors influencing the use of specific ergogenic aids. 
a) Sports drinks/gels 
There were no significant relationships between the use of sports drinks/gels and the predictor variables analysed 
in Table 3.27. 













 10.73 0.003   8.60 
Age (years) 
 0.84 0.76 0.27 2.58 0.09 
BMI 
 0.54 0.28 0.18 1.63 1.19 
Education 
 2.30 0.43 0.29 18.45 0.61 
Preferred 
cycling event 1.70 0.29 0.64 4.57 1.12 
Cycle 
competitively 1.09 0.88 0.34 3.47 0.02 
Km.wk-1 













b) Vitamin B 
There were no significant relationships between the use of Vitamin B and the predictor variables analysed in Table 
3.28. 













 0.13 0.001   11.86 
Age (years) 
 1.72 0.14 0.84 3.51 2.22 
BMI 
 1.06 0.87 0.52 2.15 0.03 
Education 
 1.56 0.37 0.59 4.09 0.81 
Preferred 
cycling event 0.63 0.17 0.32 1.22 1.87 
Cycle 
competitively 1.36 0.43 0.64 2.90 0.63 
Km.wk-1 














There were no significant relationships between the use of NSAIDs and the predictor variables analysed in Table 
3.29.  













 0.05 0.00   16.57 
Age (years) 
 1.93 0.13 0.82 4.60 2.26 
BMI 
 0.96 0.92 0.40 2.27 0.01 
Education 
 1.49 0.49 0.49 4.53 0.48 
Preferred 
cycling event 2.18 0.09 0.89 5.35 2.90 
Cycle 
competitively 1.32 0.56 0.52 3.40 0.34 
Km.wk-1 








1.33 0.61 0.45 3.96 0.26 
 
